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Abstract 
The presence of many human pharmaceuticals in the aquatic environment is now a 
worldwide concern and yet little is known of the chronic effects that these bioactive 
substances may be having on aquatic organisms. This study used mammalian 
pharmacodynamics to predict the mode of action of the 13-blocker, propranolol, on fish, in 
order to identify chronic effects in fathead minnows. ß-blockers target 131- and [32- 
adrenergic receptors in humans and hence these receptors were characterised in the fathead 
minnow. It was found that fish possess 01- and 02-ARs that are structurally very similar to 
their mammalian counterparts. Further, the distributions of these two (3-ARs in various 
organs of the fathead minnow were similar to those in mammals. Pair-breeding assays 
were conducted, in which fathead minnows were exposed to various concentrations of 
propranolol. To discover whether ß-ARs had been up or down regulated by propranolol, 
molecular analysis was conducted on different tissues of the exposed fish using real-time 
polymerase-chain reactions (RT-PCR). Exposure of fathead minnows to propranolol 
caused acute toxicity at 10 mg/L. Propranolol caused a statistically significant decrease in 
reproduction at 1.0 mg/L, dose-related decreases in male weight, condition index and 
fatpad weight, and a dose-related increase in female GSI. Molecular analysis of ßl- and 
p2-AR expression levels revealed a dose-related decrease in ß2-AR expression in fathead 
liver and heart. LOEC and NOEC values were 0.1 mg/L and 0.01 mg/L, respectively. 
Propranolol plasma concentrations in fish exposed to water concentrations of 0.1 and 1.0 
mg/L were greater than the human therapeutic concentration and hence these data very 
strongly support the fish plasma model proposed by Huggett et al. (2001). 
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Chapter 1 Introduction 
1.1 Pharmaceuticals in the environment 
In Britain alone, approximately 3,000 different human pharmaceutical substances are 
registered for use, of which a variety (e. g. painkillers, aspirin, paracetamol, the anti- 
epileptic carbamazepine, and antibiotics) sell an excess of 10 tonnes per year (ENDS 
Report, 2005; Thomas & Hilton, 2004). This may be because a number of illnesses require 
long term treatment, and so a lot of some particular drugs are used and may enter the 
environment. With regard to veterinary pharmaceuticals, a trend has developed towards 
more intensive farming and more reliance is being placed in pharmaceuticals, feed 
additives, hormones and potent pesticides (Di Guardo et al., 2001). 
There are many routes of pharmaceutical entry into the aquatic environment, but the main 
route is recognised as being in effluent from sewage treatment works (STWs) (Andreozzi 
et al., 2003). Humans that are prescribed drugs excrete metabolites and often a percentage 
of the parent compound, in urine and faeces. Sewage is taken to STWs and although the 
majority of human pharmaceuticals are removed during treatment processes, complete 
degradation does not occur and so a small percentage of the pharmaceutical reaches the 
aquatic environment via effluents. In addition to this, a lot of pharmaceuticals are excreted 
as conjugates that are formed via phase II reactions within the body. Conjugation (e. g. the 
addition of a glucuronide or sulphate group to the active molecule) brings about an 
increase in molecular weight and polarity of a molecule, which also has the effect of 
making the parent molecule less toxic. However, during sewage treatment, the conjugate 
is often cleaved off, thus releasing the active moiety (Gros et al., 2007). Hence, a varying 
amount of a pharmaceutical can routinely end up in treated effluents, rivers, and lakes and 
more rarely in groundwater. Occurrence of pharmaceuticals, although less frequent, has 
also been detected in estuarine and coastal waters (Thomas & Hilton, 2004). Other routes 
of entry of pharmaceuticals into the aquatic environment can occur during the production 
of drugs, direct disposal of surplus household drugs that leach from landfill sites, runoff 
from irrigating crops with treated wastewater and leaching of compounds from the 
application of sludge onto agricultural land (Pedersen et al., 2005; Ternes, 1998). The fate 
of veterinary and human drugs is quite different from each other. Unlike human 
pharmaceuticals, veterinary pharmaceuticals don't have to pass through a STW prior to 
entering a river and hence they can enter the aquatic system directly from runoff or by 
leaching from manure (Chen et al., 2006; Ternes, 1998). 
I 
1.2 Concentrations of pharmaceuticals in the environment 
Pharmaceutical compounds such as analgesics, antibiotics, anticonvulsive drugs, cancer 
drugs, lipid regulators, psychiatric drugs and even recreational drugs have been detected in 
a range of water bodies (Jones et al., 2004). However, when the design of pharmaceuticals 
is taken in to consideration, this is hardly surprising. The majority of drugs are designed to 
be generally resistant to hydrolysis and persistent, so that their chemical structures can be 
retained long enough for their therapeutic work to be done (Jones et al., 2002). For 
example, the ethinyl group on ethinyl estradiol makes this estrogen much more resistant to 
biodegradation and conjugation in the liver, so that it is tough enough to be taken orally but 
not degraded in the gut, so that enough of the drug can reach the blood and target organ. 
These factors unfortunately may enable pharmaceuticals to remain in the environment for a 
significant period of time. As well as having the above characteristics, some 
pharmaceuticals are also designed to ensure that they can be taken at relatively low doses, 
yet can have an extremely potent effect. However, it has to be remembered that there is 
often only a small percentage of people in the population taking such potent drugs at any 
one time, and hence these drugs are often found at low concentrations in the environment. 
Concentrations of drugs in rivers are often dependent on the pharmacokinetic properties of 
the drug, i. e. what the body does to a pharmaceutical, which includes the distribution, 
metabolism and elimination of a pharmaceutical. The physical properties of a 
pharmaceutical can also give an indication of how long it may reside in the environment, 
where it partitions to, and how readily it can be degraded. For example, log Kß, µ, provides a 
measure of the hydrophobicity of a chemical, i. e. its tendency to move from water (a polar 
liquid) into a non-polar liquid (i. e. fat) when the chemical is at thermodynamic equilibrium 
(Walker et al., 1997). Pharmaceuticals with a high Ko,, have a propensity to adsorb on to 
organic particles and settle at the bottom of streams, or undergo biological uptake into fatty 
tissue of animals and plants (Brun et al., 2006). However, in addition to hydrophobicity 
partioning, independent mechanisms such as cation exchange, cation bridging at clay 
surfaces, surface complexation and hydrogen binding are also involved in determining the 
fate of a pharmaceutical compound in the aquatic environment (Calamari et al., 2003) 
Kd values define the sorption constant of a pharmaceutical, which defines the partition of a 
compound between the sludge and the water phase, and pKa values help us understand 
how much the chemical will dissociate and to what extent, at environmental pl-1 values. 
The half life of a drug in a stream is also affected by the physical dynamics of the 
environment. For example, the amount of natural stream flow will dictate the amount of 
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dilution and mixing of a drug, whilst the landscape characteristics such as drainage, soil 
and sediment type will affect partioning dynamics (Brun et al., 2006). 
Tables 1.1 and 1.2 give a rough guide to which pharmaceuticals are known to he present in 
rivers and STW effluents at some of the highest concentrations around the world. It must 
be remembered that not all pharmaceuticals were tested for in each paper, and detection 
limits and methodology between laboratories are often different. For example, matrix 
effects are often encountered when determining the concentration of a pharmaceutical, 
which can lead to signal suppression or enhancement, possibly leading to erroneous results. 
There are different ways to reduce matrix effects (e. g. selective extraction, effective 
sample clean up after extraction, improvement of chromatographic separation, internal 
standard or dilution of samples extracts) but these can often he expensive, time consuming, 
lead to analyte losses or be unavailable (Gros et al., 2006). However, these Tables do 
show that a range of pharmaceuticals can be present in the environment in the low pg/L 
range, although many are in the high ng/L range. 
Ibuprofen, an analgesic with anti-inflammatory properties, features quite frequently in 
these Tables. This is probably due to high over the counter sales of this pharmaceutical, 
and because it is poorly metabolised in humans, with 70 -- 80 % of the parent compound 
and metabolites being excreted. In addition to this, ibuprofen is not readily degradable and 
has the potential to bioaccumulate (log K,,, is 3.5), hence it is not surprising that it is found 
in both effluents and rivers at relatively high concentrations for pharmaceuticals (Ashton et 
al., 2004; Thomas & Hilton, 2004). 
3 
Country Pharmaceutical found at the highest concentration in 
each study in effluent (ng/L) 
Reference 
Drug Type of drug Range 
concentration 
(ng/L) 
U. K. Ibuprofen Analgesic and anti- <20 - 27256 Ashton et al., 2004 
U. K. inflammatory 1800 - 3800 Hilton & Thomas 
2003 
EU 
countries 
50 - 7110 Andreozzi et al., 
2003 
Canada 381 - 1191 Gagne et al., 2006 
U. S. A. Naproxen Analgesic and anti- 380 Yu et al., 2006 
U. S. A. inflammatory 81 - 106 Boyd et al., 2003 
Canada Salicylic acid Analgesic, antipyretic bld - 35,000 Brun et al., 2006 
Canada (aspirin) and anti- 
inflammatory 
1675 - 3522 Lajeunesse & 
Gagnon, 2007 
Germany Diatrizoate X-ray contrast media 80 - 8700 Ternes, 2001 
4 EU 
countries 
Diclofenac Non-steroidal anti- 
inflammatory 
bld - 5450 Ferrari et al., 2003 
Germany Bezafibrate Lipid regulator <250 - 4600 Ternes 1998 
U. S. A. Meprobamate Minor tranquilizer 1270 Vanderford & 
Snyder, 2006 
India Ciprofloxacin Antibiotic 28,000,000- 
31,000,000 
Larsson et al., 2007 
Croatia Acetaminophen 
(paracetomol) 
Analgesic and 
antipyretic 
blq - 5990 Gros et al., 2006 
S. Korea lopromide X-ray contrast media 1170 - 4030 Kim et al., 2007 
Table 1.1 Pharmaceuticals found at the highest concentrations in effluent in different 
countries. It must be noted that these data by Larsson et al., (2007) are quite unique in that 
about 90 pharmaceutical companies were discharging their liquid wastes into just one 
STW. blq: below limit of quantification. bid: below limit of detection. 
4 
Country Pharmaceutical found at the highest concentration Reference 
in rivers (ngJL) 
Drug Type of drug Range or 
actual 
concentration 
(ng/L) 
Canada Naproxen Analgesic and 94 - 551 Metcalfe et al., 2003a 
U. S. A. anti-inflammatory bid - 68 Boyd et al., 2003 
Spain Atenolol ß-blockers 160 - 465 Gros et al., 2007 
Croatia bid - 250 Gros et al., 2006 
Finland Metroprolol 39 - 107 Vieno et al., 2007 
U. K. Erythromycin Antibiotic 1000 Hilton & "Thomas 
2003 
Germany Bezafibrate Lipid regulator 350 - 3100 Ternes 1998 
Canada Salicylic acid Analgesic, bid - 17,000 Brun et al., 2006 
(aspirin) antipyretic and 
anti-inflammatory 
U. K. Ibuprofen Analgesic and <20 - 5044 Ashton et al., 2004 
anti-inflammatory 
Italy Hydro- Diuretic bid - 255.8 Calaniari et al., 2003 
chlorothiazide 
Italy Lincomycin Antibiotic 80 Castiglioni et al., 2004 
S. Korea lopromide X-ray contrast 20 - 361 Kim et al., 2007 
media 
Table 1.2. Pharmaceuticals found at the highest concentrations in rivers in different 
countries. bld: below limit of detection 
1.3 The risk pharmaceuticals pose to non-target organisms 
Many, and perhaps most, pharmaceuticals are probably present in the environment at 
concentrations too low to cause any effects on fauna and flora (Sumpter 2007). However, 
some pharmaceuticals pose a greater potential threat to the aquatic environment than 
others, as some will have a higher usage, others will be more potent at low levels, whilst 
some will be poorly degraded and have the ability to bioaccumulate in aquatic organisms. 
To highlight pharmaceuticals that may cause harm to aquatic organisms, risk 
characterisation ratios can be calculated. 
Predicted environmental concentration (PLC) 
Risk characterisation ratio = Predicted no-effect concentration (PNI? C) 
PEC is the predicted environmental concentration in surface waters calculated from a worst 
case scenario. This value is based on usage, physical properties, chemical and biological 
properties, STW effluent flows and surface water flows. PNEC is the predicted highest 
concentration considered unlikely to cause an effect, and is an estimate of the 
concentration at which no potential effects on aquatic organisms and ecosystems might 
occur. It is usually obtained using ecotoxicology data from the open literature and 
quantitative structure-activity relationships (QSAR). Substances with a ratio greater than I 
are deemed to be of `potential concern' (Ashton et al., 2004). however, these ratios can 
only be as good as the data available to feed into the calculation. Table 1.3 shows two 
different drugs with very different PEC/PNEC ratios. 
Drug UK use (tonnes per year) PEC µg/t, PNEC µg/L PEC/PNEC 
Propranolol 11.8 2.17 1.87 1.16 
Ethinylestradiol 0.029 0.005 0.84 <0.01 
Table 1.3. Summary of PEC and PNEC values and ratios for 2 pharmaceuticals found in 
the environment. Taken from Webb: Pharmaceuticals in the environment (2001) 
Propranolol, a ß-blocker, has a ratio >1 and therefore is shown to be of `potential concern'. 
Studies show it has been found to affect medaka (Oryzias lalipes) reproduction at 
concentrations as low as 0.005 mg/L, although these data have not been repeated since 
(Huggett et al., 2003a). However, from the calculations in Table 1.3a, ethinylestradiol has 
a ratio much less than 1, and therefore is deemed to be of no concern. Yet ethinylestradiol 
is found at environmental concentrations at <I ng/L and has been found to be a most potent 
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endocrine disrupter, demonstrating an estrogenic potency over a thousand times greater 
than any xenobiotic mimic, and found to elicit a response in fish at concentrations as low 
as 0.1 - 0.5 ng/1 (Purdom et al., 1994, Thorpe et al. 2003). The PNEC data from Webb 
(2001) seems to be the acute toxicity value and not the chronic PNEC, for if recalculated 
using a PNEC of 0.5 ng/L, the resulting risk characterisation ratio is 10, and hence shows 
ethinylestradiol to be of great concern, highlighting how this ratio relies heavily on 
accurate data. 
The above example shows that those drugs of environmental concern are not necessarily 
those in high production, but can also be those with a high environmental persistence, that 
have a high potency or have effects on key biological functions such as reproduction (Fent 
et al., 2006). However, the vast majority of pharmaceuticals do not exhibit high acute 
ecotoxicity, in that they are not lethal to aquatic life at concentrations less than 1 mg/L. 
More than 90 % of these compounds have EC50 values greater than 1 mg/IL, and only 1% 
have EC50 values less than 0.01 mg/L (Cunningham et al., 2004). Hence, most 
pharmaceuticals are not expected to cause lethal effects, as they are found at very low 
concentrations in the environment. 
Despite this, there is a lack of knowledge about long term risks that the presence of a large 
variety of drugs may pose for non-target organisms, even though they may be found at low 
concentrations (Gros et at., 2006). However, many pharmaceuticals do not enter aquatic 
organisms easily, and even though a drug may be very potent, for the drug to cause any 
effect, it must first get into the organism (e. g. through gills of a fish), and reach the site of 
action without being metabolized. Once the drug is inside an organism, its distribution and 
consequently its effect will be dependant on factors such the KW of the drug. For example, 
if a drug is lipid soluble it would accumulate in the fat portion of an animal, and unless 
metabolized in times of stress or deprivation, it could be assumed that the drug would 
remain in the fat as an inactive compound. However, if the drug becomes partitioned into 
the blood and circulation, the plasma concentration could increase in the organism and 
come close to, or even exceed, the therapeutic level that is set in humans (Huggett et al., 
2003). Various models have been developed to predict the internal concentration of a 
pharmaceutical based on the chemical properties of a pharmaceutical and likely 
concentration in the environment, although currently very little data are available to assess 
the accuracy of these models (e. g. Huggett et al., 2003). 
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Drugs can reach non-target animals through unexpected routes, and once inside an animal 
may act unexpectedly based on what is known of the drug, leading sometimes to 
unexpected outcomes. In 2004, diclofenac, an analgesic and nonsteroidal anti- 
inflammatory pharmaceutical, caused extremely high death rates in three species of 
vultures in India and Pakistan, resulting in the death of more than 95 % of the population 
of the oriental white backed vulture (Gyps bengalensis) (Fent et al., 2006; Oaks et al. 
2004). By eating carcasses of cows which had been treated with the drug, the vultures 
ingested diclofenac and consequently died of renal failure, visceral gout and kidney 
malfunction from the accumulation of uric acid throughout the body cavity (Fent et al., 
2006). This is a very important message, as we may be unable to predict all the different 
modes of action of a pharmaceutical, which can in turn sometimes lead to very serious 
consequences. Only time and further research will show whether the case of diclofenac 
killing vultures is a unique example, or is more common than realized currently. 
Another way of evaluating the risk posed by a pharmaceutical is the acute: chronic ratio 
(ACR) of the drug. If the ACR of a drug is high, then the patient can tolerate a high dose 
without the drug causing significant side effects and therefore it could follow that if the 
ACR of a drug is high in humans, it is also likely to be high in other organisms. For 
example, pharmaceuticals that have low ACRs (e. g. lower than 10) are perhaps more likely 
to cause an acute effect in another organisms. There are very limited data available to 
assess whether or not this is true (Fent et al., 2006), although presumably the ACR for 
diclofenac is much lower for vultures than it is for cows, since vultures receive an acute 
dose from eating a small amount of carcass of a cow that had been treated with diclofenac, 
yet the cow did not die from the drug. 
1.4 Different modes of action of pharmaceuticals 
The study of pharmacodynamics describes the biochemical and physiological effects of a 
pharmaceutical on an animal, i. e. what a pharmaceutical does to an animal and how it does 
it. In order to alter an array of structures, functions and metabolic processes within the 
body of a patient, pharmaceuticals are designed to stimulate a response in humans and 
animals at low doses, and so their design is often engineered such that they have a very 
specific mode of action (Jones et al., 2004; Calamari et al., 2003). The modes of action of 
pharmaceuticals can be categorized into four recognized groupings, as shown in Figure 
I. I. 
8 
A RECEPTORS 
Enzym 
attnst. ýr .... ti 
Agonist r"art"1ý., _", ýa too &a-n. 
ýlA 
.. a M. cnOt ;- 
(e. g. beta-blockers, 17a-ethinylestradiol 
8 ION CHANNELS 
krJ o°a 
Modulators 1i "'Ased 
rý 
rnq p"nha^ I D: 
c ENZYMES 
0 
False 
substrate 
(e. g. aspirin, ketoconazole) 
D TRANSPORTERS 
norr, al . -, - 
trdrrStirt ` 
AH 
. I. 
r 
T"a 
" 
i 
-I 
-' 
(e. g. local anaesthetics, cypermethrin) 
(e. g. imipramine, omeprazole) 
Figure 1.1. The four main modes of action of pharmaceuticals. (Taken from Rang et 
al., 2003). 
Most receptors and enzymes found in humans have also been identified and characterized 
in fish and other vertebrates, showing that between mammalian and teleost systems there is 
a great deal of conservation. For example, sequence homologies for receptors and 
enzymes in fish compared to mammals range from 31 - 88% (Huggett et al., 2003). 
Therefore if a drug has a particular mode of action in humans, we would expect to see the 
equivalent mode of action in other organisms that also have the same receptor or enzyme. 
However, it is much less clear whether invertebrates exposed to a drug would respond with 
the same mode of action that occurs in humans. This is because currently there is not 
enough information available to suggest that the same biochemical and molecular 
machinery exists in these animals. 
If it can be assumed that the same mode of action will occur in humans and other classes of 
vertebrates for a particular pharmaceutical, the next logical step might be to ask whether 
the effect of a pharmaceutical occurs at the same therapeutic dose, i. e. if the concentration 
of the pharmaceutical in the blood is the same for both humans and other vertebrates, will 
the drug elicit the same effect? Unfortunately little data are available to assess this theory, 
as very few ecotoxicology studies have included measurement of the plasma concentration 
of test drugs. 
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1.5 Metabolism of pharmaceuticals 
In humans, pharmaceuticals are mostly ingested orally, adsorbed into the blood, and once 
metabolised, a variable proportion is excreted as conjugates (Ashton et al., 2004). 
Pharmacokinetic studies have indicated that drugs are mainly excreted as metabolites and 
the concentrations of the metabolites in the environment are sometimes higher than the 
parent molecule (Ternes 1998). Metabolism occurs in the liver, where phase I and/or 
phase II biotransformation pathways are involved. Phase I metabolism results in the 
production of polar, less toxic metabolites by oxidative, hydrolytic and reductive 
processes, e. g. oxidation of an alkyl side chain (Cravedi et al., 2001). Phase 11 metabolism, 
namely glucuronidation or sulphation of the parent compound or phase I metabolite, also 
achieves a more polar, less toxic product (Cravedi et al., 2001). Phase II metabolism 
predominates over other routes of metabolism in many fish, including rainbow trout 
(Coldham et al., 1998). In humans, the main enzymes involved in Phase I pathways are 
cytochrome P450 monoxygenase enzymes (P450 cytochromes), the major ones being 
CYP2C9 and CYP3A4, and the minor ones being CYP I A2, CYP2C 19 and CYP2D6 
(Gagne et al., 2006). Fish have cytochrome P4503A but not any of the CYP2C family, and 
so fish will metabolise drugs differently to humans in an attempt to eliminate them and 
prevent toxic accumulation. Since many pharmaceuticals require phase I oxidative 
metabolism to assist in their elimination, without equivalents of the human cytochromes, 
fish have the potential to bioaccumulate these drugs (Gagne et al., 2006). 
1.6 Current legislation and testing of pharmaceuticals (guidelines) 
In the U. S. A., the food and drug administration (FDA) have monitored pharmaceuticals in 
the environment since 1977 under the National Environmental Policy act of 1969. 
Regulation occurred via an environmental review process for new drug applications and 
since 1980 this has become more extensive (Jones et al., 2004). For new drug applications, 
the expected introductory concentration (EIC) of a drug into the environment over 5 years 
had to be calculated. If this concentration does not exceed 1 µg/L, then no further action 
need be taken. But if the EIC is greater than I pg/L, then a formal environmental risk 
assessment has to be carried out, which includes a tiered set of ecotoxicology tests on 
microbial, algal, invertebrate and fish species. However, if a drug had the ability to bio- 
accumulate, then chronic testing is also considered (Jones et al., 2004). 
In Europe, up until recently, a less rigorous procedure was in place, and hence for the 
majority of medicinal products and their metabolites, an environmental risk assessment has 
never been carried out (Ternes 1998). The old system (EMEA/CHMP/96268/2005) looked 
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at PEC values; if these were less than 0.01 µg/L, then no further assessment was needed. If 
the PEC value was greater than 0.01 µg/L, then the PEC/PNEC ratio was calculated and 
phase 2 testing was conducted if the ratio was greater than I (Jones et al., 2004). However, 
there was no legal requirement for this to be done, and there were many criticisms of this 
system as no terrestrial component was considered, providing physico-cheniical data such 
as rate of adsorption (Koc) or Pow or LC50 EC50 and NOEC were not mandatory, and there 
was an inclination towards acute rather than chronic effects (Jones et al., 2004; Ternes 
1998). 
However, the recent realisation that many pharmaceuticals are present in the environment 
has triggered a new proactive approach, and a proposal to include an environmental risk 
assessment in the registration procedure for medicinal products was issued (Escher et al., 
2005). In 2000 the European Medicines Evaluation Agency (EMEA) issued guidelines to 
assess the environmental impact of veterinary medicines, and draft guidelines for human 
pharmaceuticals (CPMP/SWP/4447/00) (Escher et al., 2005). The approach is a step-wise, 
two phase procedure, as shown in Table 1.4. 
Stage in Stage in risk Objective Method TEST /DATA 
regulatory assessment REQUIREMENT 
evaluation 
Phase I Pre-screening Estimation of Action limit Consumption data, 
exposure log Kow 
Phase II Screening Initial Risk Base set of aquatic 
Tier A prediction of Assessment toxicology and 
risk fate data 
Phase II Extended Substance and Risk Extended dataset 
Tier B compartment- Assessment on 
specific emission, fate and 
refinement and effects 
risk 
assessment 
Table 1.4. Summary of the EMEA guidelines in assessing the impacts of human 
pharmaceuticals in the environment (EMEA document: CPMP/SWP/4447/00) 
The first phase estimates the concentration of a drug substance in the environment by 
calculating a PECSIRFAC1: WA. rFK value. If the PECS[JRFACI WA I ER value is equal or above 
0.01 µg/L, phase 2 Tier A is carried out. In some cases, if the drug substances may affect 
the reproduction of vertebrate or lower animals at concentrations lower than 0.01 gg/L, 
then a tailored risk assessment strategy is followed that addresses the specific mode of 
action of the drug, regardless of the PEC value obtained. Phase 2 Tier A assesses the fate 
and effects of a pharmaceutical in the environment using Organization for Economic Co- 
operation and Development (OECD) protocols on three aquatic species, one plant (algal 
growth inhibition test), one invertebrate (Daphnia reproduction test), and one vertebrate 
(fish early life stage test) (Sumpter 2007). If a potential risk is detected in Phase II Tier A, 
then Phase II Tier B is conducted into extended effects analysis. 
The recent EMEA guidelines are a vast improvement on former guidelines, and data from 
Germany collected over the last ten years show that the EMEA method provides a good 
approximation of environmental concentrations (Castglioni et al., 2004). Nevertheless, it 
is unlikely that the guidelines would have highlighted the dangers posed to the 
environment from ethinylestradiol or diclofenac (Sumpter 2007). The very nature of 
pharmaceuticals is their specificity to target particular enzymes and receptors and their 
narrow scope of biological activity and potency. These properties mean that the use of 
standard acute ecotoxicology tests may not be suitable for assessing the risks caused by 
pharmaceutical compounds (Thomas & Hilton, 2004). Another criticism of the guidelines 
is that they only consider one pharmaceutical at a time and ignore the fact that some 
compounds can. cause additive or even synergistic toxic effects when in the presence of 
other compounds (Nunes et al., 2005). For example, a number of different representatives 
of the same class of pharmaceutical may be present in the environment at the same time, 
for instance a number of different ß-blockers are undoubtedly present in the environment 
simultaneously and these might have an additive effect. Then there is the issue of the 
simultaneous presence of quite different drugs, such as an estrogen and a progesterone, and 
the question here would be whether these would act synergistically or independently of 
each other. 
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1.7 ß-blockers and their use in humans 
ß-blockers are designed to target ßi- and/or ß2-adrenergic receptors ((3i-ARs, ß2-ARs) and 
currently there are at least 14 different ß-blockers that are widely used. There are two 
types of ß-blocker; selective ß-antagonists, such as atenolol, which only block (3i-ARs and 
are prescribed most commonly for treating heart conditions such as angina, arrhythmia and 
heart attacks, and non-selective ß-antagonists, such as propranolol, which block both (3j- 
and 02-ARs. In addition to treating heart problems, non-selective ß-antagonists are also 
prescribed to treat migraines, essential tremors, stress, and some, such as timolol, are used 
for the treatment of glaucoma (Lee et al., 2007). Appendix A shows the chemical 
structures of these compounds. 
1.8 Environmental concentrations of P-blockers 
Since the aquatic environment has been termed `the ultimate sink' for natural and man- 
made chemicals, it is hardly surprising that (3-blockers have been detected in the aquatic 
environment, with them and other pharmaceutical contaminants now present in surface 
waters throughout the world (Sumpter, 1998; Lindqvist et al., 2005). After patient 
administration, non-metabolised ß-blockers and their metabolites are excreted by patients. 
Due to the incomplete removal of these biologically active compounds at sewage treatment 
plants, these drugs enter our rivers primarily via sewage treatment works effluent. Table 
1.5 details the environmental concentrations of ß-blockers that have been reported in STW 
wastewater and surface waters from different studies conducted around the world. 
Propranolol has also been detected in 41 % of estuarine water samples at a maximum 
concentration of 56 ng/L and a median concentration of 13 ng/L (Thomas & Hilton, 2004). 
It can be seem from Table 1.5 that (3-blockers are frequently detected in both rivers and 
wastewater at concentrations normally in the ng/L to low pg/L range. The maximum 
concentration recorded in effluent was 950µg/L; however this was measured in samples 
obtained from India, where the particular wastewater originated primarily from about 90 
bulk drug manufacturers (Larsson et at., 2007). 
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Compound Wastewater 
concentration (ng/L) 
Surface water 
concentration (ng/L) 
Reference 
Acebutolol <10- 130 Andreozzi et al., 2003 
80 - 230 <0.8 -8 Vieno et al., 2006 
308 Lee et al., 2007 
3-14 Vieno et al., 2007 
Atenolol 3.44-4 .7 Calamari et al., 2003 
241 Calamari et al., 2003 
23 Castiglioni et al., 2004 
49.5-169.9 Zuccato et al., 2000 
360 Ternes et al., 2003 
80 - 440 <11.8 - 25 Vieno et al., 2006 
879 6- 859 Vanderford & Snyder, 
2006 
<10 - 1,150 <10 - 250 Gros et al., 2006 
17 -55 Vieno et al., 2007 
987 Lee et al., 2007 
160 - 465 Gros et al., 2007 
Betaxolol 190 28 Ternes, 1998 
Not detected Andreozzi et al., 2003 
Bisoprolol 370 2,900 Ternes, 1998 
-- ---- ---- - 24 Lee et al., 2007 
Carazolol 120 110 Ternes, 1998 
Labetalol 81 Lee et al., 2007 
Metoprolol 2,200 2,200 Ternes, 1998 
-- -- --- --- ---- 100 - 390 Andreozzi et al., 2003 
1,200 Huggett et al., 2003a 
Table 1.5. Summary of reported levels of ß-blockers in wastewater discharges and 
surface waters from studies conducted around the world. 
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Compound Wastewater 
concentration (ng/L) 
Metoprolol 
(continued) 
Nadolol 
Oxprenolol 
Propranolol 
Sotalol 
Timolol 
Surface water I Reference 
concentration (ng/L) 
1,700 ''ernes et al., 2003 
910 - 1,070 <3.8 - 116 Vieno et al., 2006 
<34 <34 Gros et al., 2006 
800,000 - 950,000 Larsson et at., 2007 
244 Lee et al., 2007 
39 - 107 Vieno et al. 2007 
360 Huggett et al., 2003a 
60 Not detected Ternes, 1998 
56 Lee et al., 2007 
<10 - 50 Andreozzi et al., 2003 
10 - 40 Ferrari et al., 2004 
290 590 Ternes, 1998 
130-180 <10-37 Hilton etal., 2003 
300 100 ENDS Report 2005 
16 - 284 <10 - 115 Ashton et al., 2004 
26 - 1900 Huggett et at,, 2003a 
180 "fernes et al., 2003 
<16 <16 Gros et al., 2006 
30 Lee et at., 2007 
<2 - 63 Gros et al., 2007 
1320 Ternes et at., 2003 
160 - 300 <3.9 - 52 Vieno et at., 2006 
<10 - 210 <10 - 70 Gros et al., 2006 
30 - 86 Vieno et al., 2007 
264 Lee et al., 2007 
70 10 Ternes, 1998 
<6 
----------------- 
Lee et al., 2007 
Table 1.5 continued. Summary of reported levels of ß-blockers in wastewater 
discharges and surface waters from studies conducted around the world. 
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1.9 Effects of ß-blockers on aquatic organisms 
From acute EC50 data it would seem that atenolol is non-toxic to aquatic organisms, whilst 
metroprolol would be classified as toxic, and propranolol as very toxic (Cleuvers 2005). 
Atenolol and metroprolol have PEC/PNEC ratios of less than l and hence the 
environmental risk based on acute studies seems to be relatively low. However, if as stated 
by Webb (2001), propranolol has a PEC/PNEC ratio of 1.16, it is classed as being of 
environmental concern. Chronic data with respect to aquatic life and ß-blockers are not 
found in abundance. Owen et al., (2007) summarises in vivo data of P-blocker activity in 
fish and chapter 3.1.3 reviews more specifically the biological effects that ß-blockers have 
been found to have on plants, bacteria, invertebrates and fish. The chronic effects of (3- 
blockers include inhibited plant growth, reduced bioluminescence and photosynthesis in 
plants and bacteria and reduced movement, growth and reproductive capability in 
invertebrates and fish. These chronic effects have been found to occur in the low to mid 
mg/L concentrations. 
1.10 Mechanisms of action of ß-blockers 
In mammals, the `fight or flight' syndrome, or a response to stress, is controlled by two 
hormones that are produced in the adrenal medulla found within the middle of the adrenal 
gland (Roberts, 1986). The two hormones, adrenaline and noradrenaline (also termed 
epinephrine and norepinephrine, respectively), are catecholamines that are synthesised in 
chromaffin cells from the amino acid tyrosine via the Blaschko pathway (Campbell, 1993; 
Reid et al., 1998). Catecholamines are charged compounds that contain a catechol moiety 
(see Figure 1.2), and amongst other things, their presence in the blood enables an 
immediate supply of energy to be released that allows for rapid contraction of major 
locomotor muscles (Lodish et al., 2000). 
16 
OH 
A 
OH H 
H: N 
CH3 
HO 
OH H 
HO N1H 
HO R 
Figure 12. A. A catechol moiety (Lodish et al., 2000). B. Chemical structure of 
adrenaline (also known as epinephrine). C. Chemical structure of nor-adrenaline (nor- 
epinephrine). The only difference from adrenaline is that the -CH3 group has been 
replaced by 11, shown in red. (www. ch. ic. ac. uk/rzepa/mim/drugs) 
Most hormones derived from amino acids are unable to pass through plasma membranes of 
their target cells and the same is true for catecholamines. Catecholamines bind to specific 
receptors, known as adrenergic receptors, that are located on the outer surface of particular 
cells. A receptor is a molecular structure within a cell, or cell membrane, that produces a 
particular physiological response in the cell after a specific ligand binds to it. G-protein 
coupled receptors (GPCRs) are membrane-bound serpentine receptors that make up one of 
the largest families of proteins in vertebrate species. Adrenergic receptors (ARs) belong to 
the large rhodopsin branch of GPCRs and are divided into two main groups: a and ß 
(Fredriksson et al., 2003). In mammals, nine different subtypes exist; aLA, a113, aID, a2A, 
a2B, a2C and ßi, 12, and ß3. Each subtype carries out a particular function and has been 
identified as a separate subtype based on the receptor's pharmacology and relative affinity 
for adrenaline and noradrenaline. In humans, ßi-ARs are found in cardiac muscle and 
when circulating catecholamines bind to these receptors, an increase in heart rate and 
contractility is observed, which consequently increases blood supply to tissues. ß2-ARs are 
present in smooth muscle cells lining the bronchial passage, and when active enable the 
relaxation of smooth muscle, allowing the bronchioles to open (Lodish et al., 2000). ß3- 
ARs in mammals have a major role in the mediation of the adipose tissue thermogenic 
response (Nickerson et al., 2003). Liver and adipose tissues also possess ß-ARs and the 
binding of catecholamines to these receptors causes the liberation of glucose and fatty 
acids to the blood within seconds (Lodish et al., 2000). ß-ARs are also found on 
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leukocytes (white blood cells) and by neuro-immune communication they are responsible 
for many stress-related immunological changes (Jozefowski & Plytycz, 1998). 
GPCRs are made up of seven a-helical transmembrane domains (TMDs), which span the 
membrane in an anti-clockwise manner, with an extracellular amino terminal and 
intracellular carboxyl terminus, as illustrated in Figure 1.3. When comparing the 
hydrophobic TMDs and membrane proximal regions of the intracellular loops of ß- 
adrenergic receptors (ß-ARs), a high degree of amino acid sequence homology between the 
different ARs can be found. These conserved areas are thought to be involved in ligand 
binding and G-protein interaction (Strosberg 1997). In situ (in a cell membrane), ß-ARs 
have a complex three-dimensional (3D) structure in which all the TMDs, and the amino 
acids in the TMDS, are close to each other (see Figure 1.3). This important structural 
feature allows the formation of ligand binding pockets, sites of phosphorylation, and 
regions of protein interaction in ß-ARs (and other GPCRs) between TMDS. For example, 
adrenaline has been predicted to interact with amino acids in TMDs III, IV, V and VI in 
the 02-AR (Freddolino et al., 2004). Hence, the ligand-binding site is not a consecutive 
row of amino acids, but an assortment of residues spread throughout the receptor. The 
ligand binding site forms a pocket and develops hydrogen bonds, salt bridges and 
hydrophobic interactions with hydroxyl and methyl groups on the ligand (Freddolino et al., 
2004). Other key residues form similar bonds to maintain the 3D structure of the receptor 
(Rezmann-Vitti et al., 2004). 
P2AR 
Figure 1.3. Three dimensional view of a 02-AR. The numbers I to 7 refer to each TMD. 
(Ranganathan, 2007). Note the ligand in the centre of the receptor. 
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The signalling pathway in ARs (and other GPCRs) is brought about by a series of 
biochemical changes within the cell, which result in a physiological change (see Figure 
1.4). The classical signal transduction pathway involves intracellular heterotrimeric 
guanine proteins, (G-proteins) that are made up of 3 subunits; Ga, G(3 and Gy, of which the 
Ga- subunit has three different subtypes: Gaq-, to stimulate phospholipase C; Gas-, and 
Gai- to stimulate or inhibit adenylyl cyclase, respectively (Fitzgerald et al., 1999). When 
an endogenous ligand such as adrenaline or noradrenaline binds to a ß-AR, the 
transformation of GTP to GDP + Pi occurs, causing the stimulatory part of G-protein (Gas) 
to dissociate from the Gßry subunit, and interact with the enzyme adenylyl cyclase. The 
interaction triggers the synthesis of cAMP, by hydrolysis of ATP, and switches the 
receptor to an active state. However, the conversion of ATP also hydrolyses GTP in the 
Gas- protein back to GDP, and hence the synthesis of cAMP only lasts for a few seconds. 
The receptor now returns to an inactive state and the stimulatory Gas-protein moves back 
to the remaining Gßy subunit. 
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Figure 1.4. Schematic representation of the signal transduction pathway in an adrenergic 
receptor. (A) 2D diagram of a GPCR, based on the model for the rhodopsin receptor. 
(B) Adrenergic receptor in a basal state with GDP bound to Ga-s. (C) Upon a ligand 
binding to the receptor, GTP replaces GDP and Ga-s dissociates from the Gß-y complex 
and binds to adenylyl cyclase, resulting in the synthesis of cAMP. Consequently, 
intracellular concentrations of cAMP increase and activate proteins, such as protein 
kinase A (PKA), that induce a physiological response. 
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High intracellular concentrations of cAMP, ranging from tens of thousands, to millions, of 
cAMP molecules per cell are required to trigger cellular responses (Lodish et at., 2000). 
Only a few thousand (3-ARs are present on the outside of one cell and hence a method of 
amplification is needed to produce the required concentration of cAMP molecules. This 
happens in two steps; firstly, each GPCR complex can switch up to a hundred Gas 
molecules to an active state, and secondly, several hundred molecules of cAMP can be 
produced whilst adenylyl cyclase is activated, before the dissociation of GTP from the 
Gas-protein (Lodish et al., 2000). This enables a significantly increased intracellular 
concentration of the 2°d messenger, cAMP, to trigger dose-dependent changes in the cell. 
For example, in a stressful situation, noradrenaline would be released from the adrenal 
gland into the blood to bind to 131-ARs on cardiac myocyte cell surfaces. Subsequent 
activation of the Gas-protein would result in an increased concentration of cAMP inside 
the cardiac muscle cells, which would in turn activate protein kinase A. This would 
phosphorylate particular proteins, to influence cardiac Ca 2-' channels and result in an 
increase in cardiac output (Ellis & Frielle, 1999). 
When an agonist is lost from the receptor, homologous desensitisation of ßi- and (32-ARs 
occurs. The pathway is shown in Figure 1.5. Phosphorylation of the receptor Gay subunit 
by second messenger independent G-protein-coupled-receptor-kinases (GRKs), and 
subsequent binding to inhibitory ß-arrestin isoforms, prevents further coupling between the 
receptor and G-protein. The phosphorylated, (3-arrestin-bound, uncoupled receptor is then 
moved from the plasma membrane by internalisation and bound to clathrin and adapter 
protein 2 (AP2). It is then recycled via clathrin-coated vesicles, de-phosphorylated and 
either recycled back to the cell surface (re-sensitisation) or degraded in the lysosomes 
(Metaye et al., 2005; Mayor et al., 1998). 
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Figure 1.5. Summary of the endocytotic pathway, leading to recycling or degradation of 
ARs . 
(A) GRK binds to the Gs-(3y/receptor complex and phosphorylates the receptor, 
which promotes binding of ß-arrestin. ß-arrestin acts as an intermediary protein and 
binds the receptor complex to clathrin coated pits via clathrin and AP2 proteins. (B) In 
the presence of GTPase dynamin, endocytic vesicles are formed. The receptor complex 
then undergoes resensitization, where it is recycled back to the membrane surface, or it 
is trafficked to lysosomes to be degraded by proteases. 
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Heterologous desensitisation occurs regardless of whether an agonist is bound to the 
receptor, to cause a general decline in receptor responsiveness. Second messenger 
generating systems activate enzymes, such as cAMP dependent protein kinase (PKA) or 
protein kinase C (PKC), to result in phophorylation of multiple proteins and the 
desensitisation of ß-AR activity (Guimond et al., 2005; Freedman et al., 1995). However, 
heterologous desensitisation has also been discovered to be a route by which different ARs 
modulate activity via molecular `cross talk'; for example, a, -ARs can desensitise and 
regulate ß2-ARs and affect cardiac contractile responses. This pathway is brought about by 
al-AR coupling to inositide-specific phospholipases via Gaq-proteins, to activate 2°d 
messenger pathways of inositol-triphosphate and diacylgylcerol, which in turn modulate 
intracellular concentrations of Caz+ and PKC respectively, to lead to heterologous 
desensitisation of n-AR activity (Guimond et al., 2005). 
Additional mechanisms of (3I- and p2-AR signalling also occur via the mediation of distinct 
cytoplasmic proteins and trans-membrane proteins, e. g. GRKs, PKA and ß-arrestins (Hall, 
2004; Tsao & Zastrow, 2001). Further interactions of (3i- and ßz-ARs also include receptor 
specific proteins, such as endophilin-1, post-synaptic density proteins, membrane 
associated guanylate kinase-like inverted-2 (MAGI-2) and cyclic nucleotide Ras guanine 
nucleotide exchange factor (CNRasGEF), to mention but a few. These proteins have very 
particular functional effects and they exhibit distinct tissue-specific patterns of expression. 
These proteins help contribute to physiological differences between different ß-AR 
subtypes and tissue specific ß-AR function (see Hall, 2004). 
1.11 ß-Adrenergic receptors in teleost fish 
As in mammals, the secretion of catecholamines in fish occurs when they are subject to 
environmental or physiological stressors, which elicit physiological changes that minimise 
the detrimental effects of stress on physiological function (Perry & Bernier, 1999). Such 
stressors can include air exposure, environmental hypoxia or hypercapnia, metabolic 
acidosis, exercise, handling, physical disturbance, anaemia, anaesthesia or hypotension. 
However, not all stressful situations in fish have been found to elicit a catecholamine 
response. For example, rainbow trout will not release catecholamines in response to mild 
or moderate environmental hypoxia, sustained aerobic exercise or to a 20-25 % reduction 
in blood pressure (Perry & Bernier, 1999). 
Fish, like mammals, also possess a and ß adrenergic receptors and the transduction 
pathway for fish ß-ARs seems to resemble the one present in mammalian cells, whereby 
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the occupation of a GPCR receptor causes stimulation of adenylyl cyclase and the 
synthesis of cAMP (Fabbri et al., 1998). On activation of the afferent limb of the humoral 
adrenergic stress response (i. e. the secretion of catecholamines), the efferent limb (i. e. the 
physiological reactions elicited by the catecholamines) responds by modulating 
cardiovascular and respiratory function to maintain an adequate supply of oxygen to the 
blood and tissues, and mobilization of energy stores, such as glucose and lipids, to provide 
for the increased energy demands (Reid et al., 1998). 
The storage of catecholamines is different in fish. Catecholamines are still produced by 
chromaffin cells, but in teleosts these are primarily located in the walls of the posterior 
cardinal vein in the region of the head kidney and in close association with lymphoid tissue 
of the kidneys, where they have been observed to exist singularly or in clusters (Perry & 
Bernier, 1999; Reid et al., 1998). However, it must be noted that in less evolutionary 
advanced fish, the location of chrornaffin cells differs again. 
Adrenaline and noradrenaline are stored in separate types of chromaffin cells; those storing 
adrenaline contain spherical or elongated granules (30 nm diam. ), whilst chromaffin cells 
storing noradrenaline contain spherical, electron dense granules (200 nm diam. ) (Reid et 
al., 1998). Levels of catecholamine storage also differ between different groups and 
species of fish, and one particular catecholamine can be stored at greater concentrations 
than another; for example, in teleosts, adrenaline is the predominant catecholamine that is 
stored (Reid et al., 1998). However, levels of catecholamine storage can also be affected 
by pollution, nutritive and/or physical stress, hormonal inference and anoxia (Reid et al., 
1998). 
In teleost fish, three subtypes of ß-AR receptor exist (ß,, ß2 and ß3), as they do in 
mammals, with a further subdivision of (33-AR into ß3a and 133h. ß, -AR has been reported to 
be present on red blood cells of many fish species and is associated with the Na 4/H+ 
antiporter to increase intracellular pH and allow greater affinity of haemoglobin for oxygen 
and consequently increased oxygen transport in the blood (Fabbri et al., 1998). In addition 
to this, 01-AR is also reported to be present on the hepatic membrane of coho salmon, and 
on activation, increased cAMP levels activate triacylgycerol lipase, resulting in glycerol 
and free fatty acid release (Fabbri et al., 1998). 
The most characterised ß-AR receptor in fish is the ß2-AR. In the channel catfish, the 
primary ß-AR receptor present on the membranes of the liver, head kidney leukocytes and 
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spleen leukocytes is the (32-AR, whilst in rainbow trout, 02-AR, a 409 amino acid protein, is 
highly expressed in the liver and red and white muscle, with lower expression levels in the 
gills, heart, kidney and spleen (Nickerson et al., 2001; Finkenbine et al., 2002). When 
catecholamines are released into the blood, the function of liver ß2-AR in rainbow trout 
and other species of teleosts has been found to be the mobilisation of hepatic glycogen 
(Nickerson et al., 2001). 
Through phylogenetic relationships, it has been suggested that teleost (33-ARs are 
homologous to mammalian ß3-ARs. However, their roles are completely different, for in 
mammals these receptors mediate the adipose tissue thermogenic response, a response that 
fish are unlikely to have (Nickerson et al., 2003). ß3a-AR mRNA has been found to be 
highly expressed in the gill and heart of rainbow trout, whilst evidence of the presence of 
03b-AR has been found on red blood cells (Nickerson et al., 2003). Strong evidence exists 
that the activation of ß3b-AR by catecholamines, predominantly noradrenaline, results in 
an increase in the oxygen-binding affinity of red blood cells (Nickerson et al., 2003). The 
resulting rise in cAMP from the activation of the red blood cell ß3b-AR, results in 
activation of protein kinase A that consequently activates the ß-Na+/H+ exchanger by 
phosphorylation. H+ then extrudes from the red blood cell in exchange from Na+ and the 
increase in alkalisation/pH increases the affinity of haemoglobin for oxygen, and hence 
increases oxygen transport in the blood (Nickerson et al., 2003). Following adrenergic 
stimulation, the blood oxygen capacity was found to increase two-fold within minutes 
(Wang et al., 1999). The two (33-ARs in rainbow trout have been found to have an 84 % 
degree of sequence conservation, both at the nucleotide and amino-acid level, with ß3a-AR 
encoding a protein of 429 amino acids and ß3b encoding one for 477 amino acids 
(Nickerson et al., 2003). 
ß-ARs have also been found on white blood cells (leukocytes) in fish (with phagocytic, 
adherent cells bearing more receptors than lymphocytes), and in the special sphincter in 
puffer fish (Ng et al., 1973; Jozefowski & Plytycz, 1998). However, (3-AR subtypes have 
been found to be specific to species, tissues and the function of the tissues, but there is 
little explanation as to why the high diversity of adrenergic receptor systems exists in 
teleosts (Fabbri et al., 1998). The sensitivity of receptors also differs between fish species; 
for instance, adrenaline is 100 times more effective in stimulating carp liver pieces than 
noradrenaline is, whereas chinook salmon liver pieces responded equally well to both 
catecholamines (Fabbri et al., 1998). Temperature can also effect adrenergic sensitivity 
and density of ß-ARs; for example, a heart trout acclimated at 8 °C is more sensitive to 
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adrenaline than one acclimated at 18 °C, due to the cardiac cells at 8 °C having a greater 
cell surface adrenoreceptor population (Keen et al., 1993). 
Almost all fish tissue is potentially able to remove catecholamines from the blood via two 
deactivation enzymes; monoamine oxidase and catechol-o-methyl transferase (Fabbri et 
al., 1998). Once circulating catecholamines have been deactivated, the blood level of 
catecholamines returns to the resting concentration of between I to 10 nM, which is a 100- 
fold reduction from circulating catecholamine concentrations occuring during periods of 
acute stress (Fabbri et al., 1998). 
1.12 Differences between ß-ARs of different species 
A lot of research and information has been gathered with regard to the structure and 
genetics of mammalian ß-ARs, but few studies have dealt with ß-ARs of non-mammalian 
species. The completion of the zebrafish (Danio rerio) and pufferfish (Takifugu rubripes 
and Teiraodon nigroviridis) genomes has allowed ß-ARs to be identified in these species 
of fish, showing that ß-ARs in fish and humans demonstrate a high sequence homology. In 
humans, the sequences of (3j- and 32-ARs are 54% identical (71% when only TMDs are 
compared). However, the efficacy (the inherent ability of the receptor to produce a signal) 
of ßi-ARs in humans is six times lower than that of ß2-ARs in transducing a given receptor 
occupancy signal, yet the molecular basis for this difference is poorly understood 
(Birnbaumer et al., 1994; Frielle et al., 1987). It seems that changes in efficacy may occur 
as a consequence of relatively small molecular differences within a single species, let alone 
when data are extrapolated across species. 
The specificity of ß-ARs for adrenaline and noradrenaline, and other agonist and 
antagonists, is a feature that distinguishes each ß-AR subtype. ß-ARs in the goldfish head 
kidney share a similar affinity for adrenaline and noradrenaline to mammalian ß-ARs 
(Jozefowski & Plytyczt, 1998). However, in rainbow trout (Oncorhynchus mykiss), the 
ß3b-AR shows a high affinity for propranolol and nadolol (non-selective ß-AR antagonists), 
which is not consistent with mammalian 03-ARs, which show low affinities for these 
compounds (Nickerson et al., 2003). Currently, not enough is known about the 
specificities of fish ARs to know whether they will be similar or different from their 
mammalian counterparts. 
Physiological endpoints between humans and fish P-ARs also differ. For example, in 
mammals, (3l-, (32- and ß3-ARs are all found to stimulate lipolysis in fat cells. However in 
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carp, (31-ARs inhibit lipolysis, whereas ßz-ARs stimulate it (Vianen et al., 2004). Hence, 
the signal transduction of (3-ARs may be similar between mammals and teleost fish, yet the 
physiological outcomes may be completely different. Small structural differences may 
account for some of the above differences, such as the lack of phosphorylation sites within 
G-protein binding domains and the finding of three potential phosphorylation sites in the 
carboxyl terminus in rainbow trout (32-ARs (Nickerson et al., 2001). These sites play an 
essential role in desensitisation pathways in mammals, and the change or removal of them 
has unknown consequences. 
1.13 Evolution of ß-ARs 
It is most likely that all ARs arose from a common gene, and despite 350 million years of 
evolution, overall ligand-binding character, order of potency and efficacy of agonists has 
been found to be highly conserved between zebrafish and human a2- adrenergic receptors 
(a2-AR) (Ruuskanen et al., 2005). However, gene duplication, in particular complete 
genome duplication in the bony fish lineage after the split from mammals (leading to some, 
but not all, families of fish being tetrapoloid), and amino-acid polymorphisms, may 
account for some of the differences between teleost and mammalian ß-ARs (Yang-Feng et 
al., 1990). The abundance of trace-amine receptors in zebrafish (Danio rerio) compared to 
Japanese puffer fish (Takifugu rubripes) is an example of how protein evolution can 
proceed at a rapid rate (Gloriam et al., 2005). Hence, despite transduction pathways for 
fish ß-ARs seeming to resemble, in all details, the ones present in mammalian cells (Fabbri 
et al. 1998), it has to be considered that the pharmacodynamic activities of ß-blockers, and 
their metabolites, could induce effects that are totally different, or even if similar, more 
potent, than the original therapeutic actions that were intended for humans (Laville et al., 
2004). 
1.14 Aims and objectives 
The general aim of my research was to improve the understanding of the consequences to 
fish of the presence of human pharmaceuticals in the aquatic environment. I chose to focus 
on ß-blockers, mainly because it is well documented that these are present in the aquatic 
environment. If ß-blockers do affect wild fish, they are most likely to do so via the AR 
system of the fish. Hence, basing my research on the fathead minnow (Pimephales 
promelas), because of its widespread use in ecotoxicology, I investigated several of the key 
issues that need to be resolved if any possible effects of ß-blockers on fish are to be 
understood. Specifically, to demonstrate that fathead minnows are capable of responding 
to ß-blockers in the expected manner, I characterised two of their ß-ARs, namely (31- and 
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P2-AR. Then, as an aid in indicating what physiological processes these ß-ARs regulate 
(and hence what effects n-blockers might cause), I determined the tissue location of these 
receptors. Finally, to begin the process of determining the possible effects of n-blockers on 
fish, I investigated whether the (3-blocker propranolol affected reproduction. 
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Chapter 2 ßl- and ß2-adrenergic receptors in fathead minnow 
2.1 Introduction 
ß-adrenergic receptors (ß-ARs) have been found in many species of organism from 
mammals to plants. Whether their functions are the same in each organism it is not yet 
known. However, the completion and annotation of genome databases has enabled 
bioinformaticists to identify ß-ARs in a range of organisms. 
2.1.1 The genetic code 
An organism develops by replicating information that is held within the nucleic acids of 
genes. Nucleic acids are found in all living cells and viruses and the two main types are 
deoxyribonucleic acid (DNA), which is found in the nucleus of cells, and ribonucleic acid 
(RNA), found mostly in the cytoplasm (Roberts, 1986). The building blocks of nucleic 
acids are known as nucleotides and consist of a 5-carbon sugar (deoxyribose in DNA and 
ribose in RNA), phosphoric acid and an organic base. There are four organic bases, 
(adenine (A), guanine (G), cytosine (C) and thymine (T), which is replaced by uracil (U) in 
RNA) and the organic base determines the name of the nucleotide. It is the sequence of the 
bases that carries the information which determines an organism's development. 
DNA consists of two parallel polynucleotide chains and these are held together by pairs of 
bases that are linked by hydrogen bonds. The pyrimidine bases, T and C, have a single 
hexagonal ring and join to the larger purine bases, A and G, which have a hexagonal ring 
joined to a pentagonal ring. However, the only possible pairings are A to T via two 
hydrogen bonds, and C to G via three hydrogen bonds (see Figure 2.1). Other variations of 
bonding are not possible because either the bases repel each other, or the pattern of 
hydrogen donors and acceptors does not correspond. 
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Figure 2.1. Chemical structure of nucleotide bases showing the hydrogen bonds 
between adenine and thymine, and between cytosine and guanine. 
(www. ncc. gmu. edu/dna/three. htm) 
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The two strands of polynucleotide chains run in opposite directions and are twisted to form 
a double helix. This model was proposed by James Watson and Francis Crick in 1953. 
The 5' and 3' ends of the polynucleotide strand are identified with regard to which carbon 
in the sugar is attached to the phosphate group, e. g. carbon 5 or 3 of the sugar, respectively. 
One strand runs in the 5' to 3' direction, this is known as sense strand, and the other 
complimentary strand runs in the 3' to 5' direction, and this is known as the anti-sense 
strand. 
A triplet of bases, known as a codon, codes for a particular amino acid and is the basis for 
the genetic code. Table 2.1 details the 20 amino acids and the codons that are required to 
produce them in DNA (In RNA the same code applies except thymine is replaced by 
uracil). As shown, most amino acids can be coded for by more than one codon, e. g. 
leucine and serine. In order to make proteins, DNA instructs the cell which amino acids 
have to be put together in which order for the protein to be synthesised. 
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First Second Letter Third 
Letter T C A G Letter 
TTT Phenylalanine TCT Serine TAT Tyrosine TGT Cysteine T 
TTC (Phe, F) TCC (Ser, S) TAC (Tyr, Y) TGC (Cys, C) C, 
T 
TTA TCA TAA TGA Stop A Leucine Serine Stop 
TTG (Leu, L) TCG (Ser, S) TAC TGG I'yptophan G 
(Trp, W) 
CTT Leucine CCT Proline CAT Histidine CGT Arginine T 
CTC (Leu, L) CCC (Pro, P) CAC (His, H) CGC (Arg, R) C 
C 
CTA Leucine CCA Proline CAA Glutamine CGA Arginine A 
CTG (Leu, L) CCG (Pro, P) CAG (Gin, Q) CGG (Arg, R) G 
ATT Isoleucine ACT Threonine AAT Asparagine AGT Serine T 
ATC (lie, I) ACC (Thr, T) AAC (Asn, N) AGC (Ser, S) C 
A Isoleucine ATA 
(l le I) 
ACA Threonine AAA Lysine AGA Arginine A 
(Thr, T) (Lys, K) (Arg, R) 
ATG Methionine 1CG AAG AGG G 
GTT Valine GCT Alanine GAT Aspartic GGT Glycine T 
GTC (Val, V) GCC (Ala, A) GAC 
acid (Asp, 
D) GGC 
(Gly, G) C 
G 
GTA Valine GCA Alanine GAA Glutamic GGA Glycine A 
GTG (Val, V) GCG (Ala, A) GAG 
acid (Glu, 
E) GGG 
(Gly, G) G 
Table 2.1. A table depicting the amino acids specified by each codon of three 
nucleotides. The abbreviation of each amino acid with its coded letter are in brackets. 
The bold letters refer to nucleotides. ATG codes for the start codon, and TAA, TAG or 
TGA codes for the stop codon. Adapted from www. people. virginia. edu 
2.1.2 Gene expression 
Gene expression is the process whereby information encoded in a particular gene is 
decoded to generate a protein (Lodish et al., 2000). Proteins are synthesised in ribosomes 
which are found in the cytoplasm. In order to transfer the information stored in DNA from 
the nucleus across to the cytoplasm, another molecule, messenger RNA (mRNA), is made, 
which consists of only one strand of polynucleotides. In this process an enzyme, RNA 
polymerase II, splits the double stranded DNA apart at the appropriate point. This is the 
most important step in transcription, for it determines which genes are expressed and how 
much mRNA and subsequently proteins are produced (Lodish et al., 2000). The DNA 
sequence that specifies where RNA polymerase II starts this process is known as a 
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promoter, and transcription from the promoter is controlled by DNA binding proteins 
named transcription factors (Lodish et al., 2000). 
The anti-sense strand (3' to 5') acts as a template for the formation of mRNA. Free RNA 
molecules, which can only be added to the 3' end of the polymer, align themselves to pair 
with their complimentary base, and in this way the mRNA strand elongates in the 5' to 3' 
direction. Once assembled, the mRNA, which has the same sequence as the sense strand 
of DNA, peels itself off from the template and the DNA strands re-join. This whole 
process is known as transcription. Immediately after transcription, a poly(A) tail is added 
to the cleaved 3' end of the mRNA, a process catalyzed by polyadenylate polymerase. The 
function of the poly (A) tail is to protect the mRNA molecule from exonucleases, for the 
export of mRNA from the nucleus, and for translation (www. en. wikipedia. org). Nearly all 
mRNAs contain the sequence AAUAAA, 10 - 35 nucleotides upstream from the poly (A) 
tail, which enables the poly(A) tail to be added. 
Once the mRNA is in the cytoplasm, it attaches itself to the surface of a ribosome, which 
provides a suitable surface for the attachment of mRNA and protein assembly. The protein 
is formed via transfer RNA (tRNA), which reads the information from the mRNA and 
translates the message into amino acids. tRNAs are clover-leaf shaped and have three 
unpaired bases projecting from them; these line up to the appropriate complimentary bases 
in the mRNA. Attached to the other end of the tRNA is the correct amino acid which 
codes for the codon sequence of the unpaired bases. When the tRNAs are lined up, peptide 
bonds form between adjacent amino acids, after which the polypeptide chain breaks away 
from the tRNA and a protein is formed. 
A third kind of RNA, not described so far, is ribosomal RNA (rRNA). This type of RNA 
is synthesised in the nucleolus by RNA polymerase I and makes up the central part of the 
ribosome. Recently a fourth kind of RNA has also been discovered. This type of RNA, 
known as micro RNAs, are short lengths of RNA that control gene transcription through 
silencing genes (Grophans & Filipowicz, 2008). 
Not all nucleotides code for amino acids. At the start and end of mRNA there are two 
untranslated regions (UTR). Within the 5' UTR there is a component known as the DNA 
promoter region, otherwise known as the initiation site, or TATA box, (5' Y-Y-A+'-N- 
T/A-Y-Y-Y 3'), where Y codes for C or T, which is found 25 -- 30 bases from the start 
codon. The TATA sequence acts as a promoter to position RNA polymerase 11 for 
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transcription initiation (Lodish et al., 2000). Another nucleotide sequence in the 5' UTR 
includes the ribosomal binding site (RBS; also known as the Kozak sequence in 
eukaryotes). The RBS is the region where the ribosome binds to an mRNA to begin the 
translation of the mRNA into a protein (Oiveira et at.. 2004). This series of purinc rich 
hasc, ý (_A and (; ) are located roughly I- 14 bases from the beginning of the gene. and their 
consensus sequence is AGGAG. However, the RBS sequence is highly degenerative, and 
may have a great deal of variation with respect to its location and its sequence. 
Other specific nucleotide sequences include start and stop codons (see Table 2.1 for their 
coding). Most start codons encode for the amino acid methionine, but stop codons are 
known as nonsense codons. This is because they cannot be translated because they do not 
code for an amino acid, instead their purpose is to act as a signal to release the protein from 
the ribosome during translation. 
2.1.3 Topology 
Topology refers to the number of times a membrane protein spans the membrane, and the 
orientation of these membrane-spanning segments, all of which can be determined from a 
receptor sequence. For example, GPCRs and other serpentine receptors characteristically 
span the lipid bilayer of the cell membrane in seven a-helical trans-membrane domains 
(TMDs) (see Figure 2.2). Each TMI) contains 20 to 25 hydrophobic amino acids and each 
particular TMD shows significant sequence homology to other corresponding TMDs 
within the GPCR gene family, e. g. The first TMD is similar in all classes GPCRs. The 
amino acid terminus of ß-ARs is extracellular and the carboxy terminus is intracellular, 
whilst the 3 `d cytoplasmic loop is characteristically longer than the 1St and 2 "a (Strosberg, 
1997; Frielle et al., 1987). 
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Figure 2.2. Diagrammatic representation of a ß-AR in a cell membrane, showing the 
cytoplasmic loops (( L) and the trans-membrane domains (TN11)). 
2.1.4 GPCR motifs 
In a similar way that start and stop codons are specific nucleotide sequences that are found 
in all genes, GPCRs also have conserved short nucleotide sequences that have specific 
functions and these sequences can be used to identify, characterise and distinguish GPCRs 
from each other and other genes. These motifs are often sequences that ensure the three 
dimensional (3D) structure and functional properties of GPCRs are conserved and some 
molecular sequences are preserved because of the ligand. Adrenergic ligands are small 
positively charged amines and in human ßl -, 02- and 03-ARs, two asparagine residues are 
found in analogous positions and these are thought to act as counterions in order to 
maintain electric neutrality (Devic et al., 1997). 
Because of the (3D) structure of GPCRs, the ligands bind with amino acid residues dotted 
throughout the molecular sequence. At least four of the seven TMDs are essential for 
ligand binding (Strosberg, 1997; Libert et al., 1989). For instance, in human ß2-ARs, 
adrenaline binds with aspartic acid in TMD III by the formation of a salt bridge (seen as 
part of the `DRY' motif), three serine residues in TMD V and asparagine in TMD VI via 
hydrogen bonds, isoleucine in TMD IV, and with both valine in TMD III and phenylanine 
in TMD VI by van der Waals interactions with the ligand (Freddolino et al., 2004; Cao et 
al., 1998). These residues (especially the serine residues in TMD V) are especially 
important for binding ligands, and the efficacy with which the ligand binds may be due to 
the ligand's orientation in the ligand binding pocket which affects the different affinities 
(strengths) between the ligand and the receptor. Subtle changes in the conformation of 
these bonds consequently provide weaker or stronger interactions between receptors and 
different ligands (Freddolino et al., 2004). 
A region in ßl-ARs that is highly conserved between ß1-ARs is the start of the 
cytoplasmic COOH tail. This region of eleven amino acids (RSPDFRKAFKR) is 
considered important for receptor coupling (Mason et al., 1999). Another distinguishing 
feature of ß-ARs are the proline rich residues in the third cytoplasmic loop and it is 
possible that the cytoplasmic loops are also involved in interactions with the Gs part of the 
G-protein (Freille et al., 1987). 
N-linked glycosylation is often the principle post-translational chemical modification to 
most proteins. The process, which takes place in the rough endo-reticulum (ER) of a cell, 
results in the addition of saccharides (sugars) to proteins. Some proteins require the 
addition of an oligosaccharide in order to fold properly and to maintain stability (Lodish et 
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al., 2000). One agreed site for N-linked glycosylation in GPCRs is the asparagine residue 
in the NH2 terminal region before TMD I (Cao et al., 1998; Frielle et al., 1987). 
Phosphorylation is the process whereby a phosphate group is added to an amino acid in the 
presence of a protein kinase receptor, and this process is often crucial in regulating the 
activity of many cellular responses to an external signal (Lodish et al., 2000). There are 
consensus cAMP-dependent kinase phosphorylation sites in GPCRs which include serine 
and threonine residues in the 3rd cytoplasmic loop (between TMD V and TMD VI) and the 
COOH terminal region (after TMD VII), which may mediate receptor desensitization 
through phosphorylation (Machida et al., 1990; Emorine et al., 1989). 
Disulfide bonds form covalent bonds between sulfhydril groups on two cysteine residues in 
the same or different polypeptide chains to help stabilize the tertiary and quaternary 
structure of many proteins (Lodish et al., 2000). A lot of GPCRs have conserved cysteine 
residues. These are believed to create a disulphide bridge between the loops to help keep 
the structural integrity of the protein (Cao et al., 1998). 
2.1.5 ß-Adrenergic receptors in mammals 
ARs are found in many species and a blast search (www. ncbi. nlm. nih. gov) reveals that 
they have been characterised in many mammals. Table 2.2 shows the species for which ß- 
ARs have been identified. 
Mammal Latin name ß-AR subtype 
Human Homo sapiens P15 Ni P3 
Domestic cat Felius calus 13I , 
(32, ß3 
Rhesus monkey Macaca mulall ßi, ß21 ß3 
Dog Canis familiaris ß1, ß2, ß3 
Brown rat Rattus norvegicus P15 ß29 ß3 
Gorilla Gorilla gorilla ß2, ß3 
Chimpanzee Pan troglodytes ß2,03 
Domesticated cattle Bos taurus Pi, ß2, ß3 
Mouse Mus musculus Pig 029 ß3 
Cotton top tamarin Saguinus oedipus ß2g ß3 
Table 2.2. A list of mammals that have had 13-ARs identified in their genome. 
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In the mammals named above, all three ß-ARs have been characterised in most animals. 
However, just because the 01-AR has not been identified in the gorilla, chimpanzee or 
tamarin, does not mean that these animals don't have these receptors. It is more likely that 
they are present, but have not been annotated or characterised. 
2.1.6 ß-Adrenergic receptors in fish 
Table 2.3 details the ß-ARs found in fish. One noticeable difference between the fish and 
the mammalian data are that fish appear to have two subtypes of the p3-AR (03a- and (33b- 
AR), whereas mammals only have one subtype. The division of the fish ß3-AR was 
initiated by Nickerson et al. (2003). In this paper it is stated that the two novel 3-ARs that 
had been discovered were both homologs of the mammalian ß3-AR (52.0 and 52.8 % 
homology, respectively). However, due to the clearly different expression patterns of these 
two genes, and the 84% identity between them, they were considered two subtypes, namely 
ß3a- and ß3b-AR. 
Fish species Latin name ß-AR subtype Source 
Zebra fish (Danio rerio) 131, (32, ß3, ß3b www. ncbi. nlm. nih. gov 
Rainbow trout (Oncorhynchus 
mykiss) 
ß2, ß3a, ß3b Nickerson et at., 
2001; 2003 
Tiger puffer fish (Takifugu rubripes) 131, ß2 www. Ensembl. org 
Spotted green 
puffer fish 
(Tetraodon 
nigroviridis) 
(31, (32 www. genoscope. cns. fr 
Stickleback Gasterosteus 
aculeatus 
ß 1, (33 www. ensembl. org/ 
Hagfish (Myxine glutinosa) ß www. ncbi. nlm. nih. gov 
Marine lamprey (Petromyzon 
marinus) 
(3 www. ncbi. nlm. nih. gov 
Catfish (Ictalurus 
punciatus) 
(31 (fragment), (32 www. ncbi. nlm. nih. gov 
Table 2.3. A list of the ß-ARs reported in various species of fish. 
These data in Table 2.3 were found from a variety of sources and sometimes initial results 
could not be taken at face value. For instance, with respect to annotation of the stickleback 
ß-ARs, a search under `beta adrenergic receptor' of the stickleback genome at 
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www. ensemble. org provides eight matches and identifies each sequence with an 
annotation. However, on comparison of these matched sequences to 3-ARs in zebrafish, 
sequence identity analysis suggests that some of the annotations are incorrect, due to the 
extremely low overall sequence similarity and lack of identity in TMD regions. Analysis 
suggest and that only one of the annotated ßl -ARs has its identity predicted correctly, and 
that another of the named (31-ARs is in fact a ß3-AR, as detailed in Table 2.4. 
ß-AR as 
assigned by 
ENSEMBL 
ENSEMBL gene ID Subtype of 
zebrafish ß-AR to 
which each 
ENSEMBL gene 
was compared 
% 
Identity 
Proposed 
ß-AR 
subtype 
ßl-AR ENSGACG00000006578 1-AR 76 1-AR 
ENSGACGO0000005437 1-AR 2 - 
ENSGACG0000000781 1 01-AR 2 - 
ENSGA0000000011022 1-AR 48 - 
ENSGA0000000011022 2-AR 45 - 
ENSGA0000000011022 ß3-AR 65 ß3-AR 
(XM 681440) 
p2-AR ENSGA0000000011022 03b-AR 49 - 
(XM 696013) 
P3-AR ENSGACG00000006598 3-AR 6 - 
ENSGAC000000015178 ß3-AR 3 - 
Table 2.4. A comparison of putative stickleback ß-ARs as annotated by ENSEMBL, 
compared to authentic zebrafish 13-ARs. The % identity is the result of the pair wise 
comparison between the Ensemble stickleback gene and a particular zebrafish gene. 
Zebrafish is another species that required some analysis to fully understand the (3-AR 
sequences given in the annotation. From the NCBI database, two ß2-ARs have been 
annotated for zebrafish, one has been placed on chromosome 14 (Accession number 
XM_689100) and appears to begin half way through the first TMD, as shown in Figure 
2.3, and the second sequence has not yet been placed on a chromosome (Accession 
number XM_695628). 
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XM689100 ---- ------------------------------------------------- 1 
XM 695628 MEGDNTLITENTSLYMNISAGLNASSPVSLSVSEYSDAEVVLISILIGILVLVIVFGNAL 60 
XM689100 VITAISRFQRLQNVTNCFITSLACADLVMGLVVIPFCALYMVGDTWHFGHFLCDFWTATD 61 
XM_695628 VISAIVRFQRLQTVTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCEFWTATD 120 
XM689100 VLCVTASIETLCVIAMDRYIAITSPFRYQSLLTKNRARFIVLMVWVIAGLVSYLPIHMEW 121 
XM695628 VLCVTASIETLCVIALDRYIAIMWPLRYQSMLTKRKACGMVIGVWAVAALISFLPIHMEW 180 
XM 689100 WISTDNETLCCYNNTYCCEFDITYSYAIVSSIISFYIPLVIMVFVYSRVFQEARKQLKKI 181 
XM695628 WVSEDPEALSCLEEPTCCDFNTNAAYAVPSSIISFYIPLVIMAFVYSRVFQEARRQLQKI 240 
XM689100 NKTEGRFHAQKSNSRNQDVANNHSEMRSTKKAKFYLKEHKALKTLGIIMGVFTLCWLPFF 241 
XM 695628 DRIEGRIRTQSLSTQEGNEIKN------- RRTKFCMKDHKALKTLGIIMGTFTMCWLPFF 293 
XM_689100 VLNVIP---KGSVDIWTFRILNWIGYANSAFNPLIYCRSPDFRYAFKEILCLNRSRYPNV 298 
XM 695628 VLNVVAAIWKMDNIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCWRPSHLPST 353 
XM689100 RPNNGYIYNAHSWQSENREQSKGSSGDSDHAEGNLAKEECLSADKTDSNGNCSKAQMRVL 358 
XM 695628 RSKKGYLYSGHSWKVHTKTTRPREP--SPACETEIG-AECLTAGTKNKNGNYNKTVTSI- 409 
Figure 2.3. Clustal alignment of probable zebrafish P2-ARs (Accession no's 
XM_689100, XM_695628): TMDs highlighted in yellow in XM_689628, were 
predicted using the programme www. ch. embnet. org/software/TMPRED with a window 
size of 19. 
On further investigation, the upstream data for XM_689100 in the NCBI website can be 
found by looking at contig 14. which is accessed through NN 
_(3,7,7(. 
However, 37 
nucleotides upstream from the 5' end XM ( 9100 in the contig information, 10 unknown 
nucleotides (NNNNNNNNNN) occur. The translation of the extra sequence information 
obtained from contig 14 shows that it very closely resembles the protein sequence found in 
the zebrafish ß2-AR, accession number: NM_ 695628 up to the point of the unknown 
nucleotides (\ \\ \), see Figure 2.4. 
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Cxtended XM_689100 -. '. F-*ICENF-rBAREN-ETERSRIHDCIKVFMGILVDNLYLKKVLSLI-TH-NHH 
cM 695628 ------------------ MEG---DNTLITENTSLYMNISAG-LNASSPVSLS------- 
: xtended 7ßt689100 SDHFECFI: ý-P'FIL. 'F Fi . EI FAI<MF SV MWi'LýIý'; FR.: ýTVIM 
aI695628 ---- VSEYSDAEVVLIS------------------------------------- 
......... .... ...... .......... .... ...... 
xtended XM689100 F;; E Ts1 
Ort 695628 ---------------------------------- -------------------------- 
. ...... .... .... . ...... .... .... 
xtended XH 689100 ITAISRFQRLQNVTNCFITSLACADLVMGLVVIPFCALY 
0M695628 ILIG---- ILVLVIVFGNALVISAIVRFQRLQTVTNYFISSLACADLVMGLMVVPFGACY 
xtended XM 689100 MVGDTWHFGHFLCDFWTATDVLCVTASIETLCVIAMDRYIAITSPFRYQSLLTKNRARFI 
CH 695628 ILLNTWHFGNFFCEFWTATDVLCVTASIETLCVIALDRYIAIMWPLRYQSMLTKRKACGM 
xtended 3ät689100 VLMVWVIAGLVSYLPIHME 
CI 695628 VIGVWAVAAL--------- 
Figure 2.4. Alignment of the translation of the extended XM_689100, using coring 14, 
and XM_695628. The extension of contig. 14 is shown in purple, and unknown 
nucleotides have been represented by `. The gold highlighted amino acids show the 
very close resemblance of the extended part to XM 695628 
Upstream of the unknown nucleotides (\) in the extended section, homology is lacking 
between the two sequences. This may be because there are more than 10 nucleotides that 
are unknown in this region. However, when different frames of translation are used and 
compared to XM_695628, no homology is found. 
Hence, XM_696100 could be a truncated protein. If the methionine (ATG) start codon 
highlighted in blue, in Figure 2.5, is the actual start codon, then the initiator element 
sequence (5' Y-Y-A+'-N-T/A-Y-Y-Y 3') expressed at _ý, can be found 25-30 bp 
from the start codon. This cannot be found if the alternative methionine start codon (M 
is used. However, in the truncated form the ribosomal-binding site (RBS) (ACCAUGG) 
cannot be found 7-13 bp before the start codon, but it can also not be found up to 600bp 
upstream of the alternative methionine start codon (M) either. Hence, because the RBS 
cannot be found upstream regardless of whether the receptor sequence is extended or not, 
may mean that this receptor is not actually expressed and is a pseudo gene. 
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AAACTAAGAAACTGAGCGATCACGCATACATGACTGCATAAAAGTGTTTATGGGTATTCTTGTAGATAATCT 
TTACTTAAAAAAAGTTTTGTCTCTCATCTAAACACACTGAAATCATCACATTTGGTGAAAAAAAAACATCAG 
AGTTTGAGTCATTCAGTCTAGTGATCACAAAGAGTGTTTCATTTCTTAAATCTGTTTCATTTTGTCCAAATT 
TTACCAAGAAATTCCAGCAAAAATGTTTTGAAGTGTTTAAATGTGGTGTGACTAAATATGCCAACCACGTTC 
CACCGTAATCATGTCTTCCACTTTACAACACGTTATAACTCGAATTAAACAAGAATGAACATG-TTTTAC 
AGTGGTGTGTAAGACACAGTACAACCCAGTAAAATGTAGGGTATCATCTGTCCTGTAATCAATCAC'ACACAC' 
AAAAAACTCATAGATTTGTTTTATGTGCACATGAAATTATACTGCAAATATCATAATTGNNNNNN NNNGT 
-GTCTTGATCATCGTCTTTGGCAATGTGATGGTGATTACAGCCATTAGCCGCTTCCAGCGTCTTCA 
GAACGTCACTAACTGCTTCATTACATCACTTGCGTGCGCTGATCTGGTCATGGGATTGGTGGTGATTCCCTT 
CTGTGCCCTTTA 
Figure 2.5. The 5'UTR of ß2-AR zebrafish accession number XM_689100 as obtained 
from contig 14 is shown in purple. The 5' end of XM_689100 is highlighted in black. 
shows a region of unknown nucleotides. A TG is the start codon before the extension. 
is the initiator element sequence. - is the alternative start codon in 
the extended area. 
Because gene XM_695628 (protein accession number NP 7(_)O7`'O) has 7 TMDs. an 
initiator element sequence found 22 bp from the start codon, an RBS, as is found in the 
human and fathead minnow 02-AR sequences, start and stop codons, and the `AAUAAA' 
motif 10 to 35 nucleotides upstream from the poly (A) tail, as shown in Figure 2.6, this 
gene was used to represent the zebrafish ß2-AR. 
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catggagggagacaatacgctgatcacggagaacacctccctgtat 
NNi EGDNTLITENTSLY 
atgaacatttcagctgggctaaacgcttcctcaccagtgtctctctctgtctcagagtac 
MNISAGLNASSPVSLSVSEY 
agcgatgcagaggtggtcttaatcagcatcttaataggcattctggttctagtcattgtc 
SDAEVVLISILIGILVLVIV 
tttggtaatgcgctggtcatcagtgccattgtacgattccagcgcttgcagactgtcaca 
FGNALVISAIVRFQRLQTVT 
aactacttcatcagctccctggcgtgtgctgatctagtcatgggtcttatggtggtgccc 
NYFISSLACADLVMGLMVVP 
ttcggcgcatgctacattctcctcaatacatggcactttggaaacttcttttgcgagttt 
FGACYILLNTWHFGNFFCEF 
tggacggctacggatgtattgtgtgtgaccgctagcattgagacattgtgtgtgattgct 
WTATDVLCVTASIETLCVIA 
ctggaccggtacatagccatcatgtggcctctgcgttatcagtctatgcttacaaagcgg 
LDRYIAIMWPLRYQSMLTKR 
aaggcctgcgggatggtcataggggtgtgggcagtggccgcccttatctcgttcctaccc 
KACGMVIGVWAVAALISFLP 
atccacatggagtggtgggtgtcagaggatcctgaggcgctgagctgcttggaagaaccc 
IHMEWWVSEDPEALSCLEEP 
acctgctgcgacttcaacaccaacgctgcgtacgccgtgccctcctccattatctccttc 
TCCDFNTNAAYAVPSSIISF 
tacatcccgctggtcatcatggcgttcgtgtacagccgggtcttccaagaggcccgtagg 
YIPLVIMAFVYSRVFQEARR 
cagcttcagaaaatagaccgcattgaggggcgaatacgaacacagagcttaagcacccag 
QLQKIDRIEGRIRTQSLSTQ 
gagggaaatgagataaagaacaggaggaccaagttctgcatgaaggaccacaaagctctg 
EGNEIKNRRTKFCMKDHKAL 
aagaccttggggatcatcatgggaaccttcaccatgtgttggctgccattttttgtgctt 
KTLGIIMGTFTMCWLPFFVL 
aatgtggtggcagccatctggaagatggacaacatcatgttgcccttcaggatcttaaat 
NVVAAIWKMDNIMLPFRILN 
tggattggctacgccaactctgccttcaacccattaatctactgcagqaqtcctgagttt 
WIGYANSAFNPLIYCRSPEF 
agatgtgcttttcaggaaatcctgtgctggagaccctctcatctaccttccacaaggagt 
RCAFQEILCWRPSHLPSTRS 
aaaaagggatatctctacagtggtcacagctggaaggttcacacaaagaccaccagacca 
KKGYLYSGHSWKVHTKTTRP 
cgagagccctcgccggcttgtgaaacagaaattggtgctgaatgtttgactgcaggcacc 
REPSPACETEIGAECLTAGT 
aaaaacaaaaatgggaattataataaaactgtgacgtccatttagggcactaaatatatc 
KNKNGNYNKTVTSI-GTKYI 
cggttgaaactgtttttgtctgtgacaaaacatccattttagatatttaagcctttgaac 
RLKLFLSVTKHP F- 
gaatatgtggattatagatcagaaggagcagtgtcttit 
Figure 2.6. The translated sequence of XM_695628 (protein accession number 
XP_700720). Orange nucleotides represent the UTR, atg and tag are the start and stop 
codons respectively, _ is the initiator element sequence, the RBS sequence is 
catgg, the 3' UTR motif is _ found 10-35 nucleotides from poly(A) tail, TMDs are 
highlighted in yellow and the positions of the TMDs were predicted using the programme 
TMPRED. 
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These analyses carried out here of the putative (provisionally named) ß-ARs of both the 
stickleback and the zebrafish demonstrate the considerable difficulties associated with 
firstly identifying genes that definitely code for a functional ß-AR, secondly, the naming of 
any ß-AR correctly (i. e. is the sequence a ß1-, 02- or ß3-AR? ), and thirdly, comparing the 
sequences of ß-ARs. The latter issue includes comparisons of ß-AR sequences within a 
single species (e. g. how similar are ßl-, ß2- and ß3-ARs in a given species? ), and between 
species (e. g. how similar are the ßl-ARs of different species? ). It is apparent that unless 
the (3-AR genes can be identified and named correctly, any sequence comparisons can be 
misleading, if not incorrect. 
2.1.7 Aims 
To characterise the sequences of the ßl-AR and ß2-AR in the fathead minnow. This will 
be carried out by first isolating a short sequence from each receptor using polymerase 
chain reaction (PCR), and then the remaining sequence in each direction, will be found 
using 3' and 5' rapid amplification of cDNA ends polymerase chain reaction (RACE 
PCR). 
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2.2 Materials and Methods 
2.2.1 Tissue acquisition 
Fathead minnow (Pimephales promelas) and rainbow trout, (Oncorhynchus mykiss), as 
shown in Figure 2.7, were both used in experimental procedures and tissue samples from 
both species were collected in the same way. 
Figure 2.7. (A) Image of a fathead minnow (Pimephedes promelas) taken from 
duluth, trcams. orýý unhlerst, mndinL läth. 1dminfOvv. htnil. 
(B) Image of a juvenile rainbow trout (Oncorhvnchus myki. c. c) taken from 
vvv\i,, rU NI' l i-oI Ic Internal/NR stills fish 1111'w" i11Jcy1. htnl 
All bench surfaces and equipment were wiped down with RNase away (Molecular Bio 
Products) and the microtubules were autoclaved before use to remove any enzymes or 
other sources of contamination. The fish were anaesthetised in methanesulfonate salt (MS- 
222) (Sigma, Dorset) until the fish rolled onto one side and no fin movement was 
observed. Each fish was killed by lobotomy, and the relevant tissues such as the heart, 
liver, brain and gonads were extracted from each fish by dissection. Each organ was placed 
in a microtubule and immediately snap frozen in liquid nitrogen to be later stored in a- 
80°C freezer. 
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2.2.2 RNA isolation 
Before any work began, all work surface, and instruments were wiped down with RNase 
away. A tissue sample was obtained from the -80°C freezer and immediately put on ice. 
The sample was weighed, and 1 ml of TriReagent (Sigma, Dorset) was added per 50 to 100 
mg of tissue. The tissue sample was homogenised (initially with only 200 µl of TriReagent 
in a 1.5 ml eppendorf tube, after which the remaining 800 µl was added), and then left to 
stand at room temperature for 5 minutes. 0.2 ml of chloroform (Sigma, Dorset), per ml of 
TriReagent, was added to the tube, which was shaken for 15 seconds, at which stage the 
sample looked like a milkshake, as shown in Figure 2.8. The tube was left to stand at room 
temperature for 10 minutes, after which the sample was spun in a centrifuge (Gilson, 
Anachem, Bedfordshire) at 12,000g for 15 minutes at 4°C. 
RNA 
DNA 
Protein 
tT 
B 
Figure 2.8. (A) An eppendorf tube containing TriReagent, chloroform and 
homogenised tissue. Its appearance is similar to a milkshake. (B) Appearance of tube 
(A) after centrifugation. RNA, DNA and protein have become separated into three 
distinct layers. 
The RNA supernatant was very carefully removed, using a pipette, and placed in a clean 
eppendorf tube. To ensure no DNA contamination occurred, chloroform was added again 
to the RNA supernatant and the previous steps were repeated. Following this, 0.5 ml of 
Isopropranol (Sigma, Dorset) per ml of TriReagent used was added to the RNA 
supernatant and the sample was mixed and left to stand for 6 minutes. The sample then 
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underwent further centrifugation at 12,000g, for 10 minutes at 4°C, after which a pellet 
formed at the base of the tube. The supernatant was removed and I ml of 75 % ethanol for 
1 ml TriReagent was added, and the sample vortexed until the pellet came detached from 
the base of the tube. The sample was then centrifuged at 7,500g for 5 minutes at 4°C, the 
supernatant was removed with a pipette, and the remaining pellet was left to air dry for 5 to 
10 minutes or until it became clear around the edges. Depending on the size of the pellet, 
30 to 400 gI of Milliq water was added to the pellet before it was then placed in a 55 °C 
water bath (Grant, Chelmsford) for 10 minutes. If the pellet had not dissolved, further 
small amounts of Milliq water were added to re-suspend the pellet, taking care not to over- 
dilute the sample. 
To measure the concentration and quality of the total RNA, 1 gl of RNA sample in 70 µl of 
TE buffer (see Appendix A) was analysed on a GeneQuant (Pharmacia, Surrey) machine 
against a blank reading of 71 µl of TE buffer. In the later stages of the project, 1.5 µ1 RNA 
was quantified on a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, 
Loughborough) against a blank reading of 1.5 µl Milliq water. In addition to this, 1-2 µg 
of RNA in 9 µl of water mixed with 2 pl of loading buffer were run on aI% ethidium 
bromide agarose gel at 80 volts for 45 minutes against a1 Kb DNA ladder (Helena 
Bioscience, Tyne & Wear). 
2.2.3 Agarose Gel 
The gel was made using 1.0 g (1 % gel) or 1.2 g (1.2 % gel) certified molecular biological 
agarose (BioRad, Hemel Hempstead) with 100 ml, 1x TBE buffer (see Appendix A) in a 
250 ml conical flask. A tissue was used to plug the top of the flask, which was placed in a 
microwave at `MED HIGH' for about 3 minutes. When the mixture reached boiling point, 
the flask was gently swirled and returned to the microwave until it boiled a second time. 
The flask was removed from the microwave and constantly swirled under cold running 
water to cool the contents. 5 µl of ethidium bromide (Sigma, Dorset) was added to the 
flask and the solution mixed by swirling. The gel was poured into a plastic mould that had 
been taped at either end with autoclave tape, and the comb inserted 1 cm from the top 
edge. The gel was left to set for at least 30 minutes before the samples were loaded. 
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2.2.4 Messenger RNA (mRNA) isolation 
Four types of RNA exist, messenger RNA (mRNA), ribosomal RNA (rRNA), transfer 
RNA (tRNA) and micro RNAs, and it is only mRNA that contains the coded information 
obtained from DNA during transcription (Lodish et al., 2004). Since mRNA only 
constitutes 1-5% of total RNA, a significant reduction of sample occurs when mRNA is 
isolated. In addition to this, isolation of mRNA is an extra step which can result in a 
further loss of sample. However, if maximum sensitivity is required, then mRNA is the 
preferred choice of material (Bustin, 2000). 
mRNA was isolated from 50 to 100 µg total RNA in 200 to 500 µl of water using a 
Nucleotrap nucleic acid purification mini kit (BD Sciences, USA) using the protocol 
supplied with the kit. The maximum mRNA yield using this mini kit is 10 µg. To 
calculate the concentration of mRNA, 1 µl of mRNA in 70 µl of TE buffer was analysed 
on a GeneQuant machine against a blank reading of 71 µl of TE buffer. In the later stages 
of the project, mRNA was isolated using Genelute mRNA miniprep kit (Sigma, Dorset) 
and 1.5 µl mRNA was quantified using a Nanodrop ND-1000 spectrophotometer (Thermo 
Fisher Scientific, Loughborough) against a blank reading of 1.5 µ1 Milliq water. The 
Genelute kit required 5 to 500 pg total RNA in 250µl water to give a yield of 2- 5% of the 
starting material. 
2.2.5 Reverse transcription 
Complementary DNA (eDNA) was obtained using Superscript III reagents and protocol 
(Invitrogen, Paisley). I ng to 5 µg of total RNA or mRNA was required together with I µl 
10mM deoxynucleoside triphosphate (dNTP) mix, I µl Oligo (dT), and enough DEPC- 
treated water to make the total volume up to 10 µl. These ingredients were mixed and 
placed in a heated block (PCR machine, Omnigene, Cambridge) for 5 minutes at 65 °C to 
denature the RNA. The tube was placed on ice for at least a minute, after which 2 µl 10 x 
RT buffer, 4 gl 25mM magnesium chloride, 2 µl 0.1 M DTT, and 1 µl RNase OUT were 
added. The tube was mixed and returned to the incubator for 2 minutes at 42 °C and I µl 
Superscript III RT was added, and the mixture was left on the incubator block for a further 
50 minutes. During this time, reverse transcription took place, whereby adenine is 
replaced by thymine, and vice versa, and cytosine is replaced by guanine, and vice versa. 
To terminate the reaction, the incubator temperature was changed to 70 °C for 15 minutes, 
after which the tube was left to cool on ice for 1 minute. To complete the process, any 
remaining RNA is destroyed by the addition of l µ1 of E. soli RNase H 2U/ µl and the tube 
incubated at 37 °C for 20 minutes. This ensures only the newly made cDNA remains. 
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2.2.6 Primers 
All primers were oligonucleotide primers, i. e. short single strand pieces of DNA between 
20 to 30 nucleotides long, and were ordered from Sigma Genosys (http: //orders. sigma- 
genosys. eu. com) and dissolved with Milliq water to 100 µM. Primer pairs were designed 
to have the same melting points; these were calculated using the oligo-calculator on the 
Sigma Genosys website. Taq polymerase has a melting temperature of 72 °C and therefore 
primers were designed to have melting points between 60 - 68 °C. Primers were also 
designed to have a guanine and cytosine (GC) content of between 40 - 60%. Guanine and 
cytosine bind to each other using 3 covalent bonds, which make the link stronger than 
between adenine and thymine, which link using only 2 covalent bonds. Because of this, 
primers were designed to end in aC or aG so that the enzyme, taq polymerase, could 
easily bind and start the amplification process. Degenerate primers were also designed 
and used when the sequence was unknown and an educated guess meant that the sequence 
could be either one of two different nucleotides. 
In order to ensure that the primers did not bind to themselves or other primers and 
consequently reduce the yield of the reaction, secondary structures of the primers were 
investigated. Secondary structures are produced through inter- and intra-molecular 
interactions and include structures such as hairpins, self dimers and cross dimers. The 
possibilities of these forming can be identified using programmes such as 
http: //frodo. wi. mit. edul and www. basic. northwestern. edu/biotools/oligocalc. html. If a 
primer design had a secondary structure potential that was stronger than a weak 
association, or if it produced a primer dimer, then it was re-designed. 
2.2.7 Polymerase Chain Reaction (PCR) 
PCR allows specific regions of DNA to be amplified. The enzyme, DNA polymerase, 
extends primers, designed to be complementary to particular parts of a DNA sequence, 
onto a single DNA template in the presence of dNTPs. AmpliTaq Gold (Applied 
Biosystems, Warrington) was used in all PCR reactions. Under optimum conditions, this 
results in the synthesis, in the 5' to 3' direction, of new complimentary DNA strands 
(Newton & Graham, 1997). Figure 2.9 details how this process works. Amplification of 
the target region occurs exponentially after cycle 3 of the PCR. Single adenine residues 
form at the end of each PCR product and these are utilised by the Uracil overhang during 
ligation of the PCR product into a vector. 
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B 
Target region S' 
it 
Target region 5' 
Cycle 111 emperature 2 
5. 
3 
Cycle 1 Temperature 3 
1 
1" 
J 
__________ 
3 
5L iiff 
Target region 
Figure 2.9. Diagrammatic explanation showing how a specific region of a DNA strand 
undergoes amplification in a PCR reaction. A. Firstly, the double-stranded DNA is 
denatured by thermal denaturation. B. Once the DNA has cooled, the primers anneal 
to the target regions at a temperature specific to the primers C. DNA polymerase is 
then used to extend the primers in the presence of dNTPs and buffer, and the target 
strands re-anneal. D. In second and subsequent PCR cycles, the three processes above 
are repeated. 
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The primers used in obtaining putative ß 1- and ß2-AR fragments using PCR are as follows. 
12.2aF and 02.5R are degenerate primers. See Appendix A for the coding translation. 
ß1.2aF: 5' CCC CAT CCT AAT GCA CTG G 3' 
01.2aR: 5' AG CCT TCT GCT CTT TTA AAG C 3' 
ß1.7aF 5' GAC TCT AAA CGC GCC ACG 3' 
ß1.7aR 5' CGA GAC CCT GTG CGT AAT TG 3' 
ß2.2aF 5' CTR GTK MTR KKC ATW GTC TTT GG 3' 
ß2.2aR 5' CAC ACC SYY AYS ACC AYC MCG CA 3' 
ß2.5F 5' G TAC GTC GCC ATC ATG TGG 3' 
ß2.5R 5' GTT GTC CAY CTT CCA GAT GGY YR 3' 
There are several limiting factors that can affect the efficiency of the PCR technique. 
1) Enzyme degradation 
Due to thermal degradation, the amount of enzyme present in the reaction tube becomes 
limiting after 25 - 30 cycles. This causes the primer annealing and the re-annealing of 
target strands to start competing with each other for enzyme, which reduces the efficiency 
of both processes. 
2) Temperature 
This is crucial at several stages of the PCR reaction. Initially, the denaturation of the DNA 
template has to be between 95 and 100 °C, whilst from the second cycle onwards it is 
sufficient for the temperature to be between 92 and 95 °C. If either of these temperatures 
are any higher, thermal damage can occur to the DNA. The temperature that the primer 
anneals to the DNA strand is also crucial and is specific to each primer, whilst the 
optimum temperature for primer extension is 72 T. 
3) Number of cycles 
If the number of cycles is increased to over 30, it is usual to see an increase in the number 
of unwanted artefactual products. 
4) Quantities of other components 
Magnesium chloride (MgC12) forms soluble complexes with dNTPs to allow them to be 
incorporated into the extending strand, and also stimulates the polymerase activity of the 
enzyme. Hence the concentration of MgC12 in the final reaction mix can radically affect 
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the specificity and yield of PCR reactions, whereby insufficient MgClz results in a low 
yield or too much MgC12 can produce an accumulation of non-specific products. 
Table 2.5 details the quantities of components added for first and second (with nested 
primers) rounds of PCR. 
Component 1S' Round PCR 2" Round PCR 
(With nested primers) 
Double distilled water 35.75 µl 37.25 
5 µl GeneAmp 10 xB II Buffer 5 µl 5 µ1 
25 mM Magnesium chloride 5 pI 5 µl 
10 mM dNTP mix 1 p1 1 pl 
Forward primer 0.5 µl 0.5 µl 
Reverse primer 0.5 µl 0.5 pl 
AmpliTaq Gold 0.25 µl 0.25 µl 
Sample 2 µ1 RNA or mRNA 0.5 µ1 PCR product 
Table 2.5 Table detailing the amounts of the various components used in each PCR 
reaction. 
Nested primers are used in a second round of PCR and are primers that amplify a smaller 
amount of more specific DNA from the previously amplified segment obtained in the first 
round of PCR. Nested primers were used to increase the specificity of the PCR. A 
gradient PCR (Icycler, BioRad, Hemel Hempstead, see Figure 2.10) was used, for which 
the annealing temperature for most reactions was between 50 to 64 °C. 
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Figure 2.10. An Icycler made by BioRad, Hemel Hempstead. In a temperature 
gradient PCR, wells Al to A12 (top left to bottom left) function at the highest 
temperature in the gradient. Wells IIl to 1112 are set to the lowest temperature in the 
gradient (top right to bottom right). 
The PCR programme used for most primers pairs is set out in Figure 2.11. 
Holding 
I cycle 30 cycles I cycle temperature 
95.0 95.0 72.0 72.0 
5.0 1.0 1.0** 10.0 
50.0- 00 
64.0 * 
1.0 
15.0 
Figure 2.11. Diagram detailing the PCR program used. The number above the line 
represents the temperature (°C) and the number below represents the time (minutes). 
* This is the annealing temperature, which is specific to each set of primers. ** this is 
the extension time, during which the DNA is synthesised within the target region. 
Both these parameters can be altered to improve the efficiency of the PCR. As a rule 
of thumb. extension occurs at about 1 Kb per minute. 
2.2.8 Extraction of DNA from agarose gel 
Once the PCR run had been completed, 25 µl of the product mixed with 5 µl loading buffer 
was run on a 1.2 % agarose gel for 45 minutes at 80 Volts (see section 2.2.3 on gel set up). 
If a band appeared that was the correct size, it was quickly cut from the gel under UV light 
using a sharp scalpel (Swan-Morton, Sheffield). The band was weighed and then the 
protocol from the MinElute gel extraction kit (Qiagen, Crawley) was followed. Firstly, the 
gel containing the band was dissolved in a pH-sensitive buffer by incubation in a water 
bath (set at 50 °C) and periodic vortexing. The now yellow solution was transferred into a 
MinElute spin column and spun in a mini-centrifuge, whereon the nucleic acids adsorbed 
to the silica-gel membrane of the spin column, and impurities such as enzymes, mineral 
oil, salts, agarose and ethidium bromide were washed away and discarded. The I)NA on 
the spin column membrane was then eluted in 10 µl of a low-salt buffer. 
2.2.9 Ligation 
Ligation of the DNA into a vector (See appendix A) was carried out using the protocol and 
kit components supplied in a PCR cloning plus kit (Qiagen, Crawley). I to 4 µl of 
extracted DNA solution was added to 1 µl pDrive cloning vector (50 ng/µl) and 5 µl 
ligation master mix 2x. The solution was made up to 10 µl with distilled water and 
incubated for 15 °C for 2 hours in an incubator. During incubation, under optimal 
conditions provided by the master mix, the linear vector, which has a Uracil (U) overhang 
at each 3' end, hybridises to the A overhang of each PCR product (see Figure 2.12). 
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5' A 3' 
+ 3' A 5' 
DNA from PCR 
Linear vector 
A 
U ýr+ 
AýýU 
Circular vector, 
now containing the PC R product 
Figure 2.12. Diagrammatic explanation of the orientation of the PCR product in the 
vector. 
After incubation, 2 µl of the ligation-reaction mix was added to QIAGEN EZ Competent 
Cells (Qiagen, Crawley) and left on ice for 5 minutes. The cell mixture was then heat 
shocked for 30 seconds at 42 °C and returned immediately to the ice. 250 µl of room 
temperature SOC medium was added, and after mixing, the solution was spread over 4 
agar plates using a sterilised glass spreader. The agar plates were made up of 100 ml agar 
(see appendix A), 100 µl ampicillin, 160 µl Xgal and 50 gl IPTG. Once the cells had sunk 
into the agar, the plates were turned upside down and left overnight at 37 °C. 
The next day, the plates were left in the fridge for 30 minutes to let the colour develop. 
The vectors that had DNA incorporated into the plasmid appeared white, whilst those that 
did not have incorporated DNA appeared blue (see Figure 2.13). 
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Blue 
colony 
White 
colony 
Figure 2.13. Appearance of an agar plate that had ligation mix spread over the surface 
and then been incubated overnight at 37 °C. White dots are colonies with the DNA 
incorporated into the vector; blue colonies contain vectors without the incorporation 
of DNA 
The white colonies were then selected and run on a PCR with SP6 (5' AT TTA GGT GAC 
ACT ATA G 3') and M13 reverse (5' CAG GAA ACA GCT ATG ACC ATG 3') primers. 
The PCR products were then run on aI% agarose gel to ensure that a DNA fragment of 
the expected size had been inserted into the plasmids. The successful colonies were picked 
from the agar plates and grown up in a culture of 5 ml L broth (see Appendix A) and 5 . i1 
ampicillin overnight in a 37 °C shaker. 
2.2.10 Preparation of glycerol stocks 
250 µl of 20 % glycerol and 250 µl of a colony were mixed in a 1.5 ml eppendorf tube and 
stored at -80 °C. These stocks can be used to grow up the same colony repeatedly, by 
streaking a loop from the stock over an agar plate and growing colonies overnight at 37 °C. 
2.2.11 Plasmid (mini-prep)preparation 
The culture tubes were spun at 2,500 rpm at room temperature for 10 minutes. The 
supernatant was poured away and any excess liquid was blotted out onto tissue. Using the 
protocol set out in the QIA prep spin miniprep kit (Qiagen, Crawley), a buffer was added 
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and the cells re-suspended by repeat pipetting. After several steps, the bacterial lysates are 
adsorbed to a silica-gel membrane in the QIA prep spin column, and any impurities are 
washed away using a washing buffer. The remaining DNA is then eluted in 50 gl of 
buffer. To ensure that above procedures were successful, 2 µl of DNA with 2 gl loading 
buffer were run on a1% agarose gel at 80 V for 45 minutes, and I . tl of DNA in 70 µl of 
TE buffer was analysed on a GeneQuant machine against a blank of 71 µl of TE buffer. In 
the later stages of the project, the 1.5 µl of DNA was quantified using a Nanodrop ND- 
1000 spectrophotometer (Thermo Fisher Scientific, Loughborough) against a blank reading 
of 1.5 µl elution buffer. 
2.2.12 Sequencing 
Dilutions of each DNA sample were made with Milliq water so that each 30 µl sample 
contained 500 ng of DNA. These dilutions were sent off to Dundee University's 
sequencing service (www. dnaseq. co. uk). The information that was sent back was the 
nucleotide sequence from the Ml 3R primer in the vector, and a chromas plot that showed 
the quality of the sequence. Figures 2.14 and 2.15 are examples of chromas plots. 
20 30 40 00 60 70 00 90 
GAG : ", =GGGG? ----,: GG:. G G -__ GT GGG-".. -,; G,:. ' G;. TC Gý_AT 1GA GGGAGI-AT Ä=GC - Gl- ;GG 
Start 
1 
would be collected from the sequence. This point was determined by myself. Once the 
peaks become sharp and well defined, the quality of these data is good enough to start 
obtaining the sequence. 
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Figure 2.14. This shows peaks from a chromas plot and at which point the information 
i80 690 700 710 720 730 740 750 760 
TGGTAC CCAGCTTTC CC TATAGTGAGTCGTATTAGAGCTTGGCGTAATCATGGTC A TAG CTGTTTCCTGTGTGA A ATTGT TAT( 
are overlapping each other. The amino acids translated from plots such as these would 
not have been used for sequencing characterisation, as the quality of the peaks is too 
poor (they are not distinct and separate enough). 
2.2.13 Rapid Amplification of cDNA Ends (RACE PCR) 
Once a fragment from a ß-AR had been obtained, RACE PCR was used to obtain the 
sequence of each end of the receptor. For each type of RACE (3' and 5'), gene specific 
primers (GSPs) are designed from the known fragment that has been characterised. 
Because the 3' end of a receptor sequence is made up of a string of adenine nucleotides, 
otherwise known as a poly(A) tail, the protocol of 3'RACE uses this to find the end of the 
receptor sequence by using it as a generic priming site in PCR During the making of target 
cDNA from mRNA (which has been extracted from the tissues), an oligo(dT) adapter 
primer is incorporated into the cDNA. A PCR is then run using the GSP and an adapter 
primer (AP). The former anneals to part of the known fragment and the latter anneals to 
the poly(A) tail. Another round of PCR follows, with a nested GSP, to make this process 
more specific. 
The 5' end of the receptor does not have a poly(A) tail or an equivalent marker at the 5' 
end of the receptor. So in the 5' RACE protocol, an anchor is inserted at the 5' end of the 
receptor during the synthesis of cDNA from mRNA. After this process is complete, 
5'RACE works in a similar manner to 3'RACE. GSPs are designed from the known 
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Figure 2.15. Peaks from a chromas plot. These peaks are poorly defined and in places 
fragment and these are run with primers that detect the inserted anchor during two rounds 
of PCR. In this way the receptor is sequenced in 2 parts, i. e. from the known fragment to 
the 3' end and from the known fragment to the 5' end of the receptor, as diagrammatically 
illustrated in Figure 2.16. 
5' end 3' end 
AAA 
Anchor 
TTVF 
Gene ei rimers 3' RACE 04 
5' RACE 
OEM 
Figure 2.16. Diagrammatic explanation of 3' and 5' RACE PCR. The red line 
represents the whole length of a receptor with a poly(A) tail. 
Two different methods were used to complete RACE PCR. The first was the RACE 
system from Invitrogen (Paisley), and the second was from Clontech (California, USA). 
When using both kits, the PCR was broken down into 3 stages to make it more specific, as 
shown in Figure 2.17. The annealing temperature for the first 5 rounds of PCR were 
carried out at minus 3°C of the GSP melting temperature, followed by 5 cycles of an 
intermediate annealing temperature, followed by 20 cycles of an annealing that was minus 
3°C of the AP melting temperature. 
1 
cycle 
94.0 
5 cycles 
95.0 72.0 
5 cycles 
95.0 72.0 
20 cycles 
95.0 72.0 
1 
cycle 
72.0 
Holding 
temp 
3.0 1.0 2.0 1.0 2.0* 1.0 2.0 10.0 / 
j 
'S 
Umid UALJ 
L 
15. 
1.0 1.0 1.0 00 
Figure 2.17. Diagrammatic representation of the l'CR programme used in V RACE 
PCR. * denotes annealing temperature (°C). ** denotes extension time (minutes). 
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The GSPs used in 3' and 5' RACE PCR to successfully complete the sequence 
characterisation for the (31- and f32-ARs are as follows (U represents any nucleotide) 
9 3' RACE ßl-AR: 
ß1.4F: 5' GAC ACC GTG GAT ACA TCA TGC TAT AAC G 3' 
ß 1.4aF: 5' CCA GGG TAT ACA GAG AAG CCA AAC AAC AAC TG 3' 
ß1.4bF: 5' GCA AAC CTA ACC GAA AAC GAA CCA C 3' 
AP: 5' CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT AC 3' 
" 5' RACE ßl-AR: 
ß1.6RR 5' TCG TTC TTC TGT GAA TTC TGG ATA TCT CTT GAT 3' 
AP: CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT 
0 3' RACE ß2-AR: 
ß2.7F 5' CAG GAC GGG AAC GAG ACG AAG AAC 3' 
ß2.7aF 5' G ACC ACA AAG CTC TGA AGA CCT TGG G 3' 
ß2.7bF 5' AAC ATT CAC CCT CTG CTG GCT GC 3' 
AP: 5' CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT AC 3' 
5' RACE ß2-AR: 
B2.8RR 5' CAC TTC GGA AAC TTC TTC TGC GAG TTT TG 3' 
02.8R 5' TAC ATC CTC CTC AAC ACG TGG CAC TTC 3' 
ß2.8aR 5' CAG ACG GGC ACC AAC TAC TTC ATC AG 3' 
ß2.8bR 5' GTC ATC AGC GCC ATT GTA CGA TTT CAA C 3' 
AP: 5' CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT AC 3' 
2.2.14 Primer Walking 
To ensure fragments obtained from PCR and RACE PCR were from the same receptor, a 
process known as primer walking was undertaken. Once the whole receptor had been 
provisionally characterised, primers were designed in the 3' and 5' un-translated regions 
(UTRs) to amplify the whole receptor using proof reading taq (Pwo SuperYield DNA 
polymerase, Roche, Sussex). Because proof reading taq does not add an overhang adenine 
to the end of the PCR product (i. e. it produces blunt-ended PCR product), one has to be 
added in order for the product to be inserted into a vector. This was carried out by adding 
A-addition master mix (Qiagen, Crawley) to the PCR product and incubating for 30 
minutes at 37 °C. The PCR product was cloned and inserted into a plasmid. This sample 
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was then used through out the whole primer walking process. When a sequence that 
consists of roughly 1250 amino acids is sent for sequencing, only the first 350 amino acids 
can be reliably characterised, after which the sequence quality degenerates. To overcome 
this, a primer is designed at the start of the sequence, then an internal primer is designed 
after approximately 350bp and another is designed after approximately a further 350bp, 
and so on. This process is repeated until the end of the receptor has been reached, and was 
carried out in both the sense and the anti-sense directions, (see Figure 2.18). 
5' 3' 
5' to 3' walking 
Receptor sequence 
3' to 5' walking 
5' 3' 
Figure 2.18. A diagrammatic explanation of the process of primer walking. Each grey 
rectangle 
U. 
represents a gene specific primer. ()range rectangles represent UTR. 
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The primers used to obtain and verify the complete sequences (in italics) and also those 
used in primer walking, were as follows: 
PI-AR: 
ß1.10R 
131.1IaF 
ß1.12F 
ß1.13F 
ß1.14F 
ß1.15F 
ß1.16F 
ß1.12R 
ß1.13R 
ß1.14R 
ß1.15R 
ß1.16R 
131.11aR 
P2-AR: 
[12.9F 
ß2.9R 
ß2.9aF 
ß2.9aR 
02.1 OR 
ß2.11F 
ß2.12R 
ß2.13R 
ß2.14F 
ß2.15R 
ß2.16F 
5' CGT TTC AGA CAA ATT CGA AAA TAT TTC C 3' 
5' GAGAGCGCGGATGGAAG 3' 
5' GGCTCCAGACGCTCACC 3' 
5' GCCTTTTAACGAAAGCACG 3' 
5' GAGAAGCCAAACAACAACTG 3' 
5' GAACTGGCTGGGGTACG 3' 
5' CTGCAGTCTAGAGAGGAACG 3' 
5' CTGCTCCATTGAGTTCACAAAG 3' 
5' GCACCACGTTAACGATGAAG 3' 
5' GACTATTAAAGGGATGTAAAACGATATAAC 3' 
5' GCGATGTACCTGTCAA'I'TGC 3' 
5' CAGTATATTCCCCACTACAATGAC 3' 
5' CTTCCATCCGCGCTCTC 3' 
5' CGACAT TTAGTCTACAGCCGAGAG TG 3 
5' GTC TGT GAC AAA ACA TGG TTT TTA GAT GT 3' 
51 CAT GAC CAG GTG ATC AAG AGT CGA GTG 3' 
5' CCC TGG AGC ACT TGA GAG ATT TCT GC 3' 
5' GCA GTA GAT GAG GGG ATT G 3' 
5' TCA ACG CTT GCA GAC G 3' 
5' CT TGG GGA TCA TCA TGG 3' 
5' CG CTA TCA GTC GAT GCT TAC 3' 
5' CCA CAA AGC TCT GAA GAC G 3' 
5' CTC AAC ACG TGG CAC TTC 3' 
5' CATCGTCTCCTTCTACATCCC 3' 
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2.2.15 Sources of established ß-AR sequences 
Nucleotide and protein sequences of different ß-ARs from different species were obtained 
from the websites detailed in Table 2.6. 
Source Website 
NCBI http: //www. ncbi. nlm. nih. gov/ 
Wellcome trust Sanger Institute http: //www. sanger. ac. uk/ 
Ensembl Genome Browser http: //www. ensembl. org/index. html 
Genoscope http: //www. cns. fr/ 
Table 2.6. A list of the databases and their websites that were used to obtain sequence 
data. 
The accession numbers of selected sequences were from the NCBI website unless 
otherwise stated, and are as follows: For ßl-ARs, Homo sapiens; NP 00675.1, Dania rerio; 
XP 685300, Tetraodon nigroviridis; CAG 12607.1, Takifugu rubripes; from 
www. ensembl. org: SINFRUG00000121458, Gammarus aculealus; www. ensembl. org/, 
ENSGACG00000006578 
For 02-ARs: Homo sapiens; AAB 82149, Danio rerio; XP_700720, Oncorhynchus 
mykiss; AAK94672.1, Tetraodon nigroviridis; CAG10129.1, Takifugu rubripe; 
AAQ02695.1, Myxine glutinosa (hagfish); CAA06539.1, Petromyzon marinus (Marine 
Lamprey); CAA06540.1, Ictalurus puncatatus (Catfish), (nucleotide only) AF 127775. 
Sequences were aligned using CLUSTAL W (1.83) multiple sequence alignment 
(www. ebi. ac. uk/Tools/clustalw/index. html) using default settings for pairwise alignment. 
To find the reverse complement of a sequence, the website 
www. bioinformatics. va/bioinformatics tool s/reversecomplement. shtml was used. 
Translation of a nucleotide sequence to a protein sequence was carried out by ExPASy, a 
proteomics server of the Swiss Institute of Bioinformatics 
(www. expasy. ch/tools/dna. html). This website translates the nucleotide sequence into 6 
possible reading frames. Frame 1 was obtained by translating the sequence from the first 
input nucleotide, frame 2 and 3 are from the second and third nucleotides, respectively. 
Frames 4 to 6 are the same as frames I to 3, but are the translations in the reverse direction. 
To try to annotate an unknown nucleotide sequence, a blastx programme was run at the 
website www. ncbi. nlm. nih. gov/blast/Blast. cpi to find regions of local similarity between 
sequences of the input fragment and listed NCBI proteins. This programme translates the 
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nucleotide sequence into 6 frames and searches its large database against each of them. 
Against each result the programme denotes an E number, which describes the number of 
hits one can `expect' to see just by chance when searching a database of a particular size. 
The closer the E value is to zero, the more significant the match is. 
2.2.16 Hydropathy analysis 
GPCRs are made up of seven hydrophobic trans-membrane domains (TMDs), as shown in 
Figure 2.19. Each TMD needs a row of 18-20 hydrophobic amino acids to be able to cross 
the very hydrophobic bilipid layer of a cell membrane, which means that hydrophilic 
amino acids are found primarily outside of the membrane. 
predicted. In these programmes each amino acid is designated a hydropathy score from 
the Kyte-Doolittle Hydropathy index from between -4.5 and 4.5. A score of 4.5 is the most 
hydrophobic and a score of -4.5 is the most hydrophilic. The hydrophobicity of the amino 
acids determines where the amino acid will be located in the final structure of the protein 
(Kyte & Doolittle, 1982). Once the hydropathy score has been assigned, a window size is 
set. A window size is the number of amino acids whose hydrophobicity scores will be 
averaged and assigned to the middle amino acid in the window. When looking for surface 
regions in a globular protein, a window size of 9 is found to give the best results. When 
looking at GPCRs, a window size of 19 is best. TMDs are identified by peaks with scores 
greater than 1.8 using a window size of 19. 
The software programmes used were: 
www. ch. embnet. org/software/TMPRED form. html, 
ConPred_all (http: //bioinfo. si. hirosaki-u. ac. jp/-ConPred2/), 
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From sequence information put into a software programme, the TMD topology can be 
http: //bp. nuap. nagoya-u. ac. jp/sosui/cgi-bin/adv_sosui. cgi, 
www. cbs. dtu. dk/services/TMHMM-2.0/, and 
www. sbc. su. se/-miklos/DAS/tmdas. cgi 
TMD topology prediction calculations vary between programmes and criteria were 
established to help decide which programme was the most accurate. As discussed in 
section 2.1, some nucleotides appear in set motifs in certain parts of a GPCR and the 
literature states that they appear in certain TMDs. By using this information, the best fit 
topology programme could be determined. The programme that fitted the TMDs to allow 
the motifs to appear within or around certain TMDs was used to determine the TMDs for 
the 0 1- and ß2-ARs. 
2.2.17 Phylogenetic analysis 
Phylogenetic trees are constructed from the study of systematics in which binary rooted 
trees are formed to link species of families by their co-ancestral relationships (Holmes, 
2003). In this analysis, all the translated 131- and (32-AR sequences available were aligned 
in a clustal W (1.83) multiple sequence alignment and then input into a software 
programme for phylogenetic analysis (www. genebee. msu. su). Bootstrap values indicate 
the inference of the trees and are a similar verification of results as p values are to 
statistical analyses, in that they are a determination of confidence. For example, it gives 
information about the stability and robustness of the tree topology (the branching order), 
and it helps assess whether the sequence data are adequate to validate the topology (Berry 
& Gascuel, 1996). 
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2.3 Results 
Each procedure was carried out as described in the Methods and Materials section. 
Initially, to gain experience in molecular techniques, a fragment was cloned and sequenced 
from the already characterised ß2-AR using the liver of a rainbow trout (Oncorhynchus 
mykiss). Once this procedure had been successfully carried out, liver, and sometimes 
heart, tissues from female fathead minnow (Pimephales promelas) were used to 
characterise the unknown ßl - and ß2-AR sequences of this species. 
2.3.1 RNA extraction 
RNA was isolated and run on aI% agarose gel to give an indication of quality. Good 
quality intact RNA should appear as two distinct bands (28S and 18S), and the 28S band 
should be approximately twice as intense as the 18S band, as shown in Figure 2.20. If any 
DNA contamination is present, it can be seen on a gel under a UV light as this DNA 
sample remains in the well into which the sample was pipetted, because it is a larger, 
heavier molecule, and so does not migrate into the gel. 
I Kb DNA ladder 1 Kb DNA ladder RNA Slight DNA contamination 
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Figure 2.20. A photograph taken under UV light of RNA samples run on a1% 
agarose gel. Lane 1 is a1 Kb DNA marker. Lanes 2 and 3 are RNA samples. Both 
show good quality intact RNA as the 28S band is approximately twice the intensity of 
the 18S band. However, the RNA sample in lane 3 shows slight DNA contamination. 
The 260/280 ratio of RNA read on a spectrophotometer also gives an indication of quality; 
a ratio greater than 1.8 shows that the RNA is of a good quality. 
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2.3.2 Characterisation of ß2-AR in trout 
As a practise exercise, a fragment of trout 02-AR was isolated from the liver. The 
sequence had been characterised by Nickerson et al. (2001), and so primers were designed 
to isolate a fragment that was about 450bp in length. It was discovered that the ß2-AR 
could only be detected in PCR when mRNA (not total RNA) was used, and that nested 
primers increased this signal (see Figure 2.21). 
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Figure 2.21. Photographs taken under UV light of PCR products run on a 1.2 % agarose 
gel where trout liver RNA was used in the PCR reaction. 1kb DNA markers are in lanes 
1, and negative control samples are in lanes 0. 
(A) PCR run was with total RNA in lane 2 and shows the PCR reaction was 
unsuccessful because no bands are visible. 
(B) PCR run was with mRNA. Lane 2 shows the DNA product (as a faint band) from 
the first round of PCR, lane 3 is from the 2"" round of PCR with nested primers, and 
shows a much more intense hand. The bands in lanes 2 and 3 show that this method 
(using mRNA) was sensitive enough to amplify a fragment of DNA. 
The DNA was extracted from the agarose gel, cloned and sent for sequencing. The 
sequencing results showed that the fragment was 100% homologous to a part of the 
published sequence of trout ß2-AR, as shown in Figure 2.22. This demonstrated that the 
methodologies were sensitive and specific enough to detect 02-ARs in liver tissue. 
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Fragment VNIC'IVI GNVI. VI"I: MVRI (, RLQ"I'V"I'NMFITSLA('AI)1, 
ß2-AR trout VMCIVFGNVLVITAIVRFQRLQTVTNMFITSLACADL 
hraýýmcnt "1ý1(ýLf. 'VPI (; A('YJIi NI\I II: GýI: I. ('Fl: \k I. ý, -\I)V1 ('V 
02-AR trout VMGLLVVPFGACYILLNTWHFGSFLCEFWTAADVLCV 
Fraýýmýnt 1: ýSII: I l. ('V1: 11. [)Rl'I.: ýI I-SI'I. R\ I'ti1. I. I V 
P2-AR trout TASIETLCVIALDRYLAITSPLRYPSLLTKRKACVVVVTV 
Figure 2.22. Results from the sequenced fragment isolated from trout liver, compared 
to a section of previously characterised trout p2-AR. The amino acids in both 
sequences are identical. 
2.3.3 Characterisation of the p1-AR in fathead minnow 
The sequence for the 01 -AR in the fathead minnow was obtained by piecing together seven 
different fragments that were obtained from PCR, 3' RACE PCR and 5' RACE PCR to 
eventually obtain an entire sequence that was confirmed by primer walking. Figure 2.23 
shows a representation of these fragments in comparison to a complete receptor sequence. 
5 Trans-membrane domain 3' 
UTR I UTR 
1. 
2. IUTR 
F -. 1-. 1 
6. 
UT 7. 
f`ntirc scqucncc 
UTh R- UTR 
Figure 2.23. A diagrammatic representation of the 7 different fragments that were 
obtained to complete the entire molecular sequence of the PI-AR of fathead minnow. 
Fragment 8 was the amplification of the whole receptor sequence. UTR: Un-translated 
region. 
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Fragment I was obtained from 2 rounds of gradient PCR (see Figure 2.24). Gradient PCR 
was ideal for this task as it meant a range of temperatures could be used. This was 
extremely beneficial, as the primers only amplified DNA at certain temperatures and a 
difference of 4°C could determine whether the result was positive or negative (i. e. whether 
Figure 2.24. Photos of 1.2 % agarose gels showing the PCR products derived from 
primers designed to isolate a 01-AR from fathead minnow. Lane 1 shows the lkb DNA 
marker. (A) Lanes 2-9 show the PCR products from the first round of gradient PCR, 
where no band is seen. The PCR product from lane 9 was used for the second round of 
PCR with nested primers. (B) Results from the 2nd round of gradient PCR which was 
run at an annealing temperature specific to the nested primers. The band from lane 3 
was cut out and the DNA extracted for cloning and sequencing. 
Fragments 2 and 3 (in Figure 2.23) were obtained by 3' and 5' RACE PCR respectively. 
3' RACE PCR was successful and provided the complete 3' sequence to the poly(A) tail, 
whereas 5' RACE produced a product (fragment 3) that stopped half way through the first 
TMD. This could be due to the fact that either the receptor actually stopped at this point, 
or that due to a complex structure in the receptor, the 5'RACE method was unable to get 
past this point in the sequence. Repeated efforts were made to further the sequence in the 
5' direction. This was done by using different GSPs in 5'RACE, with different annealing 
temperatures and extension times, new kits (to ensure the enzymes were working 
properly), open-ended PCR, freshly isolated RNA (to ensure there had been no degradation 
of the RNA sample during storage) and use of heart tissue instead of liver tissue, since ß 1- 
ARs (rather than other ß-ARs) are predominant in human hearts. It was thought that ß 1- 
AR may be expressed at greater levels in the heart compared to the liver. All attempts at 
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the desired fragment was or was not amplified). 
extending the sequence in the 5' direction either gave no result or produced the same 
truncated product as fragment 3, as shown by fragments 4 and 5. Assuming that the 
receptor didn't finish at this point, PCR primers were designed to amplify a short fragment 
that would move us past this particular point. This strategy was successful, and a further 
short fragment of the 01-AR was obtained, which is represented by fragment 6 in Figure 
2.23. 
Having read different reviews on the Invitrogen 5' RACE kit that had been used up to this 
point, it seemed that many people had encountered problems with this particular kit, in that 
it often produced truncated products. These reviews recommended the 5' RACE kit from 
Clonetech, and so using this kit, and fresh mRNA isolated from the heart and liver of the 
fathead minnow, the sequencing of the 5'UTR region of the ß 1-AR was again attempted. 
This was successful and produced the remaining sequence of the ßl-AR, as represented by 
fragment 7 in Figure 2.30. Lastly, primers were designed to amplify the whole ß1-AR 
from the 5'UTR to the 3'UTR, of which three products were cloned (Fragment 8, Figure 
2.23) and used in primer walking to confirm the whole sequence. The results from the 
forward and reverse walking for each clone were identical. The nucleotide and amino acid 
sequences for the 0 1-AR are set out below in Figure 2.25. 
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5' ATGGAAGCGCTCCACACAGGACCTGAAGTTC60 
TGAATGAGCGCGCTTCATTTCTCCACACCATGGGAGACGGTTTACCGTCTGTAAACTACA 120 
GCAATGACTCTAAACGCACCCCGGATAACTTATCAGAACAGTGGCTCGTGGGCATGGGAA 180 
TCATCATGGGTCTGGTAGTAATTGTCATTGTAGTGGGGAATATACTGGTTATAGTCGCCA 240 
TAGCGCGGAATCAGAGGCTCCAGACGCTCACCAATGTTTTCATAGTGTCTCTGGCGTGCG 300 
CAGACCTTATCATGGGGTTACTGGTGGTGCCATTTGGCGCAGACTTGGAGGTCAGAGGAT 360 
CTTGGATGTATGGATCGTTCTTCTGTGAATTCTGGATATCTCTTGATGTACTTTGCGTCA 420 
CGGCGAGCATCGAGACCCTGTGCGTAATTGCAATTGACAGGTACATCGCCATCACCTCTC 480 
CATTTCGCTATCAAAGCCTTTTAACGAAAGCACGAGCCAAGGTGGTGGTGTGTGCAGTTT 540 
GGGCTATATCAGCTCTTGTGTCATTTCCACCCATCCTAATGCACTGGTCCCGGGACACCG 600 
TGGATACATCATGCTATAACGAACCCGAGTGCTGTGACTTCATCACCAACCGTGAATATG 660 
CCATCTCATCCTCCGTTATATCGTTTTACATCCCTTTAATAGTCATGATATTCGTCTATG 720 
CCAGGGTATACAGAGAAGCCAAACAACAACTGAAAAAAATTAACAAATGTGAGGGAAGAT 780 
TCTACAACAATGGTACTAATTGCAAACCTAACCGAAAACGAACCACCAAGATCCTGGCTT 840 
TAAAAGAGCAGAAGGCGTTGAAAACGTTGGGAATAATCATGGGAACATTCACTCTCTGCT 900 
GGCTGCCGTTCTTCATCGTTAACGTGGTGCGGGTGTTTGGCAAAGAGGTGGTGAAAAAGG 960 
AACTCTTCGTATTTTTGAACTGGCTGGGGTACGTCAACTCCGCCTTTAACCCCATCATAT 1020 
ACTGTCGGAGTCCCGACTTTAGGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGG 1080 
CGGACCGCAGGTTGCACGTGAGCTCGTGCGATCTGTCGCGCTGCACCGGGGGCTTTGTGA 1140 
ACTCAATGGAGCAGAGCATGCTCGGGACCTGGTCGGACTGTAACGGCACGGACAGCCGCG 1200 
ACTGCAGTCTAGAGAGGAACGGAAGGGTGTCCCATTCAGAGTCTCAGCTGTAA 1260 
1320 
1380 
1412 (3' end) r 
MEALHTGPEVLNERASFLHTMGDGLPSVNYSNDSKRTPDNLSEQWLVGMGIIMGLVVIVI 60 
VVGNILVIVAIARNQRLQTLTNVFIVSLACADLIMGLLVVPFGADLEVRGSWMYGSFFCE 120 
FWISLDVLCVTASIETLCVIAIDRYIAITSPFRYQSLLTKARAKVVVCAVWAISALVSFP 180 
PILMHWSRDTVDTSCYNEPECCDFITNREYAISSSVISFYIPLIVMIFVYARVYREAKQQ 240 
T, KKTNKCEGRFYNNGTNCKPNRKRTTKILALKEQKALKTLGIIMGTFTLCWLPFFIVNVV 300 
RVFGKEVVKKELFVFLNWLGYVNSAFNPIIYCRSPDFRKAFKRLLCCPRQADRRLHVSSC 360 
DLSRCTGGFVNSMEQSMLGTWSDCNGTDSRDCSLERNGRVSH 402 
B 
Figure 2.25. The nucleotide sequence (A) and amino acid sequence (B) of the ßl-AR in the 
fathead minnow. Orange letters show the UTRs. Orange letters that are not capitals have 
not been confirmed by primer walking as the primers made to sequence the whole receptor 
did not include these nucleotides. Nucleotides in blue represent the start (-A 1(; ) and stop 
("1': 1; x) codons. Nucleotides highlighted in 4 show the 3' IJTR motif. The ribosomal 
binding site is highlighted in yellow 
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2.3.4 Characterisation of the ß2-AR in the fathead minnow 
The same approach used to characterise the ßl-AR was used to obtain the molecular 
sequence for the 02-AR in the fathead minnow. Only 5 fragments were needed to gather 
the whole receptor sequence, as shown in Figure 2.26. 
5' Trans-me rane domain 3' 
UTR UTR 
2 
ivy UTR 
UTR 
Fuhre seutience 
UTR 6 UTR 
Figure 2.26. A diagrammatic representation of the 5 different fragments that were 
obtained to complete the entire molecular sequence of the ß2-AR. Fragment 6 was the 
amplification of the whole receptor sequence. UTR: IJn-translated region. 
Fragment I was obtained by gradient PCR and despite using mRNA in the PCR reactions, 
a strong band was only obtained by extracting the DNA from the second round of PCR and 
re-amplifying it, as shown in Figure 2.27. This was done by running 0.5 pi of the extracted 
product in another round of PCR with nested primers. 
Fragment 2 was also obtained by PCR, as was fragment 3, which was used to confirm that 
fragments 1 and 2 were from the same receptor. Fragment 4 was obtained by 3' RACE 
PCR and fragment 5 from 5'RACE PCR. Fragment 6 was obtained from a PCR run using 
proof reading taq and primers designed to amplify the whole receptor. Three individual 
clones were then taken from cloning the PCR product and `primer walked' to verify the 
receptor sequence. On primer walking the three clones it was found that 2 variations of the 
same receptor existed. Figure 2.28 and Figure 2.29 compares the nucleotide and amino 
acid receptor sequences respectively, for both 02-AR sequences. From location of the 
initiator sequence and the ribosomal binding site, it is possible that the sequences for 
definitely one, and possibly two, functional 02-ARs were found. 
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Figure 2.27. Photo of a 1.2 % agarose gel showing the PCR products derived from 
primers designed to isolate a fragment of the 02-AR from fathead minnow. Lane I 
shows the lkb DNA marker. Lanes 2 to 7 show the PCR products from the second 
round of gradient PCR, of which the DNA from lane 4 was extracted and re-amplified, 
as shown in lane 8. 
1/197. ] --------------------------------------------------- 
1ý/ýU I 60 
+x x+ xxxxx 
1/15'1.1 69 
18/207 120 
1/197.1 TTATTTTT CTAATTTT TCATGGAGCGAGGGGATAGG 129 
18/207 TTATTTTT CTAATTTT TCATGGAGGGAGGGGATAGG 180 
1/197.1 TTGAGCGCGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCTTCT 189 
18/207 TTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCTTCT . '40 
1/197.1 CCGGTGTCCGAATATAGCGACGCAGAGGTGGTCTTAATTAGCATCTTAATGGGGCTTCTG Z49 
1 /207 CCGGTGTCCGAATATAGCGACGCAGAGGTGGTCTTAATCAGCATCTTAATGGGGCTTCTG 300 
1/197.1 GTTCTAGGCATCGTCTTTGGCAACGTGCTGGTCATCAGCGCCATTGTACGATTTCAACGC _09 
18/207 GTTCTAGGCATCGTCTTTGGCAACGTGCTGGTCATCAGCGCCATTGTACGATTTCAACGC =ECU 
1/197.1 TTGCAGACGGGCACCAACTACTTCATCAGCTCCCTTGCCTGCGCCGACTTGGTCATGGGT i6r+ 
1R/207 TTGCAGACGGGCACCAACTACTTCATCAGCTCCCTTGCCTGCGCCGACTTGGTCATGGGC 420 
1/197.1 CTCATGGTGGTGCCGTTCGGCGCGTGCTACATCCTCCTCAACACGTGGCACTTCGGAAAC 49 
18/207 CTCATGGTGGTGCCGTTCGGCGCGTGCTACATCCTCCTCAACACGTGGCACTTCGGAAAC 480 
1/197.1 TTCTTCTGCGAGTTTTGGACGGCTACGGACGTGTTGTGCGTGACCGCTAGCATCGAGACG 489 
18/207 TTCTTCTGCGAGTTTTGGACGGCTACGGACGTGTTGTGCGTGACCGCTAGCATCGAGACG 540 
+i.. i**fki.. *t+iffif+#+*4***+M++#kt3*+*+++#i! ***+ii***Li++4. 
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See next page for continuation 
Continued... 
1/197.1 TTGTGCGTGATCGCCCTGGACCGG'rACGTCGCCATCATGTGGCCTCTACGCTATCAGTCG 54y 
18/20? TTGTGCGTGATCGCCCTGGACCGGTACGTCGCCATCATGTGGCCTCTACGCTATCAGTCG ijI 
1/197.1 ATGCTTACGAAGCGGAAGGCGTGCGGGATAGTCCTCGCGGTGTGGGCGGTG--------- 600 
18/207 ATGCTTACGAAGCGGAAGGCGTGCGGGATAGTCCTCGCGGTGTGGGCGGTGGCCGCCCTG 660 
1/197.1 ------------------------------------ TCCGACGACCCGGCTGCGCGGAGT 624 
18/207 ATCTCTTTCCTGCCCATCCACATGGAGTGGTGGGTGTCCGACGACCCGGATGCGTTGAGT 720 
1/197.1 TGCTTGAAGAACCCGACCTGCTGCGACTTCAACACCAACGCCGCCTACGCCGTGACCTCC 6ý4 
18/207 TGCTTGAAGAACCCGACCTGCTGCGACTTCAACACCAACGCCGCCTACGCCGTGACCTCC 790 
1/197.1 TCCATCGTCTCCTTCTACATCCCGCTGGTCATCATGGTGTTCGTGTACAGCCGGGTTTTC 744 
18/207 TCCATCGTCTCCTTCTACATCCCGCTGGTCATCATGGTGTTCGTGTACAGCCGGGTTTTC 840 
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
1/197.1 CAGGAGGCCCGTCGGCAGCTTCAGAAAATCGATCGCATTGAGGGACGCATACGCACGCAG 804 
18/207 CAGGAGGCCCGTCGGCAGCTTCAGAAAATCGATCGCATTGAGGGACGCATACGCACGCAG 900 
1/197.1 AGCTTCAGCACCCAGGAGGGGAAC------------ CGGAGGACCAAGTTCGGCATGAAG 852 
18/207 AGCTTCAGCACCCAGGACGGGAACGAGACGAAGAACCGGAGGACCAAGTTCGGCATGAAG 96U 
1/197.1 GACCACAAAGCTCTGAAGACGTTGGGGATCATCATGGGAACATTCACCCTCTGCTGGCTG 912 
18/207 GACCACAAAGCTCTGAAGACCTTGGGGATCATCATGGGAACATTCACCCTCTGCTGGCTG 1020 
1/197.1 CCGTTTTTCGTGCTTAACGTGGCGGCGGCCATCTGGAAGATGGAGAACATCATGTTGCCG 972 
18/207 CCGTTTTTCGTGCTTAACGTGGCGGCGGCCATCTGGAAGATGGAGAACATCATGTTGCCG 1080 
1/197.1 TTCAGGATCTTGAACTGGATCGGATACGCCAACTCCGCTTTCAATCCCCTCATCTACTGC 1U. 3 
18/207 TTCAGGATCTTGAACTGGATCGGATACGCCAACTCCGCTTTCAATCCCCTCATCTACTGC 1140 
1/197.1 AGGAGTCCTGAGTTUAGGTGCGCCTTTCAGGAGATCCTGTGCCGGAGAACTTCTCACCTG 109? 
18/207 AGGAGTCCTGAGTTCAGGTGCGCCTTTCAGGAGATCCTGTGCCGGAGAACTTCTCACCTG 1200 
1/197.1 CCCTCCACGAGGAATAACAAGGGATTTATATACAGCGGGCACAGCTGGAAAGTGCACACG 1152 
18/207 CCCTCCACGAGGAATAACAAGGGATTTATATACAGCGGGCACAGCTGGAAAGTGCACACG 126U 
1/197.1 AAGACCGCCAGACAACGAGAGCCCTCGCCAGCTTGCGAAACCGAAATGGGTGCGGGCAAC 
18/207 AAGACCGCCAGACAACGAGAGCCCTCGCCAGCTTGCGAAACCGAAATGGGTGCGGGCAAC 1320 
1/197.1 GGGAATTGTAATAAAGCTGTGACGTCCGATTTTTAG 1l/2 
18/207 GGGAATTGTAATAAAGCTGTGACGTCCGATTTTTAG 1380 
************************************************************ 
1/197.1 ---------------------------------- 1298 
I2/%07 1440 
1/197.1 ------ 
18/207 AAAAA 1440 
72 
Figure 2.28. Comparison of the probable ß2-AR nucleotide sequences of the fathead 
minnow. One sequence has been called 1/197.1 and the other 18/207. Indicates weak 
groups of alignment. Blue nucleotides indicate start and stop codons. The ribosomal 
binding site is highlighted in yellow. The Initiator sequence (or TATA box) is highlighted 
in red or pink. Large capitals at the 3' UTL represent nucleotides not tested by proof 
reading taq. The 3' UTR motif is highlighted in ý=. 
The initiator sequence (or TATA box) has the sequence - 5' 3' (Y 
=C or T). It is usually found 25-30bp from the start codon. However, in both instances 
where the potential initiator sequence is expressed in the ß2-ARs, this is not the case. 
('T. A. ATTTT is found 11 bp from the start codon, and "1'7'; 1'1'7°I'"1'T is 32bp from the start 
codon. 
1/197.1 MERGDRLSAENTSLHMNVSSGLNDSSPVSEYSDAEVVLISILMGLLVLGIVFGNVLVISA 60 
207 MEGGDRLSVENTSLHMNVSSGLNDSSPVSEYSDAEVVLISILMGLLVLGIVFGNVLVISA 60 
1/197.1 IVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCEFWTATDVLCV 120 
207 IVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCEFWTATDVLCV 120 
+. **+++r*+*++*+++++a:. +++++*k**.. +++++#+t**++++++++++++r. *** 
1/197.1 TASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVS--------------- D 165 
207 TASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVAALISFLPIHMEWWVSD 180 
1/197.1 DPAARSCLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEARRQLQKIDRIE 225 
207 CPDALSCLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEARRQLQKIDRIE 240 
1/197.1 GRIRTQSFSTQEGN----RRTKFGMKDHKALKTLGIIMGTFTLCWLPFFVLNVAAAIWKM 281 
207 GRIRTQSFSTQDGNETKNRRTKFGMKDHKALKTLGIIMGTFTLCWLPFFVLNVAAAIWKM 300 
1/197.1 ENIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCRRTSHLPSTRNNKGFIYSGH 341 
207 ENIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCRRTSHLPSTRNNKGFIYSGH 360 
1/197.1 SWKVHTKTARQREPSPACETEMGAGNGNCNKAVTSDF 378 
207 SWKVHTKTARQREPSPACETEMGAGNGNCNKAVTSDF 397 
*#**+#1ti#i*+++*##t+#ki«+*i.. #if. ti+* 
Figure 2.29. Comparison of the amino acid sequences for the two (i2-AR sequences 
found in the fathead minnow. (*) Indicates identical amino acid sequence in that 
column. (: )Means conserved substitutions have been made. (. ) Indicates that semi- 
conserved substitutions are observed 
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2.3.5 Hydropathy analysis 
To find out where the TMDs were located in each ß-AR sequence for the fathead minnow, 
hydropathy analysis was undertaken. Using a search engine on the internet, many different 
hydropathy programmes were found. Unfortunately, none of them gave the same results. 
In order to find the `best fit', certain criteria were drawn-up based on information from 
other GPCRs and their motifs; these are summarised in Table 2.7. In addition to this, 
hydrophobic amino acids were identified and used to weight the results obtained from the 
different software programmes. Because TMDs are often areas of high conservation, other 
fish that had the same receptor sequences were aligned against the fathead sequence for 
each particular VAR and used to compare amino acid sequences in each area. Figures 
2.30 and 2.31, and Tables 2.8 and 2.9, show the results of this analysis. 
Motif Amino acid Reference 
Asparagine-linked glycosylation site in the NH2 Emorine et al., 
terminal region (before TMD 1). 1989 
Cysteine residues for disulfide bond formation Cao et al., 1998 
Aspartate residue in 2° TMD, found in most serpentine Devic et al., 
receptors regardless of their natural ligand. 1997 
Motif at border between TMD III and IL2. This is Fredriksson et 
characteristic of the a rhodopsin group. However, it is al., 2003, 
also quoted as occurring at the end of the 3d TMD of Devic et al., 
other GPCRs. 1997 
Ligand binding residues, found in TMD III (D), TMD Cao et al., 1998, 
V (S and S), and TMD VI (F). Freddolino et 
al., 2004 
Tryptophan residue found in the middle of 4` and 6` Devic et at., 
TMDs. This is found in most serpentine receptors, 1997 
regardless of ligand. 
Serine and Threonine residues in 3" cytoplasmic loop or Emorine et al., 
(between TMD V and TMD VI) and COON terminal 1989 
region (after TMD VII). 
Found in TMDVII and is characteristic of the a Fredriksson et 
rhodopsin group. al., 2003 
Found in ß 1-ARs at the start of the COOH loop after Mason et al., 
TMD VII. 1999 
Table 2.7. Summary of the different motifs found commonly in GPCRs. 
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Fathead ------------------------------------------MEALHTGPEV-LNERASF 17 
Fathead ------------------------------------------MEALHTGPEV-LNERASF 17 
Fathead ------------------------------------------MEALHTGPEV-LNERASF 17 
Fathead ------------------------------------------MEALHTGPEV-LNERASF 17 
Fathead ------------------------------------------MEALHTGPEV-LNERASF 17 
Fathead ------------------------------------------ :: E. 'ýIHTGPE--: NER.. 'Iý 17 
LHTMGDGLPS--VNYSNDSKRTPD L--SEQWLV(TMGT ýmw 73 
LHTMGDGLPS--VNYSNDSKRTPD L--SEQWI. ' 'VAIAR 73 
Fathead LHTMGDGLPS--VNYSNDSKRTPD L--SEQWI, VGMGIIMGLVVIVIVVGNILVI§AIAR 73 
Fathead LHTMGDGLPS--VNYSNDSKRTP L--SEQBVGMGIIMGLVVIVIVVGNILVIVAIAR 73 
LHTMGDGLPS--VNYSNDSKRTPD L--SEQW1,. I. I... I..: IVAIAR 73 
)"atIle-l HT'. IGDGI, PS--. 'NiSND: 'KRTPDNI, --. EQ. -. G ý; :; NI '-R 73 
Fathead 
Fathead 
Fathead 
Fathead 
Fathead 
Edthead 
133 
133 
133 
133 
133 
133 
193 
193 
193 
193 
193 
193 
NEPECCDFI RE ARVYREAKQQLKKINKCEGRFYN 253 
NEPECCDFI REYAISSSVISFYIPLIVMIFVYARVYREAKQQLKKINKCEGRFYN 253 
NEPECCDFI REY REAKQQLKKINKCEGRFYN 253 
NEPECCDFI REY EAKQQLKKINKCEGRFYN 253 
Fathead EPECCDFI REYAIS. `1SVISFYIPLIVMIFVYARVYRFAKQQLKKINKCEGRFYN 253 
Fathead SCYNEPECCDFTTNRE, I ... 
i PI, IR. RE: ýKQQI, KKINKCEGRFlIN 253 
N-GTNCKPNRKR ILALKEQKALI VFGKEVVK- 312 
Fathead N-GTNCKPNRK ILALKEQKALKTLGIIMGTFTL P IVNVVRVFGKEVVKKEL 312 
N-GTNCKPNRKR ILAL IVNVVRVFGKEVVKKEL 312 
N-GTNCKPNRKR ILALKEQKALKT FGKEVVKKE, 312 
Fathead N-GTNCKPNRKR ILALKEQKALKTLGIIMGTFTLC LP IVNVVRVFGKEVVKKEL 312 
Fathead N-GTNCKPNRKRTTKI I \I, KEQK I KT' G LT TCPR 'FGKE". '. 'KKEI, 312 
RSPDFRKAFKR. I, CCPRQADRRLHVSSCDLSRCTGGFVNS 372 
FVFLNWLG RSPDFRKAFKR. LCCPRQADRRLHVSSCDLSRCTGGFVNS 372 
Fathead FVFLNWLGYVNSAFNPI1 RSPDFRKAFKR'T. CCPRQADRRLHVSSCDLSRCTGGFVNS 372 
Fathead ýjr SPDFRKAFKR. LCCPRQADRRLHVSSCDLSRCTGGFVNS 372 
FV FLNWLGYVNSAFNPII'i RSPDFRKAFKR 1 CCPRQADRRLHVSSCDLSRCTGGFVNS 372 
F3thhcad i""IFLI3 [ GYVIISP". kt'rJPTI iCfta['DFRF' 1'hR I, CCPRQADRRI. H. 'SSCD! SRCTGG! ' 'NS 372 
Fathead MEQSMLGTWSDCNGTDSRDCSLERNGRVSHSESQL 407 
Fathead MEQSMLGTWSDCNGTDSRDCSLERNGRVSHSESQL 407 
Fathead MEQSMLGTWSDCNGTDSRDCSLERNGRVSHSESQL 407 
Fathead MEQSMLGTWSDCNGTDSRDCSLERNGRVSHSESQL 407 
Fathead MEQSMLGTWSDCNGTDSRDCSLERNGRVSHSESQL 407 
Fathead I: EQSIV. I. GT'aSDCNGTDSRDCST. ERNGRVSHSESQL 407 
Figure 2.30. Results of the hydropathy analysis of the fathead minnow ßl-AR sequence. 
Different results were obtained from hydropathy analysis using different software 
packages, with the predicted topology highlighted in the following colours; -, 
ConPred_all . miklos/DAS 
In the final sequence of 
each block, the red hi. zhIh hted letters shovv hvdropliuhic amine acids. 
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NQRLQTI, TN.: 
.SC, D. G P: G:, DI, E`JRGSWMYGSFFCEI. ': S DCTS 
F: T C DR::: 'TS P; RYQS TK: RKC_, SFLT H. SRDT. 'DT 
Table 2.8 identifies the number of TMDs predicted by each programme and summarizes 
whether the different motifs associated with GPCRs are predicted to be present. 
ConPredal E miklos/DAS 
Motif 
W 
M1/ 1 tmdas. cgi 91 
Number of 7 7 6 7 7 
TMDs 
Yes Yes Yes Yes Yes 
Yes Yes Yes Yes Yes 
Yes Yes Yes Yes Yes 
Yes Yes Yes Yes No 
in middle of TMD IV: TMD IV: TMD IV: TMD IV: TMD IV: 
4`h and 6`h YES YES YES Yes Yes 
TMDs TMD VI: TMD VI: TMD VI: TMD VI: TMD VI: 
YES YES YES YES YES 
1 or l Yes Yes No Yes Yes 
Ligand binding Yes Yes No Yes No 
residues in 
TMD 111, V. VI 
NsxxNPxxY Yes Yes No Yes No 
RSPDFRKAFKR Yes Yes Yes No Yes 
Table 2.8. A summary showing how the different hydropathy programmes predict TMDs 
and the motifs associated with GPCRs for the fathead minnow ß1-AR. 
As Table 2.8 shows, - and ConPred_all show the highest amount of motif 
conformity out of all the programmes used. 
Table 2.9 shows the percentage of hydrophobic residues in each TMD. This was 
calculated by the number of nucleotides that were hydrophobic within each predicted 
TMD, divided by the total number of nucleotides within that particular TMD. As shown, 
scores the highest percentage of hydrophobic residues within the predicted 
TMDs. Therefore, - was used to designate the TMDs for the ßl-AR, as it is one 
of the programmes to satisfy the motif criteria found in GPCRs and it is the only 
programme that predicts the highest percentage of hydrophobic residues, showing 4 out of 
7 TMDs to contain the highest percentage of hydrophobic residues when compared to 
predictions made by the other programmes. 
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TMD 
ConPred 
all 
lip W miklos/DA 
S/ 
1 76 74 74 79 
Percentage of II 71 74 74 73 
hN drophohic III 62 73 73 60 
residues IV 68 67 65 65 
found in each V 62 91 91 71 
TMD: VI 68 67 48 70 
VII 0 74 
Table 2.9. A comparison of the percentage of hydrophobic residues in each TMD as 
predicted by each programme. _ highlights show the highest score for each TMD. 
The same type of analysis was carried out for both ß2-AR sequences. Again, - 
was the most successful at predicting the TMDs with respect to the criteria set (data not 
shown). The hydropathy results (based on using TMPRED) predicting the topology of the 
TMDs for all the fathead minnow ß-ARs sequenced are shown in Figure 2.31. 
131 MEALHTGPEVLNERASFLHTMGDGLPSVNYSNDSKRTPDNLSEQWLVGMGIIMGLVVIVI 60 
132(197) ---MERGDRLSAENTSLHMNVSSGL------NDSS-PVSEYSDAEVVLISILMGLLVLGI 50 
ß2(207) ---MEGGDRLSVENTSLHMNVSSGL------NDSS-PVSEYSDAEVVLISILMGLLVLGI 50 
(''1 VVGNILVIVAIARNQRLQTLTNVFIVSLACADLIMGLLWPFGADLEVRGSWMYGSFFCE 120 
ý2(197) VFGNVLVISAIVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCE 110 
ß2(207) VFGNVLVISAIVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCE 110 
FWISLDVLCVTASIETLCVIAIDRYIAITSPFRYQSLLTKARAKVVVCAVWAISALVSFP 180 
P2(197) FWTATDVLCVTASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVS-- 164 
02(207) FWTATDVLCVTASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVAALISFL 170 
R1 PILMHWS--RDTVDTSCYNEPECCDFITNREYAISSSVISFYIPLIVMIFVYARVYREAK 233 
(; 2(197) ---------DDPAARSCLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEAR 215 
V2(207) PIHMEWWVSDDPDALSCLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEAR 230 
(il QQLKKINKCEGRFYNNGTNCKPNR--KRTTKILALKEQKALKTLGIIMGTFTLCWLPFFI 296 
72(197) RQLQKIDRIEGRIRTQSFSTQEGN---- RRTKFGMKDHKALKTLGIIMGTFTLCWLPFFV 271 
P2(207) RQLQKIDRIEGRIRTQSFSTQDGNETKNRRTKFGMKDHKALKTLGIIMGTFTLCWLPFFV 290 
VNVVRVFGKEVVKKELFVFLNWLGYVNSAFNPIIYCRSPDFRKAFKRLLCCPRQADRRLH 356 
(2(197) LNVAAAIWKMENIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCR----- RTSH 326 
(', 2(20"7) LNVAAAIWKMENIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCR-----RTSH 345 
.++++. #+*. it #*ik**+. i**++#. i+##.. ++++ 
VSSCDI, SRCTGGFVNSMEQSMLGTWSDCNGTDSRDCSLER---NGRVSHSESQL- 407 
ß2(197) LPS---TRNNKGFIYSGHSWKVHTKTARQREPSPACETEMGAGNGNCNKAVTSDF 378 
ß2(2O7) LPS---TRNNKGFIYSGHSWKVHTKTARQREPSPACETEMGAGNGNCNKAVTSDF 397 
Figure 2.31. The amino acid sequences of the ßl-AR and both versions of the [32-ARs of the 
fathead minnow presented as a clustal alignment. The red letters denote the designation of the 
TMDs as predicted using the hydropathy programme -. (*) Indicates identical amino acid 
sequence in that column. (: )Means conserved substitutions have been made. (. ) Indicates that 
semi-conserved substitutions are observed. 
77 
Fathead minnow B1-AR (%) Fathead minnow B2-AR 
Version 207 
Whole TMDs Whole TMDs 
sequence 1 11 111 IV V VI VI1 sequence 1 11 111 IV V VI VII 
Fathead 46 62 52 84 33 65 86 72 98 100 100 100 92 100 100 100 
minnow 
B2-AR 
version 
197 
Fathead 45 65 82 84 60 61 88 76 
minnow 
B2-AR 
version 
207 
Table 2.10 Percentage identity for the pairwise alignment for the whole sequence, and 
each TMD, for the fathead minnow ß 1- and both versions of the ß2-ARs. 
As shown by Figure 2.31, there is quite a lot of conservation between the different ß-ARs, 
especially within the TMDs. Table 2.10 reports the results of the analyses the percentage 
identity (pairwise alignment) between different fathead minnow ß-ARs, with respect to the 
whole sequences and their TMDs. TMD pairwise alignment was worked out by counting 
the number of identical aligned amino acids in the TMD in the overlapping parts of the 
TMDs, divided by the number of nucleotides in the TMDs that overlap, rounded to a whole 
percentage. 
These results show that the homology between each receptor for each TMDs on the whole 
is very high (i. e. >60 %), with the only exception being in TMD IV between the two 
versions of the 02-AR. 
2.3.6 Comparison of fathead minnow ß1- and ß2-ARs and their similarity to ß-ARs 
of other fish species and humans 
ß1- and ß2-ARs have been characterised in other fish species, and Table 2.11 and Table 
2.12 show the percentage identities between different 0 1-ARs and 02-ARs, respectively, at 
amino acid level. 
Other species Fathead minnow ßl-AR 
Zebrafish 01-AR 91 % 
Tetraodon ß 1-AR 76 % 
Takifugu 01-AR 73 % 
Stickleback ß 1-AR 75 % 
Human 0 1-AR 57% 
Table 2.11. Percent homology between 01-AR in the fathead minnow and the PI-AR of 
other species of fish and the human 0 1-AR. 
Other species Fathead minnow p2-AR 
(version 197) 
Fathead minnow ß2-AR 
(version 207) 
Zebrafish ß2-AR 87 % 88 % 
Trout 02-AR 62 % 63 % 
Tetraodon ß2-AR 57 % 62 % 
Takifugu 02-AR 57 % 58 % 
Human ß2-AR 53% 52% 
Table 2.12. Percent homology between the (32-AR in the fathead minnow and the (32-AR 
of other species of fish and the human ß2-AR. 
For the 01 -AR, other fish species show the highest amount of homology to the ßl -AR in 
the fathead minnow. Human ßl-AR shows the least homology of the species tested, 
although 57% is still a high degree of conservation. 
There is a greater degree of homology between other fish ßl-ARs and fathead minnows 
ß 1-ARs, than there is between the fathead minnow 02-AR and other fish 02-ARs (as 
shown in Tables 2.11 and 2.12). In the fathead minnow, the 02-AR 207 version shows a 
slightly greater degree of homology to the 02-AR of the other species than the 02-AR 
version 197. Both fathead minnow 01- and 02-ARs show the highest degree of homology 
to their counterparts in the zebrafish. They have significantly less homology to the ß-ARs 
of other fish species (e. g. trout and pufferfish). 
As can be seen from Figures 2.33 and 2.34, when sequences for fish and human 01- and 
02-ARs are aligned respectively, the greatest amount of conservation is found within the 
TMDs. 
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Fathead -------------------------------------------MEALHTGPEVLNERASF 17 
Zebrafish ---------------------------------------------- -------------- 
Gammarus ------------------------------------------------------------ 
Tetraodon ------------------------------ 
Takifugu MSPPALVSWPTAQLGQAEGESASPAGAGARRTSSWSLRDSLPKAALHCLDELDLATHTAQ 60 
Human -----------------------------------------MGAGVLVLGASEPGNLSSA 19 
Fathead LHTMGDGLPS--VNYSNDS--KRTPDNL-------SEQWLVGMGIIMGLVVIVIVVGNIL 66 
Zebrafish ---MGDGLPS--VNYSNDS--KRATVDLN----- VSEQWLVGMGILMGLIVFVIVVGNIL 48 
Gammarus ---MGDGGAHSALSLPNAS--GTEAPDAPDSATAASERWMAGMSVLMGLIVVSIVLGNIL 55 
Tetraodon ---MGDGDLSSAPNSHNGS--ASDASNA-----GASEHWVACLSLVMGSIVLFIVFGNIL 50 
Takifugu QPVMGDGDPSSPVNLQNSS--ASDAPDS----- AASEHWLACMSLVMGLIVLFIVFGNIL 113 
Human AP-LPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAGMGLLMALIVLLIVAGNVL 78 
Fathead VIVAIARNQRLQTLTNVFIVSLACADLIMGLLWPFGADLEVRGSWMYGSFFCEFWISLD 126 
Zebrafish VIVAIARNQRLQTLTNVFIVSLACADLIMGLLVVPFGAALEVRGAWMYGSFFCEFWISLD 108 
Gammarus VIVAIAKTQRLQTLTNVFIVSLAGADLIMGLLVVPFGAALEVRGSWLYGSFFCEFWISVD 115 
Tetraodon VIVAIARTQRLQTLTNVFIVSLASADLIMGLLVVPFGAALEVRGSWQYGSFFCEFWISVD 110 
Takifugu VIVAIAKTQRLQTLTNVFIVSLASADLIMGLLVVPFGAALEVRGSWQYGSFFCEFWISVD 173 
Human VIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVVWGRWEYGSFFCELWTSVD 138 
Fathead VLCVTASIETLCVIAIDRYIAITSPFRYQSLLTKARAKVVVCAVWAISALVSFPPILJ-IW 186 
Zebrafish VLCVTASIETLCVIAIDRYIAIISPFRYQSLLTKARAKVVVCAVWAISALVSFPPILMHW 168 
Gammarus VLCVTASIETLCVIAIDRYVAITSPFRYQSLLTKARARTVVCVVWAISALVSFLPILMHW 175 
Tetraodon VLCVTASIETLCVIAIDRYVAITSPF'RYQSLLTKARARAMVCAVWAISALVSFLPILMHW 170 
Takifugu VLCVTASIETLCVIAIDRYVAITSPFRYQSLLTKARAKAMVCAVWAISALVSFLPILMHW 233 
Human VLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVCTVWAISALVSFLPILMHW 198 
Fathead SRDTVDTS--CYNEPECCDFITNREYAISSSVISFYIPLIVMIFVYARVYREAKQQLKKI 244 
Zebrafish SQDSEETS--CYENPECCDFVTNRAYAISSSIISFYIPLIVMIFVYARVYREAKQQLNKI 226 
Gammarus SRDSVDTA--CYDDPECCDFVTNRAYAISSSIISFYIPLLVMIFVYARVYREAKQQLRKI 233 
Tetraodon SRDSVHTS--CYQNPECCDFITNKAYAISSSIISFYIPLLVMIFVYARVYREAKMQLRKI 228 
Takifugu SRDSVHTA--CYEDPKCCDFITNKAYAISSSIISFYIPLVVMIFVYARVYREAKLQLRKI 291 
Human WRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIMAFVYLRVFREAQKQVKKI 258 
Fathead NKCEGRFYNN-GTNCKPN------------------------------- RKRTTKILALK 272 
Zebratish NKCEGRFYNNHGTNCKPT-------------------------------RKRTTKILALK 255 
Gammarus DKCEGRFHNTLTGLTSKF------------------------------- KKRPSKILALR 262 
Tetraodon DKCEGRFHNTLTGLTSKC-------------------------------KKRPSKMLALR 257 
Takifugu DKCEGRFHNTLTGLTSKC-------------------------------KKRPSKILALR 320 
Human DSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAPLANGRAGKRRPSRLVALR 318 
Fathead EQKALKTLGIIMGTFTLCWLPFFIVNVVRVFGKEVVKKELFVFLNWLGYVNSAFNPIIYC 332 
Zebrafish EQKALKTLGIIMGTFTLCWLPFFIVNVVRVFCAQVVDKELFVFLNWLGYVNSAFNPITYC 315 
Gammarus EQKALKTLGIIMGTFTLCWLPFFIVNVVRVFCAEVVDKDLFVFLNWLGYANSAFNPVIYC 322 
Tetraodon EQKALKTLGIIMGTFTLCWLPFFIVNVVRVFSAAMVDQDLFVFLNWLGYVNSAFNPIIYC 317 
Takifugu EQKALKTLGIIMGTFTLCWLPFFIVNVVRVFSAATVDKDLFVFLNWLGYVNSAFNPIIYC 380 
Human EQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFVFFNWLGYANSAFNPIIYC 378 
Fathead RSPDFRKAFKRLLCCPRQADRRLHVSSCDLSRCTGGFVNSMEQS---------------- 376 
Zebra fish RSPDFRKAFKRLLCCPRQADRRLHVSSCDLSRCTGGFGNSMEQS---------------- 359 
Gammarus RSPDFRKAFKRLLCCPRQADRRLHASSCDLSRYSGGFVSALEPG---------------- 366 
Tetraodon RSPDFRKAFKRLLCCPRQADRRLHVSSCDLSRCSGGFASPL------------------- 358 
Takifugu RSPDFRKAFKRLLCCPRQADRRLHISSCDLSRCSGGFVSPLENG---------------- 424 
Human RSPDFRKAFQGLLCCARRAARRRHATHGDRPRASGCLARPGPFP: PGAASDDDDDDVVGA 43R 
Fathead -----MLGTWSDCNG--TDSRDCSLERNGRV-SHSESQL-- 407 
7, ebrafish -----MLGTWSDCNG--ADSSDCSLERNGRM-SHSESQL-- 390 
Gammarus ----- ALGLWSDCAA--LD---------------------- 378 
Tetraodon ----------------------------------------- 
Takifugu -----TLGMWSDCAA--LDNSDSSLVGTAKR-SHSESTM- 455 
Human TPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV- 477 
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Figure 2.33. Clustal multiple sequence alignment of the amino acid sequences of fish 
and human (3l-ARs. Red letters indicate TMDs in fathead minnow sequence as 
determined by the software programme TMPRED. (*) Indicates identical amino acid 
sequence in that column. (: )Means conserved substitutions have been made. (. ) 
Indicates means that semi-conserved substitutions are observed 
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Fathead197 MERGDRLSAENTSLHMNVSSGLNDSSP----VSEYSDAEVVLISILMGLLVLGIVFGNVL 56 
Fathead207 MEGGDRLSVENTSLHMNVSSGLNDSSP---- VSEYSDAEVVLISILMGLLVLGIVFGNVL 56 
Zebrafish MEGDNTLITENTSLYMNISAGLNASSPVSLSVSEYSDAEVVLISILIGILVLVIVFGNAL 60 
Trout MENVSTPAVFNLS---DLSVEMNSSSR-QWSYSEYSEAVAVLLGILMALLVMCIVFGNVL 56 
Tetraodon ------------------------------------EVTMILLGIVMSFLVLCIVFGNIL 24 
Takifugu MGSTAPTGYLNAS----- TEKIPTSDP-TKQEEGYSEVTMILLGMVMSFLVLCIVFGNIL 54 
Human MGQPGNGSAFLLAP--NRSHAPDHDVT----- QERDEVWVVGMGIVMSLIVLAIVFGNVL 53 
Fathead197 VISAIVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCEFWTATD 116 
Fathead207 VISAIVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCEFWTATD 116 
Zebrafish VISAIVRFQRLQTVTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCEFWTATD 120 
Trout VITAIVRFQRLQTVTNMFITSLACADLVMGLLVVPFGACYILLNTWHFGSFLCEFWTAAD 116 
Tetraodon VITAIARFQRLQNITNCFITSLACADLVMGLIVIPFGACYIIFKTWHFGSFWCEFWTATD 84 
Takifugu VITAIARFQRLQNVTNCFITSLACADLVMGLIVIPFGACYIIFKTWHFGSFWCEFWTATD 114 
Human VITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSID 113 
Fatheadl97 VLCVTASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVS------------ 164 
Fathead207 VLCVTASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVAALISFLPIHMEW 176 
Zebrafish VLCVTASIETLCVIALDRYIAIMWPLRYQSMLTKRKACGMVIGVWAVAALISFLPIHMEW 180 
Trout VLCVTASIETLCVIALDRYLAITSPLRYPSLLTKRKACVVVVTVWGVAALISFLPIHMKW 176 
Tetraodon VLCVTASIETLCVIAIDRYLAITSPFRYQSMLTKCRARIVVVLVWVIAALISFLPIHMKW 144 
Takifugu VLCVTASIETLCVIAIDRYLAITSPFRYQSMLTKCRARIVVVLVWVIAALISFLPIHMKW 174 
Human VLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHW 173 
Fathead197 ---DDPAARSCLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEARRQLQKI 221 
Fathead207 WVSDDPDALSCLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEARRQLQKI 236 
Zebrafish WVSEDPEALSCLEEPTCCDFNTNAAYAVPSSIISFYIPLVIMAFVYSRVFQEARRQLQKI 240 
Trout WVSDEPEALSCLEDAHCCDFNTNAAYAVASSVVSFYIPLAVMAFVYGRVFQEARKQLEKI 236 
Tetraodon WISDDEDAKRCIEDSSCCEFYTNMAYAITSSIISFYIPLVIMVFVYSRVFQEAKRHLKKI 204 
Takifugu WISDDEEAKRCIEDSSCCEFYTNMAYAITSSIISFYIPLVIMVFVYSRVFQEAKQQLKKI 234 
Human YRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKI 233 
F, it}iead197 DRIEGRiR---TQSFSTQEGN------------- RRTKFGMKDHKALKTLGIIMGTFTLC 265 
Fathead207 DRIEGRIR---TQSFSTQDGNET---------KNRRTKFGMKDHKALKTLGIIMGTFTLC 284 
Zebrafish DRIEGRIR---TQSLSTQEGNEI---------KNRRTKFCMKDHKALKTLGIIMGTFTMC 288 
Trout RGSEGRFH--- AQMIDNNQGQDGGDGSGGGGGNGKRPKFCLKEHKALKTLGIIMGTFTLC 293 
Tetraodon DQSVGRFQISDDSNLNSLEANSTR--------SQKKAKFCLREHKALKTLGIIMGIFTLC 256 
Takifugu DQSVGRFHNNDDNNLRSLDANSTR-------- SQKKAKFCLREHKALKTLGIIMGIFTLC 286 
Human DKSEGRFH---VQNLSQVEQDGRTG-----HGLRRSSKFCLKEHKALKTLGIIMGTFTLC 
*+*+. ************ 
285 
Fathead197 WLPFFVLNVAAAIWKMENIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCRRTS 325 
Fathead207 WLPFFVLNVAAAIWKMENIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCRRTS 344 
Zebrafish WLPFFVLNVVAAIWKMDNIMLPFRILNWIGYANSAFNPLIYCRSPEFRCAFQEILCWRPS 348 
Trout WLPFFVLNVVVTIWKVDNIKMPFRILNWIGYANSAFNPLIYCRSPEFRYAFQEILCLRGA 353 
Tetraodon WLPFFLLNVVVAIWKEQHNDLAFRILNWIGYANSAFNPLIYCRSPEFRYAFKEILCLKRN 316 
Takifugu WLPFFLLNVVVAIWKEQHNDLAFRILNWIGYANSAFNPLIYCRSPEFRYAFKEILCMKRN 346 
Human WLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRS X14` 
Fathead197 HLPSTRN---NKGFIYSGHSWKVHT--KTARQREPSPACETEMGAG------------- N 367 
Fathead207 HLPSTRN---NKGFIYSGHSWKVHT--KTARQREPSPACETEMGAG------------- N 386 
Zebrafish HLPSTRS---KKGYLYSGHSWKVHT--KTTRPREPSPACETEIGAECLTAGTKN---- KN 399 
Trout AFPTN------- GYIYRGHSLRLSP--KDKPGSLSNNVGTVELGSLSSVTN------- IN 397 
Tetraodon RLTNPAP---VNGYIYSKQGWQSEQQGRSKVSLEDSEANESYLG---------------- 357 
Takifugu RLTNPGP---VNGYIYSRHSWQSEQQGRSKVSLEDSEANESCLGKGMEVCTVIDKTVDPN 403 
Human SLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRN 405 
Fatheadl97 GNCNKAVTSDF--- 378 
Fathead207 GNCNKAVTSDF--- 397 
Zebrafish GNYNKTVTSI---- 409 
Trout GYCNNPPLASIV-- 409 
Tetraodon -------------- 
Takifugu GNCNKGLTTVTTVL 417 
Human CSTNDSLL------ 413 
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Figure 2.34. Clustal 2.0.3 multiple sequence alignment of the amino acid sequences of 
fish and human (32-ARs. Red letters indicate TMDs in fathead minnow sequence as 
determined by the software programme TMPRED. (*) Indicates identical amino acid 
sequence in that column. (: )Means conserved substitutions have been made. (. ) Indicates 
means that semi-conserved substitutions are observed. 
2.3.7 Phylogenetic analysis 
Figure 2.35 and Figure 2.36 show the results of the phylogenetic analyses for fish and 
human species in which ß-ARs have been characterised. 
cluster algorithm PHYLOGENETIC TREE Rectangular oüh bootsfrag -1-11. ¢s 
Rat 
Hou :c 
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Hneiurus 
Figure 2.35. A phylogenetic tree for (il-AR with bootstrap values. Analysis was 
carried out at in PIIYLIP format 
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Figure 2.36. A phylogenetic tree for (32-ARs with bootstrap values. Analysis was 
carried out at www. genebee. msu. su in PI LYLIP format 
The results from the phylogenetic analysis mimic those seen in Tables 2.11 and 2.12, as the 
sequences which are the most similar to fathead minnow ß-AR's, i. e. zebrafish, are those 
that have most recently split from the genetic line. The bootstrap values show that the (32- 
AR results are much more robust than those of the (i 1-AR phylogenetic analysis. 
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2.4 Discussion 
ß-ARs have been found to be present in a wide range of animals and fish, so it was not 
surprising that this study managed to isolate a ßl-AR and possibly two ß2-ARs in the 
fathead minnow. Due to the structure of GPCRs, there are parts of the receptor that have 
remained constant throughout the evolution of different species. For instance, the high 
amount of conservation in the TMDs and the identification of GPCR motifs made it 
possible to characterise the new sequences that were discovered. A third (3-AR subtype, 
namely ß3-AR, has also been characterised in many genomes, and it would be expected to 
be present in the fathead minnow genome. However, no attempt was made to characterise 
this receptor because this project focused on the (potential) role of ß-blockers in fish and 
these would be expected to act primarily through the ß 1- and ß2-AR. 
2.4.1 Evolution 
As whole genomes of different animals throughout the animal kingdom are being 
sequenced, GPCRs are being found in a wide range of organisms from plants to humans, 
and often more than one gene of each (3-AR subtype can be found (Grill & Christmann, 
2007). The presence of more than one gene for a particular subtype is due to different 
duplication events, such as the duplication of individual genes, chromosomal segments and 
even entire genomes that occurred through evolution (Gloriam et al., 2005). From the 
study of genomics it is now recognised that three whole genome duplications (WGDs) 
have taken place since the origin of vertebrates some 500 - 800 million years ago, as 
shown in Figure 2.37 (Froschauer et al., 2006). The first of these events (1 R) happened 
after divergence of ciona and amphioxus from the vertebrate lineage but before the split 
between jawless (hagfish and lampreys) and jawed vertebrates. The second WGD (2R) 
happened after the split of the jawless vertebrates but before the split between cartilaginous 
(sharks, rays) and bony vertebrates (Froschauer et al., 2006). This means that teleosts and 
humans, although separated by approximately 450 million years of evolution, arose from 
the same vertebrate lineage and share a common ancestor from the Palaeozoic era 
(Froschauer et al., 2006). The discovery of this common ancestor facilitated the 
completion of the human genome (Jaillon et al., 2004). It is now possible by carrying out 
four-way comparisons with human, pufferfish, medaka and zebrafish genomes to establish 
that since the divergence of humans and teleosts, eight major interchromosomal 
rearrangements took place in a very short period of time (-50 million yr), to result in this 
evolutionary divergence (Kasahara et al., 2007). 
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Medaka 
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1000 Mb, 2n=48 
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Figure 2.37. A diagrammatic explanation of the evolution of teleosts, depicting where 
each WGD occurred (Adapted from Froschauer, 2006) 
The occurrence of a third WGD event (3R) was highly debated for a long time. During 
evolution, duplicated genes can undergo a range of processes and this makes the 
identification of the 3`d WGD a complicated process. Some duplicated genes are often 
deleted, some copies evolve at different evolutionary rates, whilst other duplicates become 
pseudogenes, whereby degenerative mutations cause the gene to become non-functional 
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(Volff et al., 2005). Non-functionalisation occurred to 90% of the duplicated pairs of 
genes generated by the fish specific WGD (3R), which was one reason why the hypothesis 
of a third duplication was so difficult to validate (Froschauer et al., 2006). However, the 
characterisation of the Tetraodon genome resolved this debate, as due to the relatively few 
interchromosomal rearrangements in the Tetraodon lineage during 100 millions years of 
evolution and the striking pattern of chromosomal pairing, it was possible to identify the 
basic structure of the ancestral bony vertebrate genome, which was composed of 12 
chromosomes (Jaillon et al., 2004; Volff et al., 2005). In addition to this, due to the 
presence of hundreds of ancient pairs of duplicate genes, and the presence of a large 
number of paralogons, a feature distinctive of WGDs, a third WGD was confirmed. 
Because many fish express co-orthologs of a single mammalian gene, this suggests that the 
fish-specific WGD occurred in ray-finned fish (Actinopterygii) after divergence from lobe 
finned fish, and before the origin of teleosts (Hahn et al., 2006; Christoffels et al., 2004; 
Volff et al., 2005). 
The phylogenetic analysis of ßl- and ß2-ARs (see Figures 2.35 and 2.36) in a range of 
different animals reflects the same evolutionary pattern as seen in Figure 2.37. For 
instance, in the ß-AR phylogenetic trees, mammals and teleosts separate from a common 
ancestor after the divergence of the jawless fish, the lamprey and hagfish. The pufferfish, 
takifugu and tetraodon, both have the smallest known vertebrate genomes, yet they are 
more evolutionary divergent than human and mouse, which is probably due to a higher rate 
of gene mutation (Jaillon et al., 2004). However, as seen in the ß-AR phylogenetic trees 
and Figure 2.37, both pufferfish ß-ARs are closely related. Fathead minnow and zebrafish 
are part of the cyprinid family (Cyprinidae) of the super family Cyprinoidea in the order 
Cypriniformes, which mean that the zebrafish is one of the closest relations, evolutionarily 
speaking, to the fathead minnow (Volff et al., 2005). The results from the phylogenetic 
analysis also show that fathead minnow and zebrafish ß-ARs are very similar, and this is 
probably why using primers based on the zebrafish sequence to amplify unknown fathead 
minnow ß-AR sequences was successful. In the ß2-AR analysis, the trout is shown as 
being the next closest family to the fathead minnow, which was why degenerative primers 
designed from zebrafish and trout ß2-AR sequences were successful in amplifying 
unknown fathead minnow ß2-AR fragments. The 01-AR phylogenetic analysis shows the 
sea urchin, an echinoderm, to have a closer evolutionary relationship with teleosts 
compared to Ameiurus melas, an Actinopterygian fish. This may be due to the 
conservation of some genes through evolution. The sea anemone, a cnidarian, has within 
its very simple and ancestral genome some blocks of DNA that have been found to have 
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the same compliment of genes as the human genome (Pennisi, 2007). The brown bullhead, 
Ameiurus melas, is divergent from the teleosts in both ß-AR analyses. Ameiurus is an 
Actinopterygii (ray-finned fish), and as shown in Figure 2.37, this group of fish diverged 
before the major evolution of teleosts and this is reflected in the results of the ß-AR 
analyses. 
Teleosts are a large and very successful group of vertebrates and they constitute 99.8 % of 
ray-finned fish (Actinopterygians), which in turn make up 95% of all fish species (Volff et 
al., 2005). Because of the three rounds of WGD that have occurred in teleosts, multiple 
numbers of receptors can be found, and so if no gene deletions had occur, we could expect 
to find eight copies of each AR subtype. For example, in the pufferfish (Fuge rubribes) 
genome, eight a2-ARs can be identified (Ruuskanen et al., 2005). So, finding two 
different versions of the 02-AR in the fathead minnow is an indication that at least two 132- 
AR genes are present, and a further possible six may yet be found. 
When genes become duplicated, one copy often evolves as a pseudogene. Pseudogenes are 
genes that accumulate disabling mutations in the absence of a selective pressure to 
maintain the additional duplicated gene on an evolutionary time scale. The mutations can 
vary from multiple disruptions of a coding sequence to just the loss of one nucleotide 
which results in a frame shift leading to a truncated protein, although care must be taken in 
this instance as a nucleotide change or loss could be a polymorphism or a sequencing error 
(Foord et al., 2005). Gene deletions may have occurred, for example, in the zebrafish suite 
of a2-ARs. Zebrafish have five distinct a2-ARs, however after three rounds of WGD it 
could be predicted that eight a2-ARs should be present (Ruuskanen et al., 2005). This 
suggests that three a2-ARs are either yet to be annotated or they have been deleted. 
Genes that lack a ribosomal binding sequence and a TATA box or initiator sequence in the 
5' UTR of a nucleotide sequence are often pseudogenes, as without these specific 
sequences, mRNA is unable to translate them into proteins. Of the two 02-ARs found in 
the fathead minnow, both genes have a ribosomal binding sequence and TATA box in the 
5'UTR and this suggests that both these genes are functional. However, although the 
1/197 ß2-AR gene found in the fathead minnow was shorter in places than the 207 02-AR 
gene, hydropathy analysis showed it to have seven TMDs with a non-disrupted reading 
frame, which is further evidence to suggest that this is not a pseudogene. The presence of 
two genes coding for the same protein may be beneficial to some organisms, as the genes 
can undergo functional divergence, whereby the function carried out by a single ancestral 
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gene is now carried out by two genes, a process known as subfunctionalisation, which is 
often found in teleosts. For example, in atlantic killifish, two distinct aryl hydrocarbon 
receptor genes were found, and although they were both functional, they showed different 
expression patterns throughout the fish, which may suggest they carry out the same 
function but in different tissues (Hahn et al., 2006). 
The ßl-AR in the fathead minnow lacked both a TATA box or an initiator sequence, 
however it does possess a ribosomal binding sequence. This could meant that this gene is 
a pseudogene or that the 5' UTR sequence, which was not confirmed by proof reading taq, 
is incorrect or incomplete. The reading frame of this gene is undisturbed and hydropathy 
analysis shows it to have seven TMDs, which suggest that this gene is not a pseudogene. 
Another genetic evolutionary pathway is via transposable elements (TEs). These mobile 
sequences are most active in germ cells and are able to integrate into new sites within 
genomes. This can lead to major disruption from deletions, duplications, inversions, 
modification of flanking genes and translocations, but they are also big drivers of evolution 
(Froschauer et al., 2006; Volff et al., 2005). Teleosts, including pufferfish which have very 
compact genomes, have a much higher diversity of TEs than mammalian genomes (Volff 
et al., 2005). 
In summary, teleosts have undergone an extra round of WGD compared to other animals, 
have a high turnover of mobile TEs, and often subfunctionalize duplicated genes. These 
processes are known to lead to major evolutionary transitions and it may be these factors 
that contributed to the vast diversity of fish, which is especially noticeable in the many 
possible forms of sex determination, and could be the reason why teleosts are a most 
diverse and successful taxa, with over 24,000 species (Froschauer et al., 2006; Volff et al., 
2005). 
2.4.2 Chromosomal organisation of receptors 
The mapping of different receptors to specific chromosomes provides further information 
on the evolutionary pathways, for if genes are found in close proximity on a chromosome, 
then this strongly suggests that they are evolutionary related (Yang-Feng et al., 1990). For 
example, the genes coding for the human ßl-AR and a2-AR are found on the same 
chromosome very close together (chromosome 10, q24 - q26), and p2-AR and al-AR can 
both be mapped to chromosome 5 (q32 - q34) (Yang-Feng et al., 1990). Hence, it can be 
deduced from chromosomal locations that different receptor subtypes have been generated 
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by whole genome duplication. A third round of duplication in the teleost lineage brought 
the total number of a-ARs up to 8, as in the pufferfish (Fugu rubrihes) (Ruuskanen et al., 
2005). 
It is most likely all ARs arose from a common ancestral receptor gene and subsequently 
diverged through gene duplication and chromosomal duplication to perform distinctive 
roles (Yang-Feng et at., 1990). For example, the 01-AR gene most likely arose from 
ancestral gene duplication, whilst the (32-AR may have arisen from chromosomal 
duplication (Yang-Feng et al., 1990). 
2.4.3 GPCR structure 
GPCRs are the largest and most diverse group of transmembrane receptor molecules, and 
occur in nearly every eukaryotic cell (Ranganathan, 2007). There are more than 1000 
GPCRs in the human genome and these have been categorised into five families. (3-ARs 
and rhodopsin are in the largest subgroup and are structurally and evolutionary related to 
each other (Libert et at., 1989). Rhodopsin is a light sensitive photoreceptor found in the 
mammalian eye and the crystalline structure for this GPCR has been determined. 
However, obtaining the three dimensional structure of other GPCRs has proven difficult, 
primarily because of their natural low abundance and secondly because, unlike the fixed 
inactive state of rhodopsin, other GPCRs have an inherent structural flexibility and 
instability (Rosenbaum et al., 2007). This has meant that although 50 % of modem drugs 
are targeted to a wide variety of GPCRs, they have all been designed on a rhodopsin-based 
model (Cherezov et al., 2007; Rosenbaum et al., 2007). 
The ligand 11-cis-retinal binds to rhodopsin and it is the covalent bonds between this 
ligand and the receptor that keeps rhodopsin in a tightly locked inactive state 
(Ranganathan, 2007). However, it is the plasticity of many other GPCRs that enables them 
to elicit a range of responses from various different ligands. Hence, by determining the 
structure of human ß2-AR, similarities and several differences between it and the structure 
of rhodopsin have come to light, as shown in Figure 2.38. The main structure of both 
receptors is very similar in that they have a roughly ellipsoid arrangement of seven 
membrane spanning alpha helical segments (TMDs) that surround a ligand binding site 
(Ranganathan, 2007). 
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Figure 2.38. The crystalline structure of rhodopsin (left) and p2-AR (right) with a 
ligand bound in the ligand binding pocket. The numbers I to 7 refer to each helical 
segment (TMD) (Ranganathan, 2007). 
There are a lot of similarities between the ligand binding pockets in that both receptors 
have a tryptophan side chain and all amino acids deep within the binding pocket are 
conserved between the two receptors (Rosenbaum et al., 2007). The main differences are 
found in the cytoplasmic and extracellular loops. For example, when carazolol is bound to 
p2-AR to stabilize it, some amino acids in the helical structure of the second extracellular 
loop make direct contact with the ligand, which does not occur in rhodopsin (Ranganathan, 
2007). 
It may be that this sequence variability in the second extracellular loop in the ß2-AR 
accounts for the receptor's affinity for different ligands (Cherezov et al., 2007; Ruuskanen 
et al., 2005). Some differences are also found in the amino acids present at the entrance to 
the binding pocket. This variation in ß2-ARs compared to rhodopsin may be especially 
important to larger ligands, such as peptide molecules, that bind closer to the membrane 
surface near the extracellular loops, and may account for the plasticity of (3-ARs to bind a 
large variety of ligands (Cherezov et al., 2007). 
Subtle differences in the orientation of the helices are also found between the two GPCRs 
(Rosenbaum et al., 2007). The main difference is that TMD I in the ß2-AR, compared to 
rhodopsin, lacks a proline-induced kink and angles away from the centre of the receptor, 
due to a need for an accessible binding site in ß2-AR, which is provided in part by lack of 
interactions between the N terminus and extracellular loops (Cherezov et al., 2007). 
Additionally, TMDs II and V are moderately divergent to those in rhodopsin in that TMD 
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II pivots further from the binding site and TMD V is translated closer to the centre of the 
receptor (Cherezov et al., 2007). 
Due to the successful, recent characterisation of the ß2-AR structure, it has been found that 
GPCRs are highly polarised molecules that have a negatively charged binding cleft at the 
tip of the molecule, and a negatively charged groove between helices III, IV and V in the 
middle of the lipid membrane. Unexpectedly, the Asp-Arg-Tyr (E/DRY) motif found on 
the cytoplasmic face at the bottom of the molecule (unlike in the structure of rhodopsin) is 
positively charged and acts as an ionic lock (Cherezov et al., 2007). The result of this is 
that the overall negative charge of the receptor facilitates the binding of catecholamine 
ligands to GPCRs. 
All three (3-ARs genes isolated in the fathead minnow did not contain introns (non-coding 
regions of DNA) in their sequence. This is like many GPCRs, eg rat ßl-AR, whose coding 
sequence is not interrupted by introns (Machida et al., 1990). The length of each fathead 
ß-AR also compared favourably to ß-ARs in other species, with the total ßl-AR being 
1412bp, 1/197 ß2-AR totalling 1298 bp and 207 ß2-AR equalling 1445 bp. Each sequence 
contained 7 TMDs and the motifs that are associated with GPCRs and ß-ARs. 
With such complexity it is remarkable that despite 350 million years of evolution, the 
ligand binding characteristics, the order of potency and efficacy of tested agonists of 
GPCRs, for example between the zebrafish and human a-ARs, is so highly conserved 
(Ruuskanen et al., 2005) 
2.4.4 Concluding remarks 
From the work carried out in this chapter, two (possibly three) genes were isolated and 
characterised in the fathead minnow, namely the 01-AR gene, and two possible (32-AR 
genes. All of these genes (the PI-AR and the two ß2-AR genes) had an uninterrupted 
reading frame with no introns, a ribosomal binding site, a start and stop codon and a 3' 
UTR motif of AAUAAA. Both the ß2-AR genes had a TATA box but the ßl-AR lacked 
this in the 5' end of the UTR sequence, this may be due to it not being present or due to the 
5' end of this gene not being sequenced in totality. The seven TMDs (an integral element 
of GPCRs) were revealed in hydropathy analysis in all the characterised genes, and showed 
a high homology within the TMDs to other fish and human TMD sequences. In addition 
the above genes showed a high homology to other fish and vertebrate homologues, with 
the fathead ßl-AR and ß2-AR genes having 91 % and 88 % homology to zebralish ßl-AR 
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and 02-AR genes respectively. Phylogenetic analysis revealed the closest ancestor to the 
fathead minnow with respect to p1-AR and the ß2-AR genes to be the zebrafish (Dario 
rerio). 
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Chapter 3 Exposure of fathead minnows to propranolol 
3.1 Introduction 
Propranolol-HC1 is a non-specific ß-blocker that is prescribed to humans to treat high 
blood pressure, heart failure and other heart-related diseases by targeting ß 1- and (32-ARs. 
Due to its incomplete removal at STWs, propranolol has been detected in the aquatic 
environment in the high ng/L levels, and thus may be reaching and having effects on non- 
target organisms. 
3.1.1 Pharmokinetic action of propranolol 
Propranolol is a prescribed pharmaceutical that is used to treat angina and hypertension in 
humans by binding to (3-ARs and blocking catecholamine binding. Propranolol therefore 
acts as an antagonist that binds to the receptor, and in essence acts as an inhibitor by 
competing with the natural hormone for binding sites. This blocks the physiological 
activity of the natural ligand, adrenaline or noradrenaline, and does not activate hormone- 
induced effects. This is opposite to the reaction that an agonist type drug would have, 
which would mimic the function of the hormone by binding to the receptor and causing the 
normal hormonal response (Lodish et al., 2000). 
3.1.2 Propranolol in the aquatic environment 
Propranolol and other human and animal pharmaceuticals reach the aquatic environment 
through a variety of different routes, including soil and ground water runoff from the 
application of digested sludge onto farmland, industrial waste, leaching of domestic waste 
at landfill sites and by disposal of raw sewage or, more usually, STP effluents (Ternes, 
1998). However the majority of pharmaceuticals are present in the aquatic environment 
due to incomplete removal at sewage treatment works (STWs). In Germany it was found 
that 96 % of propranolol was removed from the influent compared to the effluent, yet the 4 
remaining is largely why propranolol has been found ubiquitously in all rivers and 
streams in Germany at concentrations in the ng/l range, with maximum and median 
concentrations reaching 590 ng/L and 12 ng/L, respectively (Ternes 1998). In studies 
conducted by Ternes (1998), concentrations of propranolol were much higher in rivers 
around STWs and in small rivers and streams receiving effluent where this effect was 
magnified due to the low dilution factor of the water body. However this is not a problem 
unique to Germany; Table 3.1 details concentrations of propranolol found in estuaries, 
rivers, effluents and streams around America, Europe and the U. K. About 12 tonnes of 
propranolol is prescribed each year in the UK, and as shown in Table 3.1, small quantities 
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of propranolol are routinely discharged into our rivers and streams through STW effluent 
alone (Ashton et al., 2004). 
Water body Maximum 
concentration 
(ngfL) 
Median 
concentration 
(ng/L) 
Reference 
U. S. effluent samples 2200 < 1900 Huggett et al., 2003a 
German STW effluents 290 170 Temes, 1998 
German rivers 590 12 
STW effluents around 
Europe 
90 10 Andreozzi et al., 2003 
U. K. estuaries 56 13 Thomas & Hilton, 
2004 
U. K. STW effluent - 76 Ashton et al., 2004 
U. K. STW effluent 280 90 
U. K. rivers upstream of STW - < 10 
U. K. Rivers - 29 
Table 3.1. Maximum and median concentrations of propranolol found in rivers, 
streams, estuaries and STW effluents throughout America, Europe and the U. K. 
Once propranolol has been ingested, it undergoes extensive first pass metabolism by 
cytochrome P450 enzymes, and it is excreted via urine largely as metabolites, with only 10 
% being excreted as the original parent compound (Huggett et al., 2003; Laville et al 2004; 
Thomas & Hilton, 2004). The major metabolite is 4-hydroxypropranolol, and little 
information exists on the fate and concentrations of 4-hydroxypropranolol in the 
environment (Ternes, 1998). 
The chemical structure of propranolol-HCL is shown in Figure 3.1. Propranolol has a log 
P of 3.67, and has a half-life of 16.8 day at 50 °N in winter, suggesting that is has the 
potential to bioaccumulate in biota or partition into the sediment, which would 
consequently prolong its residence time in rivers and streams (Andreozzi et al., 2003; 
Huggett et al., 2003). Propranolol is also unlikely to degrade through hydrolysis, since 
pharmaceuticals made for oral consumption are usually water resistant (Andreozzi et al., 
2003). Possible natural degradation processes include photolysis, where the direct action 
of sunlight and the indirect action of natural photo-sensitizers such as nitrates and humic 
acids cause the degradation of propranolol. 
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Figure 3.1. The chemical structure of propranolol-HCI. Obtained from 
(www. rxlist. com/cgi/generic/propran. htm) 
3.1.3 Biological effects of propranolol 
Propranolol acts upon human P-ARs in order to treat angina and hypertension. However 
what is not known is how propranolol may act upon ß-ARs of fish once it reaches the 
aquatic environment. ß-ARs in fish have been shown to mediate responses to stress 
through the same GPCR mechanism that is found in humans. The effects may be chronic 
rather than acute toxic effects, since environmental concentrations of propranolol are 
nowhere near the 24-hour EC50 limit of 2 mg/L recorded by Lilius et al. (1995), although 
there are insufficient data to predict whether environmental concentrations would cause 
any long-term effects. Since little is known about the comparability of the functions of (3- 
ARs between teleost and mammalian systems, suggestions as to the effects caused may not 
be straightforward. Further, the non-specific antagonist nature of propranolol may induce 
effects in fish that are totally different from its supposed primary pharmocodynamic 
activity. 
Tables 3.2 to 3.6 summarise the in vitro and in vivo ecotoxicology work in the literature 
that has been carried out using ß-blockers. The initial observation is that in experiments 
carried out with all (3-blockers, the work has on the whole been carried out in the low to 
mid mg/L range. This suggests that in the majority of experiments, effects were seen only 
in the mg/L range, which is much higher than the environmental concentrations of (3- 
blockers. Hence, any acute effects would not be seen in the environment. However, this is 
not true for the work carried out with propranolol, for in particular the work carried out 
with invertebrates and fish shows environmental concentrations to have fundamentally life- 
threatening toxic effects. 
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Compound Species EC50: Exposure Observations Reference 
(mg/L) duration 
Propranolol Desmodesmus 5.8 3d Reduced Cleuvers, 
subspicatus growth 2003 
Pseudokirchneriella 7.4 96 hr Ferrari et 
subcapitata al., 2004 
Synechococcus 0.67 96 hr 
leopolensis 
Lemna minor 114 7d Cleuvers, 
Metoprolol Desmodesmus 7.3 3d Reduced 2003 
subspicatus growth 
Lemna minor >320 7d 
Table 3.2. Summary of the available in vivo data on ß-blocker activity in plants. Green 
alga: Desmodesmus subspicatus and Pseudokirchneriella subcapitata. Blue-green alga: 
Synechococcus leopolensis. Duckweed: Lemna minor 
Compound Species EC50: mg/L Exposure 
duration 
Observations Reference 
Atenolol Vibrio fisheri 1304 30 min Bioluminescence Escher et 
Desmodesmus 
subspicatus 
1335 24 hour Photosynthesis 
inhibition 
al., 2006 
Metoprolol Vibrio fisheri 144 30 min Bioluminescence 
Desmodesmus 
subspicatus 
40 24 hour Photosynthesis 
inhibition 
Propranolol Vibrio. Tsheri 61 30 min Luminescence Ferrari et 
al., 2004 
81 30 min Bioluminescence Escher et 
Deomodesmus 
subspicalus 
4.1 24 hour Photosynthesis 
inhibition 
al., 2006 
Sotalol Vibrio. fisheri >1000 30 min Bioluminescence 
Deomodesmus 
subspicalus 
>3000 24 hour Photosynthesis 
inhibition 
Table 3.3. Summary of the available in vitro data on ß-blocker activity in bacteria and 
plants. Photosynthesis inhibition was measured by chlorophyll fluorescence. Bacterium: 
Vibrio fisheri Green algae: Desmodesmus subspicalus 
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The in vivo experiments carried out with plants (Table 3.2), show propranolol to inhibit 
growth at lower mg/L concentrations than metoprolol. In addition to this, algae appear to 
be more sensitive to ß-blockers than duckweed. Liu et al. (2007) report that they found 25 
candidate GPCRs in the genome of the plant Arabidopsis ihaliana for which they have 
found a ligand, a phytohormone abscisic acid, which is an important developmental 
hormone for a candidate GPCR in this plant. If the plants tested by Cleuvers (2003) and 
Ferrari et al. (2004) possess GPCRs, this could explain why plant growth is affected by (3- 
blockers. When bacteria and plants were exposed in vitro to ß-blockers (Table 3.3), there 
was approximately a 1000-fold difference in the sensitivity of the bacteria to different P- 
blockers, in that propranolol caused effects at much lower concentrations than sotalol. The 
order of sensitivity of the tested ß-blockers was propranolol < metoprolol < atenolol < 
sotalol. 
Compound Species Effect level Exposure Observations Reference 
duration 
Value (mg/L) 
Metoprolol Hyalella LC50 >100 48 hr Mortality Huggett et al., 
azteca 2002 
Daphnia EC50 > 100 48 hr Immobilization Cleuvers, 
magna 2003 
LC50 63.9 48 hr Mortality Huggett et al., 
2002 
LC50 76.21 48 hr Mortality Villegas- 
Navarro et al., 
2003 
LOEC 12.5 9d Growth Dzialowski et 
al., 2006 
Table 3.4. Summary of the available in vivo data on metoprolol activity in invertebrates. 
Amphipod: Hyalella azteca, Crustacean: Daphnia magna, 
Tables 3.4 and 3.5 summarise in vivo data from the testing of ß-blockers in invertebrates. 
At a quick glance, propranolol has been used in more experiments than any other ß- 
blocker. The LC50 for metoprolol and propranolol in invertebrates ranges from 64 to >100 
mg/L and 0.8 to 29.8 mg/L, respectively, showing that propranolol is harmful to 
invertebrates at much lower concentrations than metoprolol. 
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Compound Species Effect level Exposure Observations Reference 
(mg/L) duration 
Value (mg/IL) 
Propranolol Hyalella LC50 29.8 48 hr Mortality Huggett et 
2002 l 
azleca 0.1 27 d Reduced a ., 
fecundity 
Cyclotella EC50 0.244 96 hr Growth Ferrari et 
2004 at meneghiniana NOEL 0.094 ., 
Daphnia EC5o 7.5 48 hr Immobilization Cleuvers, 
magna 
2003 
EC50 2.75 48 hr Mortality Ferrari et 
at., 2004 
LC50 1.6 48 hr Mortality Huggett et 
at., 2002 
LOEC 0.44 9d Growth Dzialowski 
2006 t 
LOEC 0.11 Reduced et a ., 
fecundity 
0.88 Reproductive 
failure 
LOEC 0.055 Heart rate 
Ceriodaphnia ECso 1.51 48 hr Mortality Ferrari et 
dubia NOEC 0.009 7d Reproduction at., 2004 
LCso 0.8 48 hr Mortality Huggett et 
0.25 7d Reduced at., 2002 
fecundity 
Brachionus NOEC 0.18 48 hr Reproduction Ferrari et 
calyciflorus at., 
2004 
Table 3.5. Summary of the available in vivo data on propranolol activity in invertebrates. 
Some effects are seen at environmentally relevant concentrations of propranolol. 
Amphipod: Hyalella azteca, Diatom: Cyclotella meneghiniana, Crustacean: Daphnia 
magna, Daphnia pulex, Ceriodaphnia dubia, Rotifer: Brachionus calyciflorus 
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Compound Species Effect level Exposure Observations Reference 
duration 
Value (mg/IL) 
Propranolol Medaka LC50 24.3 48 hr Mortality Huggett et 
LOEC 0.5 14 d Reduced growth at., 2002 
LOEC 0.001 * 14 d Reduced 
testosterone & 
increased 
estradiol 
concentrations 
LOEC 0.0005* 4 week Reduction in egg 
production 
LOEC 0.0005* 4 week Reduction in 
hatchability 
Zebrafish NOEC 2 10d Mortality Ferrari et 
ELS at., 2004 
NOEC <4 24 hr Decrease in Fraysse et 
number of at., 2006 
spontaneous 
movements 
NOEC 4 48 hr Heart rate 
reduction 
32 80 hr No hatching 
observed 
Metoprolol Medaka LC50 >100 48 hr Mortality Huggett et 
at., 2002 
Nadolol Medaka LC50 >100 48 hr Mortality 
Atenolol Fathead NOEC 10 5 days Hatching Winter et 
minnow LOEC >10 at., 2008 
ELS 
Table 3.6. Summary of the available in vivo data on (3-blocker activity in fish. ELS: early 
life stage. Medaka: Oryias latipes, Zebrafish: Danio rerio, Fathead minnow: Pimephales 
promelas. Some queries exist over the reproducibility of some of the Huggett et at., 
(2002) data as shown by *. 
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Some queries exist over the reproducibility of the medaka data (*) reported by Huggett et 
al. (2002), for in some experiments only three pairs of medaka were used at each 
concentration, and no repeat test was carried out for any of the experiments. In addition to 
this, the exposures were not carried out in a flow through system, but instead the set up 
consisted of beakers with the test solutions being replenished daily. Further, the 
propranolol was dissolved in ethanol, which seems unnecessary at such low 
concentrations, as propranolol is readily soluble in water. Lastly, the dose-response curves 
reported are unusual in that there were no effects at high concentrations but there were 
effects observed at low concentrations, i. e. the response seen did not increase with 
concentration. 
However, even if the Huggett et al. (2002) data are discounted, in other experiments where 
fish have been exposed to ß-blockers (see Table 3.6), propranolol, in all studies, had an 
effect at lower concentrations than other ß-blockers. This may be because propranolol has 
a log Kow of 3.48, reflecting its lipophilic nature, and so has the potential to bioaccumulate 
in the fatty reserves of fish (Frielle et al., 1987). Therefore, in summary, from these data 
collected, propranolol appears to be the most bio-toxic (3-blocker and is observed to cause 
chronic and acute effects to some invertebrates and fish at concentrations as low as 0.0005 
mg/L (if the Huggett et al., 2002 data are included), which is within the concentration 
range reported for effluents and even some river waters. 
3.1.4 Fish as ecotoxicological models 
Fish have been used in toxicity tests for the last 140 years, and since the Second World 
War their use has increased in acute and chronic testing (Ankely & Villeneuve 2006). 
Today, it is generally the smaller fish such as zebrafish (Danio rerio), Japanese medaka 
(Oryias latipes) and the fathead minnow (Pimephales promelas) that are most commonly 
used in laboratory ecotoxicology tests. Such tests include acute 48 hour or 96 hour 
lethality tests using juvenile fish to screen toxicity of new and existing drugs, or as a range 
finder for longer chronic tests. Partial life-cycle tests are also conducted to measure 
endpoints at different stages of a life-cycle. These tests are advantageous in that they are 
shorter and less expensive than conducting whole life-cycle tests. Examples of established 
partial life cycles tests include the 30 day early life-stage test, where embryos are grown to 
assess survival, hatching success and growth. Alternatively, a seven day larval survival 
and growth test can be conducted using less than 24 hour old embryos. Another partial 
life-cycle test is the 42 day reproduction (or pair breeding) test, which is used to assess any 
effects on fecundity, fertility, hatchability, plasma sex steroids, vitellogenin production, 
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gonadal histopathology, alterations in secondary sexual characteristics, growth and overall 
condition of the fish (Ankely & Villeneuve 2006). 
Fathead minnows belong to the Cyprinidae family of fish, which contains 21,000 species 
distributed in North America, Eurasia and Africa, and can be found in many habitats 
ranging from big lakes to small streams. They are opportunistic omnivores and can 
tolerate a wide range of water qualities including variation in pH, alkalinity, hardness, 
turbidity and temperature (Ankely & Villeneuve, 2006). Fathead minnows are widely used 
in laboratory chronic reproductive toxicology tests, as they can easily be induced to 
reproduce in captivity (Thorpe et al., 2007). They have also been shown to be good 
predictive species in that results obtained can often be extrapolated to other fish species, 
(Ankely & Villeneuve, 2006). The consistency in reproductive capacity between spawning 
pairs can be less than 30 % when eggs are collected correctly, using a mesh and collection 
tray underneath the spawning tile, irrespective of their original source, age or body size, 
and this consistency has been demonstrated to be maintained over the course of a 42 day 
pair breeding study period (Thorpe et al., 2007). 
3.1.4 Aim of exposure experiment 
The aim of the experiment was to see if environmentally relevant concentrations of DL- 
propranolol-HC1 had any effect on the fathead minnow (Pimephales promelas), either in 
respect to the reproductive performance, or with respect to other parameters, such as the 
overall condition of the fish, by conducting two reproductive partial life cycle tests. The 
production of viable offspring is crucial to the survival of any population and so 
hatchability trials were also conducted using the eggs from the adults exposed to the test 
concentrations of propranolol (Thorpe et al., 2007). 
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3.2 Materials and Methods 
3.2.1 Experimental set up 
Prior to setting up the exposure room, the walls and surfaces of the room were washed 
down with Pinefresh and hosed down with water. The header tanks were bleached, and the 
bleach left overnight to kill any algae that may have accumulated in the system from 
previous experiments. Each glass fish tank was scrubbed down with Scale-Free and 
washed and rinsed in the tank washing machine. Each flow meter was dismantled and put 
through the washing machine, after which fresh PTFE tape was put around the screws. 
Before introducing any fish, water was run through the tanks for 48 hours. 
The exposures were carried out using a flow through system in a room that contained two 
series of identical tanks. Thermostatically heated, dechlorinated tap water from a header 
tank flowed through 6 flow meters into 6 mixing chambers, via medical grade silicon 
tubing (VWR, Leicestershire). From these the water went to 6 fish tanks through silicone 
rubber tubing (VWR, Leicestershire). In total there were 36 fish tanks which each had a 
working volume of 10.5 litres. Each tank was aerated (see Figure 3.2). The flow meters 
were set to deliver 400m1 of header tank water per minute to each mixing chamber, and by 
regulating the flow of water into each fish tank via a clamp on the connecting tubing from 
the mixing chamber, each tank received 66 ml of water per minute. This equated to each 
tank receiving roughly 9 tank renewals per day. 
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To regulate the dosing of the test substance, propranolol-HCL, during the exposure period, 
a peristaltic pump was set up and 4L amber stock bottles (Sword Scientific, 
Warwickshire), containing different stock concentrations of propranolol HC1, were 
prepared. These stock concentrations were pumped from the stock bottles through 0.16mm 
tubing (Watson Marlow, Cornwall) to a peristaltic pump set at 56 rpm, and out through 
peroxide cured silicon tubing (Watson Marlow, Cornwall) to the distribution chambers (see 
Figures 3.3 and Figure 3.4). Magnetic stirrers (Fisher Scientific, Leicestershire) were 
placed under each stock bottle, to ensure continual mixing of the contents of the stock 
bottles, and under each mixing chamber, to keep a constant concentration of propranolol 
HC1 entering the fish tanks (i. e. to mix the header tank water (40 ml/min) and the 
propranolol HCl (1 mUmin) in the mixing chamber). In the second experiment, the 
peristaltic pump was switched on one week prior to dosing and header tank water was 
pumped through the system. This ensured a more stable flow and hence less fluctuation in 
the flow was encountered during the second experiment. 
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Figure 3.3. The design and lay out of the exposure room. A. Photograph of the exposure 
room with the peristaltic pump and stock dosing bottles shown by the arrow -i 
B. Diagram of the location of each test concentration in the exposure room for each 
experiment. Each block () represents 6 tanks. I= DWC, 2=0.001 mg/L, 3= 
0.01 mg/L, 4=0.1 mg/L, 5=1.00mg/L, 6= 10 mg/L (l Omg/L was only tested in the 
Lfirst 
exposure). * shows the location of the air vents in to the room. 
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Figure 3.4. Close up photograph of a) the peristaltic pump and b) the stock bottles 
containing the propranolol, which were covered in foil and sitting on c) the magnetic 
stirrers, with tubing going from each stock bottle to the pump and out from the pump to 
the mixing chambers. 
Inside each fish tank, a half piece of PVC gutter (from here-on called a `tile') was placed 
over a stainless steel mesh and glass base (see Figure 3.5). Most eggs were collected from 
the underside of the tile, to which they had been attached by the fish. However, in the 
event that some eggs had not adhered to the tile, they would fall onto the mesh or into the 
glass base. Hence, all eggs that were produced were counted (see Figure 3.6). On some 
occasions, the fish laid their eggs on the tank out-pipe, in which case the pipe was removed 
in order for the number of eggs to be counted. 
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Figure 3.6. A. The eggs from the tile were counted under water using it ticker 
counter. The eggs from the mesh and the base were also included in the count. 
B. A close up of eggs on the tile. 
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3.2.2 Test species 
The fish in both exposure experiments were one year old fathead minnows, Pimephales 
promelas. They were virginal stock that had been kept in a stock tank and had been bred at 
Brunel University. One male and one female were placed in each fish tank. The 
identifying features between the sexes are that the males tend to be larger than the females 
and when not stressed have a black spot on their pectoral fin, whilst the females have an 
ovipositor, as shown in Figure 3.7. When sexually mature, the male shows secondary 
sexual characteristics; these include a vertical dark stripes, and a soft, mucus-secreting 
dorsal pad, known as a fatpad, with large nuptial tubercles on the front of his head (Ankley 
et al., 2001, Smith, 1978). These features become more pronounced when the male 
becomes the dominant male in a group of fatheads, or when in a tank alone with a female. 
All male fish used in the pair-breeding experiments exhibited secondary sexual 
characteristics prior to the start of the experiments. 
During the breeding season, a sexually mature male will use his tubercles to deter intruders 
in an effort to defend his territory, and his fatpad to clean the spawning surface, in this case 
the tile (Smith, 1978). When the female is ready to spawn, the male and female move 
round the tank together, accompanied by close lateral contact and body vibration between 
the male and female (Ankley et al., 2001). After sufficient stimulation, the male lifts and 
presses the female's ventral surface against the underside of the spawning object (Thorpe 
et al., 2007). The female then releases her eggs on the underside of the tile and the male 
fertilises them simultaneously. The male then expels the female from the area and stays 
underneath the tile, guarding and preening the eggs, removing any dead ones and any air 
bubbles with his fatpad (Harries et al., 2000). If the eggs are removed, the pair will breed 
again, usually within 3 to 7 days. 
3.2.3 Test substance and concentrations 
The experimental design incorporated two separate replicate experiments. This was partly 
due to a lack of space in the exposure rooms, but also for ethical and statistical reasons. 
From an ethical standpoint to repeat two smaller experiments, rather than conduct one 
large experiment, was preferable because it meant that if no effect whatsoever was found 
in the first experiment, then the second experiment need not be undertaken, hence reducing 
the number of fish used. Secondly, on ethical grounds, if a particular concentration of the 
test substance evoked a toxic effect, then that particular concentration need not be repeated 
in the second experiment, hence less fish are put under duress. For statistical reasons, two 
separate experiments allow the results of the two experiments to be compared, so if any 
effects occur, and are repeatable, the results will be more robust. 
Propranolol (DL-Propranolol hydrochloride, 1-isopropylamino-3-(1-naphthyloxy) 
proprano-2-ol hydrochloride) (CAS 318-98-9) is a racemic mixture that is 99 % pure. 
Propranolol was obtained from AstraZeneca, Brixham, and was stored in a plastic 
container in a fridge. Since it is light sensitive, a sample was taken and stored in a foil 
wrapped beaker from which the stock solutions were made. A new sub-sample was set up 
for each experiment. The amount of propranolol added to a4L stock bottle was as set out 
in Table 3.7. Once measured out, header tank water was added to the bottle to make it up 
to 4 L, and the bottle swirled to mix the propranolol and water. Because propranolol-HC1 
is light sensitive, each bottle was wrapped in foil before being placed on a stirrer. The 
tubing was placed in the bottom of each bottle so that the stock solution could be pumped 
by the peristaltic pump into the mixing vessel. 
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Nominal concentration of 
Propranolol-HCI (mg/L) in fish 
tanks 
Amount of propranolol-HCI 
added to each 4L bottle (g) 
0.001 0.0016 
0.01 0.016 
0.1 0.16 
1.0 1.6 
10.0 16.0 
Table 3.7. Amount of propranolol-HC1 added to each 4L stock bottle to make up the 
different stock concentrations of propranolol-HCI. The stock was then diluted prior to 
delivery to the fish tanks 
In the first experiment, five concentrations of propranolol-HCI, namely 0.001,0.01,0.1, 
1.0 and 10 mg/L, were used, together with a water control. In the second experiment this 
was reduced to 4 concentrations of propranolol-HCI, which were 0.001,0.01,0.1, and 1.0 
mg/L, together with a water control. There were six fish tanks per concentration; four of 
these had a male and female pair in them and the remaining two tanks were used for egg 
hatchability trials. 
3.2.4 Pair-breeding test 
One male and one female fish were placed in each tank and left largely undisturbed for 3 
days, during which the only disturbance was for feeding; this was known as the 
acclimation phase. Following on from this, breeding compatibility was determined, during 
which fish were monitored and daily records made of when each pair spawned. Not all 
pairs spawned, and if this was the case, then they were swapped for another male and 
female pair. More fish were paired up than were actually required for the experiment, and 
so criteria were needed to select the pairs that were to be used for the experiment. These 
criteria were that the pair needed to have spawned at least twice, with a gap between 
successive spawning being not greater than seven days. The pairs of fish that were the first 
to meet these criteria in each treatment group were selected for the experiment and the 21- 
day baseline period began. During the baseline period, only header tank water entered the 
tanks and the number of eggs produced during each spawning was recorded. Data and 
reproductive output of each pair were collected at the same time daily, at 12 am, noon (±1 
hour). After 21 days, a transitional phase occurred when propranolol-HCI was introduced 
to the tanks. The tanks containing breeding pairs were divided into groups of six tanks, 
which was done by drawing paper out of a hat to ensure random placement of individual 
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pairs within the treatment groups. The transitional phase lasted for three days and allowed 
the concentration of propranolol to reach the desired value, after which the fish were 
maintained for a further 21 days at these concentrations. During the transitional phase no 
eggs were collected or counted and the only disturbances to the fish were feeding and close 
external monitoring in case signs of distress developed from the introduction of the drug. 
Following this period, the 21 day exposure period started, during which the same 
parameters were measured as in the baseline period. Figure 3.8 summarises the pair- 
breeding test protocol. There were four pairs of fish in each treatment group. 
Breeding compatibility assessment 
Acclimation phase Transitional phase 
Baseline period Exposure period 
10-14 21 days - 21 days da's days days 
d-'I dU d7 d14 d21 
lime (days) 
Figure 3.8. Protocol of the pair-breeding test, with the different phases shown. 
After 21 days of exposure to propranolol-HCI, the fish were terminated using an overdose 
of ethyl 3-aminobenzoate methanesulfonate (MS-222) (Sigma, Dorset), under a schedule I 
procedure. Tissue samples (liver, gonad, brain, heart) were taken for RT-PCR analysis and 
blood samples were pooled at each concentration for analysis of the concentration of 
propranolol-HCI in the plasma. Wet weight, fork length, liver weight, gonad weight and 
fatpad weight were recorded. The number of tubercles and the prominence of tubercles 
were determined using the qualitative scheme set out by Smith (1978) (see Table 3.8 for 
details). 
Denotation Description 
0 No visible sign of tubercles 
+ Tubercles visible as white disks, not protruding above body surface 
++ Tubercles project above body surface 
+++ Tubercles are prominent, but not sharp 
++++ Tubercles are prominent and sharp 
Table 3.8. The qualitative scheme (as devised by Smith, 1978) used to assess the degree 
of tubercle development at the end of the 21 d exposure period. 
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3.2.5 Hatchability trails 
To assess whether the eggs produced by each pair were viable (i. e. successfully produced 
live young), hatchability trials were undertaken. After the first successful spawn in the 
baseline period, fifty eggs were left on the tile from the next spawn and this tile submersed 
in another tank in a wire meshed cage that was suspended in the tank, so that the eggs were 
covered by water. The new tank was from the same treatment group, i. e. the developing 
eggs were exposed to the same concentration of propranolol as were the adult fish that laid 
the eggs. The eggs were checked and counted daily and any abnormalities recorded and 
dead eggs removed. An assessment of the stage of egg development was also recorded, as 
set out in Figure 3.9. Two tanks at each concentration of propranolol were used for the 
hatchability trials. 
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0) Unfertilised egg 
1) Blastulation 
, 
41h, 
1 hr 5 hr 
2) Completion of gastrulation 
i4a 
9hr 1 0hr 13hrs 
3) Completion of somites and optic cup formation 
iff -4U 
t[ hrs 1' rs 
4) Spontaneous movement and tail detachment 
23hrs 29hrs 
5) Retinal pigmentation/heart beating/body pigmentation 
7 -r6 
46115 G91 sic:. 
6) Commencement of hatching 
ýR 
: 'ý ý^ 
Figure 3.9. Photographs of the different stages of egg development. (Taken from 
the PhD thesis of Tamsin Runnalls, 2005). 
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3.2.6 Water, light and feeding parameters 
The water temperature was set at 25°C + 1, and this was monitored twice weekly. Flow 
into the mixing chamber was set at 400 ml/min and was checked twice weekly. The flow 
into the fish tanks was 66 (+ 10 %) ml/min, which was checked twice weekly, and was 
altered by a clamp on the connecting tubing. The dissolved oxygen concentration was 
monitored weekly and kept above 75 % saturation. Water hardness and pH were also 
checked weekly and recorded. Tanks were cleaned twice weekly, during which the base, 
mesh and tile were removed and cleaned in hot water, and any debris siphoned out. This 
meant that at least half a tank of water was changed every time the tank was cleaned. 
Table 3.9 summarises the protocol used for monitoring the water parameters. 
The fish were fed twice a day with frozen adult brine shrimp (Anemia sa/ina) during the 
week and once a day during the weekend. Fish flakes were also fed once a day. The fish 
received a photoperiod of 16 hours of light followed by 8 hours of darkness, with a 20 
minute dawn: dusk transition. 
Parameter Frequency parameter was monitored 
Header tank flow Daily 
Peristaltic pump flow (during dosing) 
Temperature Twice weekly 
Flow into tanks 
Cleaning of tanks 
pH Weekly 
Dissolved oxygen 
Hardness 
Table 3.9. Summary of the monitoring and maintenance of water parameters throughout 
the pair-breeding experiments. 
3.2.7 Collection of water and plasma for analysis of propranolol concentrations 
20ml water samples were collected from 3 tanks per treatment group on days 0,4,7,14 
and 21 during the exposure period in 40 ml amber glass vials (Sigma, Dorset) that had 
been washed twice with methanol and once with ethanol. These were stored in the freezer 
until analysis, which was carried out by AstraZeneca, Brixham, UK. 
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The plasma was collected on termination of the fish at the end of the 21-day exposure 
period. Blood was pooled at each concentration, per sex, to ensure there was enough 
plasma for analysis. Each sample was then spun in a centrifuge for 10 minutes at 
2,500rpm, after which the plasma was carefully pipetted off and stored at -80 °C until 
analysis, which was carried out by AstraZeneca, Brixham, UK. 
3.2.8 Statistical analyses 
Statistical analysis of the water chemistry results, using a t-test or Mann-Whitney rank sum 
test, showed that there were no statistically significant differences at each concentration 
between experiments. Hence, the results from the first and second exposure experiments 
were pooled for each concentration and the data checked for normal distribution and equal 
variance using the Kolmogorov-Smirnov test and Levene Median test, respectively. 
To test the null hypothesis that there were no statistically significant differences in 
cumulative egg production between the baseline and exposure periods within each 
treatment group, a parametric t-test was used. In cases where data were not normally 
distributed or of equal variance, a non-parametric Mann-Whitney rank sum test was 
performed. 
To test the second hypothesis that during the exposure period there were no differences in 
cumulative egg production between any of the different treatment groups, a One Way 
Repeated Measures ANOVA was used. This test is a parametric test that assumes that all 
treatment effects are normally distributed with the same standard deviations (variances). 
Lots of individual t-tests could have been used to test this hypothesis, but by using an 
ANOVA, it avoids introducing a Type II error, otherwise known as an a error. A5% error 
is introduced during each test, whereby there is a5% chance of concluding that there is no 
difference between treatments when one exists. So instead of carrying out lots of t-tests, a 
one-way ANOVA was carried out on the exposure data. If a statistical difference was 
found, the ANOVA was followed by a post-hoc test. The test chosen in this case was a 
Holm-Sidak post-hoc test, to show which treatment groups were different from each other. 
The Holm-Sidak test can be used for both pairwise comparisons and comparisons between 
an exposed group versus a control group. It is more powerful than the Tukey and 
Bonferroni tests and is recommended as the first-line procedure for pairwise comparison 
testing; consequently, it is able to detect differences that these other tests do not. 
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Data obtained from the sampling of fish at the end of the 21-day exposure period were also 
analysed for significant statistical differences between treatments. Table 3.10 summarises 
the tests used to prove or disprove null hypotheses set up for each data group. The gonad 
somatic index (GSI) and the condition index (Cl) were calculated as set out below. 
Gonad weight (mg) 
x 100 =GSI 
Wet body weight (mg) 
Wet body weight (mg) x100 
= CI 
Fork length (mm) 3 
Hatchability data were analysed for normality and equal variance. The hatchability data 
did not show normal distribution and so a Mann Whitney rank sum test was used to 
compare baseline and exposure data for each treatment group. The data for 1.0 mg/L could 
not be analysed as there were fewer than 2 data points 
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3.3 Results 
3.3.1 Water parameters 
Figures 3.10 to 3.13 show the data on the different water parameters that were measured 
routinely during both experiments. In some tanks the temperature dropped below the set 
limits, which was either due to hot weather, which caused the in-house chiller units to start 
working, which in turn lowered the room and hence the tank water temperatures, or 
because an air bubble got stuck in the tube running from the distribution chamber to the 
tank, which stopped the flow of heated water to that particular tank. 
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Figures 3.10. Boxplots of the tank water temperatures in experiments 1 (A) and 2 (B). 
The box plots show the median, 10`t', 25th, 75th and 90th percentiles. Red lines represent 
the set temperature i. e. 25 f1 °C. 
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Figure 3.1 1. The pH in each tank during experiments I and 2. The figure shows the 
mean with standard error bars. Blue and green points are data from experiment I and 
2, respectively. 
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Figure 3.12. Dissolved oxygen concentrations in each tank during experiments I and 2, 
displayed as the mean with standard error bars. Blue and green points are data from 
experiment I and 2, respectively. Red line shows the limit below which the dissolved 
oxygen should not fall. 
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Figure 3.13. Flow rates in each tank during experiments 1 and 2, displayed as the mean 
with standard error bars. Blue and green points are data from experiment l and 2, 
respectively. Red lines shows the defined parameters to which the flow was set (66 
ml/min + 10 %) 
As shown from Figures 3.1 1 to 3.13, the water parameters for pH, dissolved oxygen and 
flow rate did not fall outside of the set parameters over the course of experiments l and 2. 
3.3.2 Exposure concentrations 
Tables 3.11 and 3.12 show the mean data obtained from the analysis of the water samples 
at each concentration for experiments I and 2, respectively. 
Nominal 
Concentration 
Mean propranolol concentration of water samples 
collected on days 0,4,7,14 and 21 (mg/t, ) 
Average 
result 
(mg/L) Day 0 Day 4 Day 7 Day 14 Day 21 (mg/L) 
DWC <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
0.001 0.00014 0.000927 0.00063 0.000733 0.001567 0.00084 
0.01 0.005867 0.003933 0.004 0.004933 0.009333 0.0053 
0.1 0.092 0.083333 0.101 0.116667 0.128333 0.098 
1.0 1.1 1.133333 1.0366667 1.166667 2.133333 1.16 
10 3.4 - - - - 
Table 3.11. Mean measured propranolol concentrations in the water samples at each 
sampling time for experiment 1. Dilution Water Control (DWC) 
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Nominal 
Concentration 
Mean propranolol concentration of water samples 
collected on days 0,4,7,13,14 and 21 (mg/L) 
Average 
result 
(mg/L) 0 4 7 13 14 21 (mg/L) 
DWC - <0.0001 <0.0001 - <0.0001 <0.0001 <0.0001 
0.001 0.00074 0.0011 0.002467 - 0.000957 0.001233 0.0013 
0.01 0.006767 0.008867 0.010567 - 0.006633 0.007033 0.0080 
0.1 0.038 0.065 0.065 - 0.113333 0.106667 0.078 
1.0 0.476667 1.043333 0.983333 1.28 1.06 - 0.97 
Table 3.12. Mean measured propranolol concentrations in the water samples at each 
sampling time for experiment 2 
Propranolol concentrations from the water chemistry analysis show that the fish were 
exposed to the drug, propranolol-HCI, and that the drug was present in the tanks containing 
fish that were being dosed, and absent from dilution water control (DWC) tanks. This 
showed that there was no contamination of propranolol into the control tanks. The 
propranolol concentration for each treatment was in the expected concentration range, 
apart from the 10 mg/L tanks in experiment 1. At a nominal concentration of 10 mg/l., 
only 34 % of the nominal dose was measured in the tanks. This may have been to 
solubility issues, and/or uptake of the drug by these fish in the tanks. In all other 
treatments, the average propranolol concentrations in experiments I and 2 ranged from 53 
to 112 % and from 78 to 130 % of the nominal concentrations, respectively, demonstrating 
that the measured concentrations were relatively close to the nominal concentrations. 
Analysis of the water chemistry results showed that there were no statistically significant 
differences in the mean results at each concentration between the two experiments, and so 
biological data from each experiment were combined to make one data set. 
3.3.3 Blood plasma analysis 
Propranolol concentrations were measured in the plasma collected from the sampled fish 
and Table 3.11 shows these data. As the Table shows, as the concentration of propranolol 
increased in the water, so did the plasma concentration of propranolol. It is also shown 
that fish in the control tanks (DWC) had no measurable propranolol in their plasma. At 
exposure concentrations of 0.1 and 1.0 mg/L, the fish started to rapidly bioaccumulate 
propranolol in their blood, and this was especially obvious in male fish. 
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Nominal 
Concentration 
(mg/L) 
Actual mean 
Concentration 
(mg/L) 
Mean propranolol 
concentration 
in plasma (mg/L) 
Plasma concentration as 
percentage of actual 
mean 
water concentration (%) 
Male Female Male Female 
DWC <0.0001 <0.00025 <0.00025 <0.00 <0.00 
0.001 0.0013 0.000555 0.000690 42.69 53.07 
0.01 0.0080 0.00605 0.00855 75.62 106.88 
0.1 0.078 0.34 0.21 435.89 269.23 
1.0 0.97 15.00 5.75 1546.39 592.78 
Table 3.1 1. Mean measured propranolol concentrations in the pooled plasma samples 
collected from fish at each concentration. Letters in red show where the internal plasma 
concentration of propranolol exceeded the external actual water concentration. 
3.3.4 Fish mortality 
At the start of the addition of propranolol to the tanks there were four pairs of fathead 
minnow in each concentration. Unfortunately during the three day transition period, in the 
10 mg/L tanks (actual concentration was measured to be 3.4 mg/L) during experiment 1, 
the fish died or had to be euthanized before the exposure period began. In all cases the 
males became ill before the females and before termination showed a lack of orientation 
and were noted to be swimming on one side or nosing the bottom of the tank. Therefore 
no egg production data or sampling data were collected for the 10 mg/l, concentration. 
Because of these unexpected results and because it was not intended to collect acute 
toxicity data for propranolol, the 10 mg/L dosing was not repeated in experiment 2. 
At the 1.0 mg/L concentration on day 5 in experiment 1, two males started to show slightly 
similar behaviour to those that died in the 10 mg/L and they were therefore euthanized. 
During experiment 2, the fish at the 1.0 mg/L concentration were closely observed during 
the exposure period. It was noted on day 2 that the fish in all the 1.0 mg/L dosing tanks 
had a reduced appetite, as a noticeable quantity of food could be seen on top and around 
the spawning tiles. By day 4 two males were euthanized as they had started to swim on 
one side with an apparent loss of orientation and the pairing females were terminated on 
day 5 as they also showed the same symptoms. The remaining fish at this concentration, 
despite having a reduced appetite, showed no signs of distress. On day 11 during 
experiment 2 of the exposure period, one of the males at the 1.0 mg/L concentration was 
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found dead outside of the tank. This was most unexpected as no signs of distress had been 
observed in the days prior to this incident. The remaining fish being maintained at 1.0 
mg/L were then culled after this event and tissue and sampling data were collected. Hence 
cumulative egg data were collected only for 11 days in experiment 2 at this concentration 
of propranolol. 
Four other deaths occurred during both experiments and in all cases it was because the 
female had become egg-bound. Tables 3.12 and 3.13 show the number of fish that were 
used to collect data at each concentration in each experiment. In experiment 2 it was 
possible to collect data from five fathead minnow pairs in the control tanks, because extra 
tanks had become available as the 10 mg/L concentration was not being undertaken. 
Concentration 
(mg/L) 
Number of fish pairs 
used in experiment 1 
Number of fish pairs 
used in experiment 2 
Total number 
of fish pairs 
DWC 3 5 8 
0.001 4 3 7 
0.01 4 4 8 
0.1 4 3 7 
1.0 2 3 for 11 days 5 (for 11 days) 
10 0 n/a 0 
Table 3.12. Number of fish pairs used to collect cumulative egg data in experiments I 
and 2, and the total number of fish that were used for data analysis of the combined 
dataset. 
Concentration 
(mg/L) 
Number of fish used 
in experiment I 
Number of fish used 
in experiment 2 
Total number of 
fish 
Male Female Male Female Male Female 
DWC 4 3 5 5 9 8 
0.001 4 4 4 4 8 8 
0.01 4 4 4 4 8 8 
0.1 4 4 4 3 8 7 
1.0 3 3 1 3 4 6 
Table 3.13. Number of male and female fish used to collect data parameters in 
experiments I and 2, and the total number of fish that were used for data analysis. 
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3.3.5 Cumulative egg production 
Table 3.14 shows cumulative egg production and a summary of egg production data during 
the baseline period from each experiment. Across both experiments, the total number of 
eggs per female in the baseline period ranged from 444 to 1068. The mean number of eggs 
per female per reproductive day ranged from 21 to 51. These data compare favourably to 
pair breeding assay data reported by Winter et al., (2008), where the number of eggs per 
female per reproductive day ranged from 27 to 50, but are slightly lower than those 
produced by Thorpe et al. (2007) (80 to 93 eggs/female/day). The mean number of eggs 
per spawn was between 125 and 251 in the baseline period. This range is slightly higher 
than data reported by Winter et al. (2008) (103 to 161 eggs/spawn) and lower than that 
reported by Thorpe et al. (2007) (358 + 14 eggs/spawn). 
Treatment Number of Cumulative Mean Mean Mean 
(mg/L) fish pairs in egg number of number of number of 
each production eggs/female eggs/female/ eggs/ 
experiment reproductive spawn 
day 
Exp Exp Exp Exp Exp Exp Exp Exp Exp Exp 
1 2 1 2 1 2 1 2 1 2 
DWC 4 5 4: 7() 4702 1 u0 h 940 S1 45 l 194 
0.001 4 4 3246 )3 812 72', 39 14 180 23 
0.01 4 4 2359 2447 590 612 28 29 147 144 
0.1 4 4 4297 , 45O 1074 863 51 41 195 2_ßu 
1.0 4 177-4 1755 4.44 Z, 8 21 ýV I ýý, 125 
Table 3.14. Summary of baseline period egg production data for experiments 1 and 2. 
Data in Imik includes data from fish that died during the exposure period but completed 
the baseline period (i. e. fish that are not included in Figure 3.13) 
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Table 3.15 shows cumulative egg production and a summary of egg production data in the 
exposure period from both experiments. The mean eggs per female in the exposure period 
ranged from 49 to 887, the mean number of eggs per female per reproductive day were 
from between 0 to 42 and the mean eggs per spawn were from between 25 to 238. In all 
egg production data for the exposure period the minimum value is a lot lower compared to 
the baseline period in this study and in comparison to data sets from other studies. The 
minimum value in all these exposure egg production data is from the 1.0 mg/L treatment 
groups in both experiments. All other treatment group data in the exposure period were 
comparable to the baseline egg production data in both experiments. 
Treatment Number of Cumulative Mean Mean Mean 
(mg/L) fish pairs in egg number of number of number 
each production eggs/female eggs/female/ of eggs/ 
experiment reproductive spawn 
day 
Exp Exp Exp Exp Exp Exp Exp Exp Exp Exp 
1 2 1 2 1 2 1 2 1 2 
DWC 3 5 2662 4046 887 809 42 39 205 238 
0.001 4 3 3185 2006 796 669 38 32 187 167 
0.01 4 4 2210 2866 553 717 26 34 138 159 
0.1 4 3 3294 2540 824 847 39 40 165 212 
1.0 2 3 98 0 49 (º 2.3 U 25 1º 
Table 3.15. Summary of exposure period egg production data for experiments I and 2. 
Data in shows where data were only taken for I1 days as fish had to be euthanized. 
Figure 3.13 shows the pooled data from experiments I and 2 of cumulative egg production 
during baseline and exposure periods. Comparison of the baseline and exposure periods 
can only be made at each concentration since the number of pairs differs between 
concentrations, which therefore automatically effects the cumulative number of eggs 
produced, and/or the slope of the line. For example, 1.0 mg/1, had the least number of fish 
pairs (n = 5), so the cumulative egg production is, as expected, much lower than for the 
DWC and 0.01 mg/L treatments, which each have the most amount of fish pairs (n = 8). 
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Figure 3.13. Cumulative egg production at each concentration during the 21 day 
baseline and exposure periods. The data from experiments I and 2 have been pooled. 
" DWC. " 0.001 mg/L. " 0.01 mg/L. " 0.1 mg/L. 0 1.0 mg/L 
* shows a statistically significant difference (p =<0.05) after 11 days of each time 
period. 
On comparison of the cumulative egg production during the baseline and exposure periods 
within each treatment group, there is a statistically significant difference (a decrease) in the 
cumulative egg production between the baseline and exposure periods for the 1.0 mg/L 
treatment group (p =<0.05). There is no statistically significant difference between 
baseline and exposure periods for any of the other treatments. 
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3.3.6 Body and organ size 
Figures 3.14 and 3.15 show the analysis of male and female wet weight data, respectively, 
which was obtained on termination of the experiments. Weight ranged from 2.433 to 
5.680 g in male fish and from 0.811 to 2.490 g in female fish. The male wet weight data 
show a dose-related decrease, in which there is a statistically significant difference 
between the DWC group and the 1.0 mg/L treatment group (p < 0.05). This trend is not 
seen in the female wet weight data, and there are no statistically significant differences 
between treatment groups. 
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Figure 3.14. Mean, standard error and individual values of male wet weight from 
experiments 1 and 2. 
Mean (0 ) and standard error bars (_ ) of the pooled results from experiments 1 and 
2. * denotes a statistically significant difference between treatment groups (p < 0.05). 
+ Individual results from experiment 1. X Individual results from experiment 2 
DWC: Dilution water control 
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Figure 3.15. Mean, standard error and individual values of female wet weight from 
experiments I and 2. 
Mean (") and standard error bars (_ ) of the pooled results from experiments 1 
and 2. There are no statistically significant differences between treatment groups 
+ Individual results from experiment 1. N Individual results from experiment 2. 
DWC: Dilution water control 
Male fork length ranged from 52 to 71 mm and female fork length ranged from 42 to 65 
mm. Figures 3.16 and 3.17 show results of male and female fork length, respectively. No 
statistically significant differences are found between treatment groups. However, a slight 
downward trend is seen in male fork length as the concentration of propranolol increases. 
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Figure 3.16. Mean, standard error and individual values of male fork length from 
experiments 1 and 2. Mean (0 ) and standard error bars (_ ) of the pooled results from 
experiments 1 and 2. There are no statistically significant differences between treatment 
groups. + Individual results from experiment 1. X Individual results from experiment 2. 
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Figure 3.17. Mean, standard error and individual values of female fork length from 
experiments 1 and 2. Mean (0) and standard error bars (_ ) of the pooled results from 
experiments I and 2. There are no statistically significant differences between treatment 
groups. + Individual results from experiment 1. X Individual results from experiment 2. 
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Gonad weight in males ranged from 0.01 to 0.074 g and GSI ranged from 0.22 to 1.39 %. 
GSI can give an indication of reproductive status, as gonad weight is expressed as a 
proportion of body weight. Figure 3.18 shows male gonadal somatic index (GSI) data 
from experiments I and 2. A statistically significant difference is found between DWC 
and 0.01 mg/L treatment groups in male GSI data. Both the 0.001 mg/L and the 0.01 mg/L 
groups had higher mean GSI values than the DWC group. However, this trend of 
increasing GSI with increasing propranolol concentration was not dose-related, as the same 
increase is not seen in the 0.1 and 1.0 mg/L treatment groups. 
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Figure 3.18. Mean, standard error and individual values of male gonadal somatic index 
data (GSI) from experiments I and 2. Mean (0) and standard error bars (71:: ) of the 
pooled results from experiments I and 2. * denotes a statistically significant difference 
between treatment groups (p < 0.05) 
+ Individual results from experiment 1. N Individual results from experiment 2. 
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Female gonad weight ranged from 0.01 to 0.357 g and GSI ranged from 1.32 to 17.14 %. 
The female GSI data exhibits a dose-related effect, for as the concentration of propranolol 
increases, so does the GSI, as shown in Figure 3.19. This produces statistically significant 
differences between treatment groups DWC and 0.1 mg/L, DWC and 1.0 mg/L, and 
between 0.001 and 1.0 mg/L. 
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Figure 3.19. Mean, standard error and individual values of female gonadal somatic 
index (GSI) data from experiments I and 2. 
Mean. = Standard error bars. X Individual result. 
* denotes a statistically significant difference between treatment groups 0.001 and 
1.0 mg/L (p < 0.05). 
A denotes a statistically significant difference between DWC and treatment group 
1.0 mg/L (p < 0.05). 
  denotes a statistically significant difference between DWC and treatment group 
0.1 mg/L (p < 0.05). 
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The same relationship is seen in the female GSI when data from experiments I and 2 are 
viewed separately, as shown in Figures 3.20. The statistically significant differences are 
still seen in experiment 1, however in experiment 2a similar trend is apparent but the 
differences are not statistically significant when p< 0.05. 
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Figure 3.20. Mean, standard error and individual values of female gonadal somatic 
index (GSI) data from experiment I (A) and experiment 2 (B). * denotes a statistically 
significant difference between treatment groups (p < 0.05). 
40 Mean. 
= Standard error bars. X Individual result. 
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Figure 3.31 shows the weight of the fatpads from male fish at each concentration of 
propranolol. The male fatpad weight ranged from 0.090 to 0.477 g. As the concentration 
of propranolol increases from 0.01 mg/L, there is a dose-related decrease in the weight of 
the fatpad, and a statistically significant difference (*) was found between treatment groups 
O. Olmg/L and 1.0 mg/L and also between groups 0.1 mg/L and 1.0 mg/L (p < 0.05). 
However, no treatment group showed a statistically significant difference when compared 
to the control group. 
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Figure 3.31. Mean, standard error and individual weight of male fat pads from 
experiments I and 2. Mean (") and standard error bars (_ ) of the pooled results 
from experiments I and 2. * denotes a statistically significant difference between 
treatment groups (p < 0.05) 
+ Individual results from experiment 1. X Individual results from experiment 2. 
Figures 3.32 and 3.33 show data on the number of tubercles and the prominence of these 
tubercles, as assessed using the qualitative scheme devised by Smith (1978), respectively. 
The number of tubercles ranged from 12 to 16, and the tubercle prominence score from 1 
to 4. There are no statistically significant differences between treatment groups in either of 
these sets of data. No secondary sexual characteristics were observed in any female fish 
sampled. 
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Figure 3.32. Mean, standard error and individual number of tubercles found on each 
male fish from experiments I and 2. Mean (") and standard error bars (_ ) of the 
pooled results from experiments I and 2. There are no statistically significant 
differences between treatment groups 
+ Individual results from experiment 1. X Individual results from experiment 2. 
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Figure 3.33. Mean, standard error and individual results of tubercle prominence on 
male fish from experiments I and 2. Mean (0) and standard error bars (_ ) of the 
pooled results from experiments I and 2. There are no statistically significant 
differences between treatment groups + Individual results from experiment 1. 
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The condition index can give an overall impression of the condition of a fish. Figures 3.34 
and 3.35 show the calculated condition index (CI) of male and female fish in each 
treatment group. These data range from a Cl of 1.21 to 1.99 in male fish and between 1.00 
and 1.58 in female fish. 
A statistically significant difference exits between the Cis of the 0.001 mg/L and I. Omg/L 
groups and between the CIs of the 0.01 mg/L and 1.0 mg/L treatment groups in the male 
data, in that fish in the 1.0 mg/L group have a lower Cl compared to other treatment 
groups. However, there were no treatment groups whose Cis were statistically 
significantly different from that of the control group. No statistically significant difference 
is found between treatment groups in the female data. 
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Figure 3.34. Mean, standard error and individual condition indices of male fish in each 
treatment group, calculated from experiments I and 2. Mean ( ") and standard error 
bars (_ ) of the pooled results from experiments I and 2. * denotes a statistically 
significant difference between treatment groups (p < 0.05) 
+ Individual results from experiment 1. X Individual results from experiment 2. 
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Figure 3.35. Mean, standard error and individual condition indices of female fish in 
each treatment group, calculated from experiments I and 2. Mean (0 ) and standard 
error bars (_ ) of the pooled results from experiments I and 2. There are no 
statistically significant difference between treatment groups. 
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3.3.7 Hatchability trials 
The data from the hatchability trials are summarized in Table 3.16, and Figures 3.36 and 
3.37. 
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Concentration Baseline or Number of Percentage Mean number Number 
of propranolol exposure trials that of days to that died 
(mg/L) period undertaken hatched hatch (SD in during 
(mean %) brackets) hatching* 
DWC Baseline 22 91.13 6.09 (0.868) 0 
I 'piº"urc 22 92.42 6.14 (0.941) I06 
0.001 Baseline 18 95.22 6.50 (1.543) 0 
l. Xposurc 16 86.31 6.56 (1.209) U. ±I 
0.01 Baseline 17 81.20 6.25 (1.000) 0 
l": xposuI"r 16 74.86 6.25 (0. WS'3) 0.19 
0.1 Baseline 19 88.38 6.19 ** (0.750) 0 
Fxposurc 18 91.14 7.24 ** (1.2oo) 0.33 
1.0 Baseline 13 84.15 6.15 (1.068) 0 
ýný. tEý, f 1lill " 0 
Table 3.16. A table summarizing the hatchability data from experiments 1 and 2. 
* calculated as the total number of progeny that died during hatching in each 
treatment group period, divided by the number of trials undertaken in that 
treatment group. 
** statistically significantly difference between the baseline and exposure period in 
the 0.1 mg/L treatment group (p<0.05) 
The mean percentage of eggs that hatched in the 0.001 mg/L and the 0.01 mg/l, was lower 
in the exposure period compared to the baseline period, as shown in Figure 3.36. This 
observation was not seen in the control group, the 0.1 mg/L group and the one hatching test 
that was carried out in the I. Omg/l, group, where the mean percentage of eggs that hatched 
was higher in the exposure period compared to the baseline period. 
The mean number of days that it took for the eggs to hatch in each treatment group 
increased during the exposure period compared to the baseline period in all treatment 
groups, except in the 0.01 mg/L group where it remained constant. In the 0.1 mg/L 
treatment group this increase between the baseline and exposure periods was statistically 
significant, as shown in Figure 3.37. The 1.0 mg/L data could not be statistically analysed 
because there were fewer than 2 data points. It was sometimes observed that the progeny 
died during hatching. This happened only during the exposure period and was observed in 
all treatment groups (except 1.0 mg/L group where only 1 batch of eggs was produced), 
including the control group, in which it happened with the most frequency. 
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Figure 3.36. Results of hatchability trials with regard to the percentage of eggs that 
hatched. B: Baseline period. E: Exposure period. " Mean baseline period " Mean 
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Figure 3.37. Mean and standard error data from hatchability trials with regard to the number of 
days it took for 50 eggs, in each hatchability trial, to hatch. B: Baseline period. E: Exposure 
period. * denotes statistically significant difference between baseline and expose period in 
0. lmg/L treatment group (p<0.05) 138 
3.3.8 LOEC and NOEC 
Table 3.17 summarises the LOEC (lowest observed effect concentration) and NOECs (no 
observed effect concentration) for each of the endpoints that were measured in the 
experiments. 
Endpoint LOEC (mg/L) NOEC (mg/L) 
Male Female Male Female 
Survival 1.0 3.4 0.1 1.0 
Egg production - 1.0 - 0.1 
Wet weight 1.0 > 1.0 0.1 >1.0 
Fork length >1.0 >1.0 >1.0 >1.0 
GSI >1.0 0.1 >1.0 0.01 
Fatpad weight >1.0 - >1.0 - 
Number of tubercles >1.0 - > 1.0 - 
Prominence of tubercles >1.0 - >1.0 - 
Condition index >1.0 >1.0 >1.0 >1.0 
Hatchability (Days to hatch) 0.1 0.1 0.01 0.01 
Table 3.17. Summary of the LOEC and NOEC values for the various endpoints 
measured in the experiments in which fathead minnows were exposed to propranolol 
LOEC values define the propranolol concentrations that caused a statistically significant 
difference between a treatment group (and treatment groups of increasing propranolol 
concentration thereafter) and the control, or when a statistically significant difference is 
found between the baseline and exposure period in the same treatment group. 
In summary, propranolol affects hatchability (with regard to the number of days it takes for 
eggs to hatch) and female GSI at 0.1 mg/L. These are the most sensitive endpoints. At 1.0 
mg/L, propranolol significantly affects male survival and male wet weight, and at 3.4 mg/l, 
propranolol significantly affects female survival. 
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3.4 Discussion 
Propranolol has been found to be toxic to other organisms and fish (see references in 
Introduction), however it was most surprising that when fathead minnows were exposed to 
the test concentrations used in these experiments, severe disruption to their health was 
caused at concentrations of 1.0 mg/L propranolol. This acute toxicity of propranolol to 
fish, and its other effects, might be explained by the reasoning below. 
3.4.1 Side effects of propranolol 
In humans, propranolol acts by blocking adrenaline and noradrenaline from binding with 
X31 and (32-ARs. The (S)-enantomer of propranolol is the active form of the drug and is a 
hundred times more potent in blocking the (3-ARs than the (R)-enantomer, hence it is 
responsible for almost all of the drug's pharmacological effects (Fgginger, 1994; 
Masubuchi et al., 1993). However, these effects also include ones which the drug was not 
necessarily designed for. For example, one side effect of propranolol in mammals is the 
drug's ability to inhibit sperm motility and fertilizing ability, and this spermicidal action 
has even been investigated as a potential way to control sea lamprey populations in the 
Great Lakes, Canada (Ciereszko et al., 2004). 
Propranolol is lipophilic (log Kow 3.48), and due to this physical property it can easily 
move across the blood-brain harrier in organisms (Vu & Beckwith 2007). Studies have 
shown that propranolol can be found in human brain tissue at concentrations ten to twenty 
six times higher than in plasma (Cruickshank & Neil-Dwyer, 1985, Westerlund, 1985). 
This is a high degree of bioaccumulation, especially when compared to brain 
concentrations of the hydrophilic (3-blocker atenolol, which has a brain: plasma ratio of 0.2 
(Cruickshank & Neil-Dwyer, 1985). Similar accumulation can also be found in the brains 
of rabbits and monkeys that were administered propranolol (Srivastava & Kapoor, 1983). 
Propranolol is also known to act as a serotonin receptor antagonist, by interacting with the 
5-hydroxytryptophan receptor (5-HT) in the brain (Dzialowski et al., 2006; Westerlund, 
1985). Serotonin is synthesised in serotonergic neurons in the central nervous system 
(CNS) from the amino acid tryptophan, and its functions are numerous. For example, 
serotonin controls appetite, sleep, memory, learning behaviour, temperature regulation, 
mood, sexual behaviour, cardiovascular function, muscle contraction, endocrine regulation, 
and depression (http: //serendlip. bfynmqawr. edu/). Some patients prescribed propranolol 
have been known to suffer adverse CNS effects such as had nightmares, hallucinations, 
fatigue, impaired short term memory and ability to concentrate, reduced anxiety, and 
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alterations in mood (Vu & Beckwith 2007; Currie et al., 1988). Less CNS-related side 
effects are reported from patients prescribed the hydrophilic 3-Mocker atenolol 
(Westerlund, 1985). 
The effects of propranolol on catecholamine levels in the brain seem to be localised. In 
rats, propranolol does not alter catecholamine levels in the brain stem, yet in the 
hypothalamus, levels of adrenaline and noradrenaline decrease. However, levels of the 
enzyme dopamine ß-hydroxylase in rats were decreased by 23 and 29 % in both the brain 
stem and hypothalamus, respectively (Srivastava & Kapoor, 1983). Dopamine ß- 
hydroxylase is the enzyme that converts dopamine to noradrenaline, and so the decreased 
activity of this enzyme could account for the lower levels of noradrenaline in the 
hypothalamus (Srivastava & Kapoor, 1983). Hence, the disorientation and reduced 
appetite observed in fathead minnows on exposure to toxic concentrations of propranolol 
may have been due to CNS effects of propranolol. In studies where rats were exposed to 
propranolol, an obviously decreased locomotor activity was also observed due to the local 
anaesthetic action of propranolol as a consequence of its CNS toxicity (Lemmer & Sailer, 
1974). 
In these propranolol experiments the GSI of the female fish showed a dose-related 
increase. This was observed in conjunction with a statistically significant decrease in 
cumulative egg production data in the 1.0 mg/L group between baseline and exposure 
periods. However, although spawning was much reduced at the highest concentrations of 
propranolol, on termination it was observed that the female fish had continued to produce 
eggs and the gonads of the female fish at the highest concentration were full of eggs. lt 
seems that due to the lack of mating behaviour by both fish, no spawning behaviour 
occurred to induce spawning. One of the CNS side effects of propranolol in humans is 
decreased sexual behaviour, and this may be due to the antagonistic affects of propranolol 
on serotonin receptors. Serotonin has been shown to be an important neuromodulator of 
sexual function in vertebrates and invertebrates and the reproductive status in fish has been 
correlated to serotonin levels (Foran et al., 2004). For example, serotonin in fish 
modulates the secretion of gonadotropin releasing hormone (GnRI-I) from the 
hypothalamus, and also induces oocyte maturation in teleost fish (Foran et al., 2004). 
Hence the lack of reproduction in the 1.0 mg/L tanks and the dose-related increase in GSI 
in female fish is probably not due to a reproductive toxic effect (i. e. a specific and direct 
effect on the reproductive system), but it is more likely that propranolol had CNS effects 
on serotonin levels, which consequently affected fathead reproduction through lack of 
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mating behaviour and lack of oocyte maturation in the female fish. If oocytes grew to a 
specific stage, but then did not mature and so were not ovulated, this could account for the 
increase in GSI in females. 
3.4.2 Lipid metabolism and ß-blockers 
When fathead minnows were exposed to propranolol, a dose-related, statistically 
significant reduction in the weight of the male fat pad was observed in the 0.01,0.1 and 1.0 
mg/L treatments. However, although fatpad weight decreased between 0.01 and 1.0 mg/I,, 
nevertheless no treatment group had a fatpad weight that was significantly less than that of 
the control group. Fatpads and tubercles in male fathead minnows are an expression of 
their secondary sexual characteristics, and when a reduction in the weight of male fatpads 
is observed, it is usually associated with anti-androgenic effects of a chemical (Villeneuve 
et al., 2006). In these experiments, a significant reduction in male wet weight at the 
highest propranolol treatment was evident (together with a dose-related decreasing trend as 
the propranolol concentration increased), yet the fork length did not change significantly 
between any treatment group. In addition, the condition index in males decreased as the 
propranolol concentration increased. These changes, taken together, suggest that the 
effects seen in these experiments were not due to anti-androgenic changes in secondary 
sexual characteristics, but could instead be due to modifications of the lipid metabolism in 
the fish that utilised the fat in the fatpad, decreased the weight, and consequently the 
condition index, of the fish at the highest propranolol concentrations. 
When ß-blockers are administered to treat hypertension (i. e. high blood pressure) in 
humans, (3-blockers are normally used as a long-term and often life-long therapy; hence 
studies have been carried out to assess the affects of ß-blockers on lipid metabolism in 
humans (Pasotti et al., 1982). Adrenaline and noradrenaline are known to strongly 
stimulate lipolysis in mammals by targeting ß-ARs, resulting in increased plasma fatty acid 
levels (van Heeswijk et al., 2005; Vianen et al., 2002). Studies in humans found that the 
effects of non-selective ß-AR antagonists, such as propranolol and pindolol, significantly 
increased plasma levels of high density lipid cholesterol, compared to selective PI-AR 
antagonists such as metoprolol and atenolol, which did not affect plasma lipids or 
lipoproteins to such an extent (Pasotti et al., 1982; Bielmann et al., 1979). Since 13- 
blockers work to stop the affects of endogenous catecholamines, this suggests that (31-ARs 
are targeted to a greater extent than (32-ARs in humans by adrenaline and/or noradrenaline 
to stimulate lipolysis. 
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As in humans, teleost fish also release catecholamines to regulate the mobilisation of 
energy. However unlike humans, lipid metabolism in teleosts dominates over 
carbohydrate metabolism, since very small quantities of carbohydrates are ingested and 
stored (Vianen et al., 2002; Fabbri et al., 1998). Adrenaline in fish acts as it does in 
mammals, in that it stimulates lipolysis (Van Den Thillart et al., 2001). However in some 
species of fish, such as tilapia, goldfish, bream and carp, noradrenaline has been found to 
inhibit lipolysis via ß-Alks (Vianen et al., 2002; Van Den Thillart et al., 2001; Van Raajj et 
al., 1995). Furthermore, in tilapia it was found that the effects of the non-selective ß-AR 
antagonist timolol could block the inhibitory effects of noradrenaline (Vianen et al., 2002). 
In studies by Van Den Thillart et al. (2001), when selective 31-AR or ß2-AR antagonists 
were infused together with isoproternol (ß-agonist), they caused either an increase or 
decrease, respectively, of plasma free fatty acids in carp. This suggests that 
catecholamines cause either an inhibition or stimulation of lipolysis when they bind to ß f- 
or ß2-ARs, respectively. Another explanation is that noradrenaline may preferentially bind 
to ßl-ARs, thus causing an inhibition of lipolysis, whilst adrenaline preferentially binds to 
02-ARs, which in turn results in the stimulation of lipolysis, as depicted in Figure 3.38. 
Results of binding studies used in the characterisation of ß-ARs support this explanation 
(Bristow, 2000; Kawai & Arinze 1983). In fact, adrenaline has up to 100-fold selectivity 
for p2-AR compared to noradrenaline (Filadelfi et al., 2002). 
Noradrenaline 
X 
PI-AR 
Adrenaline 
ß2-AR 
Figure 3.38. Summary of how noradrenaline and adrenaline preferentially bind to 13- 
ARs and whether they inhibit (X) or stimulate lipolysis ('l) in some 
teleosts. 
Previous studies hence demonstrate that lipid metabolism in fish may be under a different 
mechanism of control compared to the one found in mammals. A possible reason for the 
suppression of lipolysis in fish, compared to mammals, may be to prevent the build up of 
fatty acids during hypoxic conditions, which could potentially disrupt bio-membranes (Van 
Den Thillart et al., 2001). 
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From the effects seen in the propranolol experiments with respect to the probable 
mobilisation of lipid reserves, and presuming that fathead minnows respond to 
catecholamines in a similar way to carp, propranolol would have to enable the stimulation 
of lipolysis and prevent or reduce the inhibitory effects of noradrenaline on 01-ARs. 
Possible mechanisms of action to facilitate this would be for propranolol to block more (31- 
ARs compared to ß2-ARs. It is known that propranolol has a 2.1 greater affinity for (31- 
ARs compared to ß2-ARs. However, this is a minor difference compared to metoprolol 
and bisoprolol, which have 75 and 120 times greater selectivity for 01-ARs compared to 
ß2-ARs, respectively (Bristow, 2000). Alternatively, propranolol may compete more 
successfully with noradrenaline than adrenaline for n-AR binding sites, or desensitization 
of ßl-ARs may have occurred, or on the other hand, stimulation of lipolysis could have 
been caused by an up-regulation in the expression of 02-ARs. It would require a 
considerable amount of research to discover the exact mechanisms of action of propranolol 
on lipid metabolism. 
However, if fathead minnows do not respond in the same manner as do carp, other 
mechanisms of action may be occurring. It would seem that propranolol was acting in a 
similar way to timolol in studies by Vianen et at. (2002), for both propranolol and timolol 
(non-selective ß-antagonistic drugs) stopped the normally low levels of lipolysis in both 
tilapia and fathead minnows. Reid et al. (1998) found that in teleosts (with the exception 
of carp), the concentration of stored adrenaline can be two to four times greater than stored 
noradrenaline, and hence higher levels of adrenaline would overall favour the stimulation 
of lipolysis via (32-AR. Another possible physiological mechanism is that another type of 
adrenergic receptor is involved in the stimulation of lipolysis. Involvement of al-AR in 
adrenaline action has been found in the liver of rainbow trout, and since propranolol does 
not bind to al-ARs, the increase in levels of lipolysis would not be affected by the 
administration of propranolol (Fabbri et al., 1995). 
3.4.3 Therapeutic concentrations of propranolol 
The advent of the characterisation of many fish genomes has revealed that there is a high 
homology and conservation of many enzyme/receptor systems between mammalian and 
teleost systems (Huggett et al., 2003). When pharmaceuticals are taken by patients, the 
most relevant concentration that describes the quantity of drug needed to interact with a 
specific drug target, and initiate a physiological response, is the human plasma 
concentration, as it is plasma that brings the target and 
drug into contact (Williams & 
Cook, unpublished). Since a certain plasma concentration of pharmaceutical is required to 
144 
affect target receptors and enzymes in humans, it has been hypothesised that approximately 
the same concentration would be required to affect another species sharing the same target 
(Brown et al., 2007) The `fish plasma model' hypothesised by Huggett et al. (2003) 
compares estimated or actual drug concentrations in fish plasma with human therapeutic 
plasma concentrations, in order to assess whether it is likely that environmental or 
experimental concentrations of a drug would produce therapeutic levels in fish (Brown et 
al., 2007). The effect ratio (ER) is calculated as shown in Figure 3.39, and the lower the 
ER, the greater the potential there is for a pharmacological response to occur in fish 
(Huggett et al., 2003). 
Human therapeutic plasma concentration (HTPC) 
Fish steady state plasma concentration (FssPC) 
Figure 3.39. Calculation used to obtain the effect ratio (ER) of a pharmaceutical. 
If the ER is :S1, the predicted drug concentration in the fish plasma is equal to or greater 
than the drug concentration in human plasma that elicits a therapeutic effect. 
If the ER is > 1, the fish drug plasma concentration is lower than the plasma drug 
concentration in humans that elicits a therapeutic effect. 
Due to the different physical properties of pharmaceuticals, some drugs are more likely to 
reach human plasma therapeutic levels from waterborne exposure than are others. 
Propranolol has a log Kow of 3.48, and since it is relatively lipophilic it is likely to 
bioaccumulate in fish from exposure via water. The propranolol concentrations in the 
plasma in fathead minnows used in the experiments conducted here show a dose-related 
relationship in that as the concentration of propranolol in the water increased, propranolol 
plasma concentrations also increased. This agrees with data by Wong et al. (1979), who 
established that propranolol plasma concentration and daily dose were significantly 
correlated. Table 3.18 shows the ER at each concentration of propranolol when compared 
to human therapeutic plasma levels measured in patients prescribed 80 mg/day of 
propranolol, which would be a sufficient therapeutic dose in the majority of patients with 
hypertension (www. pbs. root v. au). All of these patients had been on this medication for at 
least one week (Wong et al., 1979). It should also be noted that the internal plasma 
concentration of propranolol often exceeds the water concentration, showing 
bioaccumulation of the drug in the fish. 
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Propranolol Log Kow HTPC FssPC (actual) (µg/ml) ER 
concentration 
(mglL) 
(µg/ml) Male Female Male Female 
DWC 3.48 0.146 <0.00025 <0.00025 >584 >584 
0.001 0.000555 0.000690 263.06 211.59 
0.01 0.00605 0.00855 24.13 17.08 
0.1 0.34 0.21 0.43 0.70 
1.0 15.00 5.75 0.0097 0.025 
Table 3.18. Effect ratios (ER) of male and female fish exposed to different concentrations 
of propranolol. HTPC calculated from Wong et al. (1979) from patients that had been 
prescribed a daily dose of 80 mg of propranolol for at least one week. FssPC is the actual 
plasma concentrations of male and female fish from the different propranolol treatments 
From the ERs shown in Table 3.18, male and female fish exposed to 0.1 and 1.0 mg/L of 
propranolol have ER values less than 1. Hence, the plasma concentration of the drug in 
these fish is greater than the drug concentration in human plasma which is needed to elicit 
a therapeutic effect. This could explain why fish exposed to concentrations of 0.1 mg/L of 
propranolol, and higher, showed statistically significant effects from the control in some 
endpoints. 
When compared to other pharmaceuticals, as shown in Table 3.19, it can be seen that like 
propranolol, diclofenac and gemfibrozil also have ER values less than 1, unlike atenolol, 
which does not reach human plasma therapeutic levels in fish plasma. Although there is a 
high homology in receptor systems between humans and fish, it must however be 
remembered that the response to a pharmaceutical could be greater in non-target organisms 
than in humans, as they could have higher receptor density, or less receptors are needed to 
trigger a response. 
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Drug Log Kow HTPC(µg/ml) FssPC (µg/ml) ER 
Ibuprofen ' 3.80 10 4.68 2.14 
Naproxen ' 3.10 20 3.64 5.49 
Diclofenac ' 4.02 0.42 3.44 0.12 
Ketoprofen ' 3.00 5 0.06 83.3 
Gemfibrozil ' 4.80 15 32.07 0.47 
Atenolol 2 0.23 1,000 (maximum) 51.8 19.3 
Table 3.19. HTPC, FssPC and ER values of different pharmaceuticals. Values in red 
show where the ER is less than 1. 
1: Data taken from Brown et al., 2007. 
2: Data taken from Winter et at., 2008. 
However, despite a few drawbacks, the `fish plasma model' uses intelligent science, based 
on the wealth of mammalian pharmacology available, to predict potential drugs that may 
cause harm to fish, and hence this approach can highlight where additional testing may be 
required. 
3.4.4 Comparisons to other studies 
The most sensitive endpoints in this study were shown to be hatchability (with regard to 
the number of days it took for eggs to hatch) and female GSI. Both of these endpoints had 
LOEC values of 0.1 mg/L. Huggett et al. (2002) also found hatchability to be a sensitive 
endpoint in medaka (LOEC hatchability & egg production) = 0.0005 mg/L). However, the data 
from this study, with fathead minnows, does not support the Huggett et al. (2002) data in 
that the difference in LOEC values between these two studies is 5,000-fold. The effects 
found by Huggett et al., (2002), although statistically significant when compared with the 
controls, did not exhibit a dose-response relationship, unlike the data from this study. In 
addition, the data from Huggett et al. (2002) were not repeated and the sample size at each 
treatment was relatively small. With respect to survival rates, fathead minnows (LOEC 
male survival = 
1.0 mg/L, LOEC female survival = 3.2 mg/L) were shown to be more sensitive to 
propranolol than medaka (LC50 = 24.3 mg/L). 
A parallel pair breeding assay using fathead minnows was conducted with another 
blocker, atenolol (Winter et al., 2008), and the results differed ten-fold from those obtained 
in this study. The most sensitive endpoint on exposing fathead minnows to atenolol was 
the male condition index (LOEC = 3.2 mg/L). Fathead minnows were also able to tolerate 
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high concentrations of atenolol (LOEC survival >10 mg/L), unlike in this study, where acute 
toxicity occurred at surprisingly low concentrations. The main reason for this could be due 
to the difference in the lipophilicity of these two 0-blockers. Atenolol has a much lower 
log Kow, compared to propranolol, and therefore reaches much lower plasma 
concentration in fish. This was reflected in the measured plasma concentrations of these 
two pharmaceuticals. Plasma concentrations of atenolol in relation to the corresponding 
measured water levels only ranged from 1.8 to 12.2 %, unlike propranolol that bio- 
accumulated up to 1550 % of the surrounding water concentration of propranolol in male 
fish at 1.0 mg/L treatment (Winter et al., 2008). 
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Chapter 4 Expression of 01- and 02-ARs 
4.1 Introduction 
Adrenergic receptors are not just found in the heart, they are also be found in many 
different tissues. Using real time polymerase chain reactions (RT-PCR) and sequencing 
information from the (31- and (32-ARs, the expression levels of these adrenergic receptor 
subtypes in different tissues can be evaluated. 
4.1.1 Expression of ß-ARs in mammals and fish 
Table 4.1 and table 4.2 show the expression of ßl-ARs and ß2-ARs in different tissues and 
in different species, respectively. This is not an exhaustive list, but instead represents a 
glance at the literature to show where expression levels have been researched. However, a 
variety of methods have been used to conclude that ß-ARs are expressed in these particular 
tissues. As science and research techniques move on, it becomes apparent that some of the 
older techniques used, such as identification of a biomarker (e. g. changes in glucose 
levels), are not specific methods in determining expression of a particular gene, as too 
many other factors can alter such biomarkers (Van den Thilliart et al., 2001). Other older 
techniques, such as radio binding assays, could also provide misleading results. For 
example, if a ß-blocker prevents the binding of radio-labelled adrenaline, you could 
conclude, maybe rightly, that the tissue contains ß-ARs (GarciaSainz et al., 1996). 
However, some ß-blockers, such as propranolol and endogenous catecholamines, can also 
bind to other receptors, such as seretonin receptors, and it could be these receptors, not p- 
ARs, that were involved in the binding. 
In addition, a response of a tissue to a (3-blocker does not necessarily mean that the tissue 
expresses (3-ARs, as the response could be controlled by another organ. For example, it 
may be thought that changes in reproduction were brought about via 13-ARs in the gonad. 
However, effects on reproduction could be affected by a (3-blocker acting on the brain, 
which then controls reproduction (Huggett et al., 2002). With regard to the specificity of 
some results, jumps in knowledge can mean that some data were incorrectly interpreted. 
For example, the fairly recent characterisation of the (33-AR meant that the specificity of 
some techniques had to be revised. For example, Nickerson et al. (2003) found the 
predominant ß-subtype to be ß3-AR in fish red blood cells, and not 13l -AR, as had been 
previously surmised by Perry et al. (1991). These problems demonstrate that some 
methods do not allow the unequivocal demonstration of the expression of ß-ARs in 
particular tissues, and also that due to new information, the ß-AR sub-type may have been 
incorrectly identified. Hence, in Tables 4.1 to 4.4, an asterix has been added where more 
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robust techniques (RT-PCR, northern blots, RNAse protection assays) have been used to 
identify ß-AR expression in different tissues. 
Animal Tissue showing H-AR Expression Reference 
Human Heart, placenta, cerebral cortex and lung Ellis and Frielle, 1999 
Pancreas, liver, heart, kidney, thalamus, 
adrenal glands 
Evanko et al., 1998 
Heart l lof fman, 2001 
Strosberg, 1997 
Lemoine et al., 1988 
Heart and fatty cells Nagatomo & Koike, 2000 
Mice Pulmonary lymphocytes Jain et al., 2003 
Rat Pineal gland of the brain, heart Machida et al., 1990 
Xenopus Mature oocyte Devic et al., 1997 
Trout Liver Van den Thilliart et al., 2001 
Table 4.1. Overview of the expression of ßl-ARs in different animals. * highlights 
where more robust techniques have been used to determine expression of P-ARs. 
Animal Tissue showing ß2-AR Expression Reference 
Human Heart Lemoine et at., 1988 
Trachea (bronchi) and capillary 
vessels 
Nagatomo & Koike, 2000 
Bronchial muscle lloffinan, 2001 
Heart Ellis and Friclle, 1999 
Hoffman, 2001 
Uterine muscle, detrusor muscle of the 
bladder 
Hoffman, 2001 
Uterus, skeletal muscle, lungs Strosberg, 1997 
Dog Liver GarciaSainz et al., 1996 
Channel 
catfish 
Head kidney, spleen, leukocytes Finkenhine et al., 2002 
Trout Liver, red muscle , white muscle, gills, 
heart, kidney, spleen 
Nickerson et al., 2001 
Liver Reid et al., 1992 
Van den Thilliart et at., 2001 
Table 4.2. Overview of the expression of 02-ARs in different animals. * highlights 
where more robust techniques have been used to determine expression of fi-ARs. 
Tables 4.3 and 4.4 show that other (3-AR subtypes (in some cases the subtype is not stated), 
have also been found in a variety of tissues in mammals and fish. 
Animal ß-AR type Tissue Reference 
Human (33-AR Adipose tissue Lemaire & Rockman, 2004 
Brown and white adipose 
tissue 
Strosberg, 1997 
Gastro-intestinal tract 
Digestive tract, urinary bladder Nagamoto & Koike, 2000 
Detrusor smooth muscle of 
urinary bladder 
Takeda et al., 1999 
(34-AR Heart Nagamoto & Koike, 2000 
ß-ARs Smooth muscle Hoffman, 2001 
ARs Virtually every cell type Small et al., 2003 
Rat P3-AR Digestive tract, urinary bladder Nagamoto & Koike, 2000 
Adipose tissue, stomach 
fundus, colon, ileum, heart 
Evans et al., 1996 
Adipose tissue, illeum Zaagsma & Nahorski, 1990 
Table 4.3. Overview of the expression of other ß-ARs in mammals. 
Animal ß-AR type Tissue Reference 
Rainbow ß3a-AR Gill, heart, red muscle Nickerson et al., 2003 * 
trout ß3b-AR Red blood cells Nickerson et al-2003 * 
(3-ARs Cardiac tissue Keen et al., 1993 
Red blood cells Wang et al., 1999 
Reid & Perry, 1991 
Thomas & Perry, 1994 
Female gonads. Dzialowski et al., 2006 
Zebrafish ß-ARs Heart Fraysse et al., 2006 
Medaka ß-ARs Gonad Huggett et al., 2002 
Table 4.4. Overview of the expression of other (3-ARs in fish. * highlights where more 
robust techniques have been used to determine expression of ß-ARs. 
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Data in Tables 4.1 to 4.4 helped decide which tissues would be selected to evaluate the 
expression of ßl and f32-ARs in the fathead minnow. Huggett et at., (2002), in a four week 
exposure of medaka to propranolol, found that the total number of eggs and the number of 
viable eggs that hatched were significantly reduced at concentrations as low as 0.5µg/l,. 
Because of this result, gonadal tissue was selected for expression analysis to test the 
hypothesis that propranolol caused an alteration in the expression of (3-ARs in the gonads, 
which could explain the results found by Huggett et al., (2002). Heart tissue was chosen 
for analysis, for as shown in Tables 4.1 to 4.4, both (31 and ß2-ARs are found in the hearts 
of mammals and fish, and it is this major organ that (3-blockers are designed to target. 
Liver was also selected for this study as the liver is a major site for catecholamine- 
stimulated glycogenolysis (glycogen metabolism) and gluconeogenesis (glucose 
metabolism) and triglyceride synthesis (lipogenesis) in humans (Dentin et al., 2006; Fabbri 
et al., 1998). Hence, if metabolic changes were occurring because of propranolol, changes 
in the ß-AR expression may be seen in this organ. The brain was chosen for 13-AR 
expression analysis because in human's, ßl- and ß2-ARs are found in smooth muscle 
around hollow organs that have to contract (i. e. not skeletal muscle) and so by choosing the 
brain, which is not skeletal muscle, it tests the hypothesis that there would be no 
expression of (31- or ß2-ARs because the brain is not made of muscle. Hence, heart, brain, 
gonad and liver were the tissues used for expression analysis. These tissues were obtained 
from female fathead minnows that had been used in the propranolol experiments (see 
chapter 3 for full details of these experiments). 
4.1.2 Absolute and Relative RT-PCR 
Two types of RT-PCR methodology exists. One is known as absolute R"I'-PCR and the 
other is relative RT-PCR. Both methods allow gene expression quantification and unlike 
northern blots are exquisitely sensitive and permit the analysis of gene expression from 
very small amounts of RNA (Freeman et al., 1999). The difference between relative and 
absolute RT-PCR lies in how results are quantified. With relative R'I'-PCR, a 
housekeeping gene, such as ß-actin, is used to help quantify results. The theory behind this 
method is that expression of a housekeeping gene is constant throughout all tissues and 
will not vary in response to external pressures, such as chemical exposure, hypoxia, 
starvation, etc. Hence the change in expression of a gene of interest can be measured 
relative to the constant expression of a housekeeping gene. This was a popular method in 
the past, as the methodology was slightly easier than absolute RT-PCR. However, it has 
recently been discovered that the expression of housekeeping genes can vary, sometimes 
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quite drastically, which will of course invalidate the use of that gene in quantification 
methods. 
Absolute RT-PCR uses a standard which is an amplicon of the target gene that is being 
measured. Once the number of molecules in a defined aliquot of external standard is 
measured, a standard curve, covering a known concentration, is run on each assay plate. 
Providing the samples fall within the standard curve, the number of molecules expressed 
per µl of sample can be calculated. This method is a much more robust way of quantifying 
the expression of a particular sequence, since the strand of RNA, or in this case mRNA, of 
the standard is the same as the mRNA strand that is being analysed. Hence both strands 
simultaneously undergo reverse transcription and amplification under the same conditions, 
using the same primers, thus introducing less error in quantification. 
4.1.3 Use of RNA in RT-PCR 
Three classic types of RNA exist, messenger RNA (mRNA), ribosomal RNA (rRNA) and 
transfer RNA (tRNA), and recently a fourth category of micro-RNAs has also been 
discovered (Grol3hans & Filipowicz, 2008). Most RT-PCR methods use total RNA, as the 
conversion of RNA to mRNA is an extra step and could result in possible loss of material. 
Further, the fact that problems include not all mRNA molecules have poly(A) tails, 
normalisation against total RNA or rRNA is not possible when using mRNA, and the 
concentration of mRNA may be insufficient to allow quality assessment using some 
machines (Bustin, 2000). However, even if total RNA is used in RT-PCR, it is only 
actually mRNA that is being measured, as it is only mRNA that contains the coded 
information stored in DNA and which is attained during transcription (Lodish et al., 2004). 
Hence, the use of total RNA when amplifying small copy numbers will result in a lot of 
background noise, and if maximum sensitivity is required, mRNA is the preferred choice 
of starting material. 
4.1.4 Aim of RT-PCR 
The up or down regulation of receptors can be affected by chemicals in the environment, 
which can result in a change in the physiological response. For example, exposure to 
environmentally relevant concentrations of ethinylestradiol alters the pattern of expression 
of estrogen receptor subtypes (ERa and ERR) in the brain, testis and liver of roach (Katsu 
et al., 2007). The up-regulation of ERa during exposure to ethinylestradiol during early 
life stages induced gonadal feminization and vitellogenin induction in male roach, hence 
providing a molecular explanation for these changes (Katsu et al., 2007). Pharmaceuticals 
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are often administered to up or down regulate receptors. For example, a nasal 
contraceptive spray is being developed that releases gonadotropin-releasing hormone 
(GnRH) agonists. If GnRH receptors are down regulated by this spray, as anticipated, this 
will in turn prevent the production of gonadotrophins which induce ovulation (Kamran & 
Moghissi, 2000). Another example where gene expression is altered by a pharmaceutical 
is provided in a study by Villeneuve et al., (2007). Using quantitative real-time PCR, an 
increase in aromatase-A mRNA expression in fathead minnow ovary after exposure to 
fadrozole was observed. The up-regulation of this isoform was consistent with the direct 
mechanism of action of fadrozole. Hence, the hypothesis behind the RT-PCR work was to 
discover whether propranolol caused an up or down regulation of ßl- and/or p2-AR 
expression levels that might explain any physiological responses observed. 
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4.2 Materials and Methods 
4.2.1 Tissue acquisition 
For the set up and validation of the RT-PCR technique, liver tissues from fathead minnows 
were used. Tissues used in the analysis of 01- and ß2-ARs were obtained from icmale 
fathead minnows from the two propranolol experiments. All tissues were acquired by 
dissection as detailed in section 2.2.1, and mRNA was obtained as set out in sections 2.2.2 
and 2.2.4. Because fathead minnow hearts are so small, to enable the analysis of (i 1- and 
p2-AR expression levels in heart tissue, all the hearts obtained from the propranolol 
experiments had to be combined into one sample for each concentration, to obtain a high 
enough concentration of mRNA for testing. All other tissues were tested per individual 
fish, making the number of samples tested a lot higher than for the heart. 
4.2.2 RT-PCR Overview 
Absolute RT-PCR was used to quantitatively assess the expression levels of fl- and 12- 
ARs in the heart, liver, gonad and brain of female fathead minnows. The starting material 
for the samples, internal standard and the external standards was mRNA. During the 
assay, mRNA was reversed transcribed into cDNA and subsequently the target DNA was 
amplified using gene specific primers. QuantiTect SYBR Green (Qiagen, Crawley) was 
added to each well in the master mix and this bound to any double stranded DNA produced 
during the assay. The amount of DNA at the end of the assay was measured in each 
sample by the amount of fluorescence emitted from the SYBR Green. Care had to be 
taken to ensure that no non-specific primer annealing occurred during the assay, which 
would produce extra DNA products as these non-target products would be included in the 
measurement of SYBR Green fluorescence, leading to an incorrect result. Additionally, all 
traces of contaminant DNA were properly removed from samples and standards before the 
assay began. 
4.2.3 RT-PCR preparation of primers, target DNA and standards 
For a high efficiency in RT-PCR it is recommended that each amplicon (piece of target 
DNA that will be amplified) is between 75 to 150 bp in length, as the shorter the amplicon. 
the greater the efficiency of the amplification. However, the amplicon must be longer than 
75 bp to distinguish it from primer dimers. Amplicons must not have any secondary 
structures and it is recommended that the guanine: cytosine (G: C) content should be 
between 50 to 60 % and that repeats of a single base pair should he avoided. Figure 4.1 
shows the location of the amplicon within the ßl-AR. The amplicon is 185 hp long and 
has a G: C content of 55%. 
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5' a tggaagcgctccacacaggacctgaagttctgaatgagc 
gcgcttcatttctccacaccatgggagac ggtttaccgtctgtaaactacagcaatgactctaaacgcaccccggataacttatcaga 
acagtggctcgtgggcatgggaatcatcatgggtctggtagtaattgtcattgtagtggggaatatactggttatagtcgccatagc g 
cggaatcagaggctccagacgctcaccaatgttttcatagtgtctctggcgtgcgcagaccttatcatggggttactggtggtgc ca t 
ttggcgcagacttggaggtcagaggatcttggatgtatggatcgttcttctgtgaattctggatatctcttgatgtactttgcgtcacggc 
gagcatcgagaccctgtgcgtaattgcaattgacaggtacatcgccatcacctctccatttcgctatcaaagccttttaacgaaagca 
cgagccaaggtggtggtgtgtgcagtttgggctatatcagctcttgtgtcatttccacccatcctaatgcactggtcccgggacaccg 
tggatacatc atgctataac gaacccgagtgctgtgacttcatcaccaacc gtgaatatgccatctcatcctccgttatatc gttttacat 
ccctttaatagtcatgatattcgtctatgccagggtatacagagaagccaaacaacaactgaaaaaaattaacaaatgtgagggaag 
attctacaacaatggtactaattgcaaacctaaccgaaaacgaaccaccaagatcctggctttaaaagagcagaaggc gttgaaaa 
gtctagagaggaacggaagggtgtcccattcagagtctcagetgta a 
3' 
Figure 4.1. Nucleotide sequence of the p1-AR in the fathead minnow. 'Ehe amplicon 
(185 bp) is shown in italics between the two primers highlighted in M. Amplicon 
length: 185 bp. G: C content: 55 % The amplicon has no secondary structure. Nucleotides 
in represent the UTRs. atg and taa are the start and stop codons, respectively. 
Figure 4.2 shows that the location of the amplicon in the ß2-AR. A part of the P2-AR 
amplicon was within the 5' UTR of the receptor. Because the primers match both types of 
02-AR characterised (i. e. 197 and 207), the RT-PCR will amplify and quantify both types. 
The amplicon selected is 226 bp long, has a G: C content of 46%, and no secondary 
structure. 
There are also criteria that are used when designing primers that will select the amplicon 
from all the cDNA present during the assay. The most important feature is that the primers 
should anneal specifically to the target and no other piece of DNA. Both primers should 
have similar melting temperatures of 50 to 60°C, and should be 18 to 30 nucleotides in 
length. The G: C content should be between 40 to 60 % and no more than two guanine or 
cytosine nucleotides should be in the last five bases, yet one of these nucleotides should be 
at each end of the primer. Additionally it is recommended that there are no repeats of any 
single nucleotide in a row and checks should be made to ensure that no primer dimers or 
secondary structures are formed, either within the primer or with the primer pair. To help 
ensure that the primers designed fell inside these criteria, each primer pair was run through 
a programme (NA-ýa-\N-. getionie. kN, i. iiiit. edu/cpi-bin/priiiier/prinier') www. ci) to assess its fit 
to the criteria. 
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197 
207 
5 --------------------------------------------------- 9 
60 
197 69 
207 120 
197 ATGGAGCGAGGGGATAGG 129 
207 ATGGAGGGAGGGGATAGG 180 
197 TTGAGCGCGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCTTCT 189 
207 TTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCTTCT 240 
197 CCGGTGTCCGAATATAGCGACGC TTAATGGGGCTTCTG 249 
207 CCGGTGTCCGAATATAGCGACGC TTAATGGGGCTTCTG 300 
197 GTTCTAGGCATCGTCTTTGGCAACGTGCTGGTCATCAGCGCCATTGTACGATTTCAACGC 309 
207 GTTCTAGGCATCGTCTTTGGCAACGTGCTGGTCATCAGCGCCATTGTACGATTTCAACGC 360 
197 TTGCAGACGGGCACCAACTACTTCATCAGCTCCCTTGCCTGCGCCGACTTGGTCATGGGT 369 
207 TTGCAGACGGGCACCAACTACTTCATCAGCTCCCTTGCCTGCGCCGACTTGGTCATGGGC 420 
Figure 4.2. A comparison of the initial part of the sequence for 197 and 207 versions of 
the ß2-ARs isolated in the fathead minnow. The amplicon (224bp) is shown in i[ulics 
between the two primers highlighted in M. Nucleotides in represent the 5' UTR. 
ATC is the start codon. 
Once the amplicon and primers had been designed, they were run on a PCR machine with 
fathead minnow liver eDNA to ensure that the primers were specific to the target amplicon 
and only amplified one product. The PCR products were run on a2% agarose gel to 
verify this, as shown in Figure 4.3. 
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Figure 4.3. Photographs taken under UV light of PCR products run on a2 '% agarose 
gel. A1 Kb DNA ladder is shown on the left of each photograph and the white circles 
highlight the fact that only one PCR product was amplified. A. PCR products 
obtained by using ßl-AR specific primers. B. PCR products obtained by using ß2-AR 
specific primers. 
External standards were made from cloning vectors that had the relevant transcript 
inserted, as detailed in section 2.2.9. Instead of using the whole vector to make the 
external standards, a PCR was run to amplify only the relevant part of the vector. This was 
done using MI3R and MI3F primers, which matched sequences in the vector. Hence the 
piece of DNA amplified in the PCR contained the DNA insert (the part of the ß-AR). 
called the amplicon, SP6 and T7 promoters and a small part of the vector, as detailed in 
Figure 4.4. This PCR reaction was carried with proof reading taq to ensure correct 
amplification of the product. 
DNA 
SP T7 
M13F ON = M13R 
Vector 
Figure 4.4. Diagram of a vector that contains a piece of [)NA inserted into it. Using 
M 13 F (5' GTTTTCCCAGTCACGAC 3') and Ml 3R (5' CAGGAAACAGCTATGAC 3) primers, the 
vector was cut almost in half, so that during PCR the part that was amplified contained 
the DNA insert and SP6 (5' CATTTAGGTGACACTATAG 3') and T7 (5' 
GTAATACGACTCACTATAG 3) promoters 
The PCR products were run on a gel and the DNA extracted, as set out in section 2.2.8 and 
2.2.9. The DNA sample was cleaned up using MinElute PCR purification kit (Qiagen, 
Crawley) to remove any salts and enzymes and to recover and concentrate the DNA. The 
end product was then quantified using a nanodrop ND-1000 spectrophotometer (Thermo 
Fisher Scientific, Loughborough) against a blank reading of 1.5µI elution buffer. 
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The extracted and cleaned DNA underwent in-vitro transcription (whereby RNA was 
generated from the DNA sample) using the Riboprobe in-vitro transcription system 
(Promega, Southampton). The orientation of the DNA insert in the vector dictates which 
enzyme is used in the reaction. For instance, if the transcript is in the anti-sense direction, 
SP6ase is used, whereas if it is orientated in the sense direction, T7ase is used. The DNA 
sample was incubated for 2 hours at 37 °C with the correct enzyme and a mix of other 
components including dNTPs, according to the protocol. The newly made RNA sample 
was DNAse treated (Invitrogen, Paisley) by adding 2 p. l of DNAse I enzyme to every 50 µl 
of sample and incubating at 37 °C for 15 minutes to remove any DNA contamination. The 
sample was then cleaned up to remove any salts and enzymes and to concentrate the RNA 
sample. To do this, 250 ltl t. e. buffer, 25 µl 4M lithium chloride and 750 µl 100 % ethanol 
was added to 50 µl of sample and left at - 20 °C overnight. The next day the sample was 
spun at 13,000 rpm for 10 minutes and the supernatant was removed and disgarded. 
Following this, 500 µl of 75 % ethanol was added to the precipitate and the sample spun 
for a further 10 minutes at 13,000 rpm. The supernatant was again discarded and the 
sample air dried for 5 minutes, after which the sample was reconstituted in the desired 
volume of sterile water (Fisher Scientific, Loughborough), and quantified on a nanodrop 
ND- 1000 spectrophotometer. The sample was then separated into 3 µl aliquots, so that one 
aliquot could be used per assay without having to thaw and refreeze the whole sample, and 
immediately frozen at - 80 °C to prevent any degradation of the external standard. The 
copy number of RNA molecules in the external standard was calculated as shown in Figure 
4.5. 
Xg/µi RNA 
=Y molecules / µl 
[transcript length x 340] x 6.022 x 1023 
Figure 4.5. Equation used to determine the number of RNA molecules per µl of 
sample. Xg/µl refers to the concentration of the RNA sample. The transcript length is 
the length of the whole transcript from (and including) M 13 F to M 13 R. 
To normalise each plate, an internal standard made from fathead minnow liver mRNA and 
diluted to 5 ng/µl was made and stored in 20 pl aliquots. The internal standard was run in 
triplicate on all assay plates. 
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4.2.4 RT-PCR assay 
All surfaces, pipettes and the centrifuge were wiped down with RNase away to remove any 
sources of contamination. All the components were defrosted on ice, and whilst this 
occurred the RT-PCR machine was set up with the plate details and assay parameters. The 
external standards were made up by serial dilution so that the working range of the 
standards was from 107 to 101 molecules/ µl. For each dilution the starting sample was 
flicked, spun for 10 seconds, added to sterile dilution water and mixed by repeat pipetting. 
The diluted sample was then left on ice for 3 minutes before the process was repeated for 
the next serial dilution. The samples were thawed on ice and diluted to 5 ng/µl using 
sterile water. The master mix for each assay plate was made up by adding SYBR Green. 
target specific primers, reverse transcriptase and RNase free. "These components were 
briefly spun to ensure proper mixing and then 20 µl was pipetted into each well with a 200 
pl pipette using reverse pipetting to reduce error from air bubbles and film retention. This 
was not carried out on ice, as some methods suggest, as ice can create primer dimers in the 
mix. Triplicate 5 µl samples of RNA sample, standard or sterile water (non-template 
control, NTC) were added to the designated wells and a clear cover was stuck to the plate, 
pushed down with a scraper and a compression pad was placed over the top of the plate. 
The plate was placed in a centrifuge and spun for 15 seconds to mix the contents of each 
well, after which the plate was placed in the RT-PCR machine and the assay started. 
4.2.5 Interpretation of the results 
To ensure there was no contamination in the assay and to determine whether primer dimers 
had formed within the master mix, the non-template control (N"l'C) was analysed. Any 
fluorescence seen in the NTC wells is deducted from the results for all other wells. If a 
DNA product is detected in these wells, it would show that contamination had occurred. 
The efficiency of each reaction is calculated as shown in Figure 4.6, and should be greater 
than 90 %. 
1 
=a 
- slope 
10 x'' a-1 x 100 = Efficiency(%) 
Figure 4.6. Calculation used to work out the efficiency of a RT-PCR reaction. 
IOU 
The actual results produced are sigmoidal-shaped amplification plots, in which the number 
of cycles is plotted against fluorescence. In each sample, the cycle number in which the 
amount of fluorescence emitted by the SYBR Green reaches a threshold limit represents 
the desired result for that sample. The threshold limit is a preset limit in which a 
significant increase in fluorescence occurs; this limit is known as the C-1 line (threshold 
cycle) and from this the amount of starting template can be deducted. Figure 4.7 explains 
how this theory works in practise. 
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Figure 4.7. Amplification plots from a RT-NCR assay. Red horizontal line is the 
automatically pre-set CI- line. A. Amplification plot. B. is a close up of A to show that the 
result for each sample is the cycle number when the sample line (the amplification plot) 
crosses the Cr line. 
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Because each assay is run with external standards of known concentrations, the C-1- results 
can be converted into the number of molecules of RNA /µl (see Figure 4.8). 
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Figure 4.8. Standard plot of results and external standards of a RT-PCR assay. The solid 
squares ( ) are the standards (three per concentration), the line shows the best fit 
through these standards, and the red crosses (\) are the results of unknown samples. 
4.2.6 Optimisation of PI-AR RT-PCR 
An initial run was undertaken using six different tissues from male and female fathead 
minnows. Where the initial concentration of mRNA was high enough. the tissue was run 
at three different concentrations, and the results tell within the external standard range. 
The results also showed that the primers only replicated one sequence of DNA, to give just 
one product. Minimal primer dinier product was seen only in the non-template control 
(NTC) and at the lowest concentration of the internal standard. However, a high amount of 
baseline noise was seen in the dissociation curve (see Figure 4.9 below). 
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Figure 4.9. Dissociation curve for the 131-AR RT-PC R assay, NTC and external 
standards. This assay was run with an annealing temperature of 53°C and an extension 
time of 15 seconds over 40 cycles. There is a large amount of baseline noise seen in this 
assay. 
A series of individual changes were made to the assay in an effort to reduce the amount of 
baseline noise, as part of an optimisation of the assay. Initially the extension time of the 
assay was reduced from 15 to 10 seconds, in an aim to reduce the amount of baseline noise 
by reducing the amount of non-specific amplification that could be caused by a longer 
extension time in the PCR cycle. The dissociation curve of this assay, as shown in Figure 
4.10, shows the background noise to be worse after reducing the extension time, compared 
to the previous assay. 
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Figure 4.10. The dissociation curve for the NTC and internal standards for the ß 1-AR 
RT-PCR assay. This assay was run with an annealing temperature of 53°C and a 
reduced extension time of 10 seconds over 40 cycles. The extension time had been 
reduced in this assay but the background noise is still present. 
It was concluded that reducing the extension time from 15 seconds to 10 seconds actually 
increases the amount of baseline noise, and hence was undesirable. 
The next alteration to the assay in an effort to reduce the amount of baseline noise was to 
increase the annealing temperature from 53 to 55 °C. The theory was that a higher 
annealing temperature would produce more specific PCR products and less non-specific 
products that might be the cause the background noise. 
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Figure 4.11. The dissociation curve for the NTC and internal standards for the (31-AR assay. 
This assay was run with an increased annealing temperature o1'55°C and an extension time of 
15 seconds over 40 cycles. The annealing temperature had been increased in this assay and 
the background noise is slightly reduced. 
As Figure 4.11 shows, the amount of background noise is slightly reduced after this change 
in the assay. The amount of primer dimer is also reduced. I fence, increasing the annealing 
temperature of the assay appeared to reduce the amount of background noise and definitely 
reduced primer dimer formation. 
To further reduce the amount of baseline noise, the amount of primer available was 
reduced so that there was less primer available to form primer dimers and non-specific 
products. As Figure 4.12 shows, the amount of background noise was slightly reduced 
when 6 and 10 µl of each primer is added to the master mix, with the best reduction in 
baseline noise being achieved with 6 µl of each primer added to the master mix. 
165 
I 
y 
es re 
1 `. 
Ro ." ee 
ornrn. ww wx. Owwýwe Ae mw 4. n0 3 ' 
ai 
ýý., iýi 
Figure 4.12. The dissociation curves 
for the NTC and internal standards 
for the p 1-AR assay. 
A. 6 µl of each primer added 
B. 10 µl of each primer added 
C. 14 µl of each primer added. 
This assay was run with an annealing 
temperature of 55°C and an extension 
time of 15 seconds over 40 cycles. 
However, as well as reducing the baseline noise, when 6 pl of each primer is added to the 
master mix. the amplification of target DNA is also reduced, and it may be that with such a 
small amount of primer available this may be becoming a limiting factor, which would 
make the assay less sensitive. Hence, it was decided that 10 d was the optimal amount of 
each primer that needs to be added to the master mix for this assay, as I)NA amplification 
is not affected but the baseline noise is somewhat reduced. 
The next optimisation step in an attempt to reduce the amount of baseline noise was to 
decrease the amount of cycles from 40 to 30. As Figure 4.13 shows, the primer dimer is 
formed after 30 cycles, so by reducing the number of cycles, the formation of primer dimer 
and perhaps background noise may be reduced. 
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Figure 4.13. The amplification plot of the P1-AR assay for NTC and standards after 40 
cycles. The red horizontal line is the Ct line which is the threshold from where results are 
taken. 
However, although the baseline noise was much reduced, when a liver sample was run for 
only 30 cycles of amplification, no result was obtained. This was probably because there 
were not enough rounds of amplification to create a measurable amount of target DNA (as 
shown in Figure 4.14). The number of cycles of amplification was therefore set hack to 40 
cycles. 
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Figure 4.14. Amplification plots of RT-PCR 01-AR assay after 30 cycles of 
amplification. This assay was carried out with an annealing temperature of 55°(', an 
extension time of 15 seconds and with 10pl of primer added to the master mix . 
A. 
Results of standards and NTC. B. Results of liver control sample. As shown, the 
control liver sample has not been amplified enough times to obtain a measurable 
amount of target DNA. 
So, in summary, the ß1-AR R"r-PCR assay was run over 40 cycles at an annealing 
temperature of 55 °C, with an extension time of 15 seconds (Figure 4.15) and with 10 µ1 of 
each primer (100 µM) added to the master mix (14004I SYRR Green, 28 µl reverse 
transcriptase and 784 µl RNase free water). 
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Figure 4.15. Diagrammatic explanation of the RT-PCR programme used for the p 1-AR 
assay after the optimisation process. The number above the line represents the 
temperature (°C) and the number below represents the time (minutes). * is the annealing 
temperature. ** shows the extension time. 
4.2.7 Optimisation of P2-AR RT-PCR 
An initial run was made using 02-AR specific primers using the procedure set out in the 
protocol (Qiagen, 2005), with an annealing temperature of 56 °C (3 °C below the primers 
melting temperature). The results showed that the primers were specific to only one 
product and that there was a minimum amount of baseline noise, as shown in Figure 4.16. 
Primer dimer formation only occurred in the NTC. 
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Figure 4.16. Dissociation curve for the p2-AR assay. This assay was carried out with an annealing 
temperature of 56°C, an extension time of 15 seconds ad with 14µl of each primer at 100 µM in 
the master mix. Only one product peak is evident with minimal baseline noise. 
A range finder assay was then undertaken. The external standard range was set between 
100 and 108 molecules /µl, and samples of brain, heart, gonad, and liver were run at 5 
ng/µl, to ensure that the sample ß2-AR results were in the mid-range of the external 
standards. Figure 4.17 shows the results of the samples to lie between 1O2 and 10" 
molecules/µl, and so for the actual sample assays, the external standard range was set 
between 10 and 106 molecules/µl. 
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Figure 4.17. Results of the (32-AR RT-PCR range finder assay. This assay was carried 
out with an annealing temperature of 56°C, an extension time of l5 seconds and with 14µI 
of each primer at 100 µM in the master mix. Sample results (; ). Iý. xternal standards 
0 
All other parameters remained the same because the assay results were satisfactory at these 
parameters. Hence the master mix per plate was made up of 1400 pl SYBR Green, 14 pl 
of each gene specific primer at 100 µM, 28 µl reverse transcriptasc and 784 µI of' RNase 
free water. The PCR settings for the 02-AR were as set out in Figure 4.18. 
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figure 4.18. Diagrammatic explanation of the RT-PCR programme used für the (32-AR 
assay. The number above the line represents the temperature (°C) and the number 
below represents the time (minutes). * is the annealing temperature. ** shows the 
extension time. 
4.2.8 Statistical analysis of results 
The tissues analysed by RT-PCR were derived from the experiments involving the 
exposure of propranolol to fathead minnows, hence the results from the first and second 
exposure experiments were pooled for each concentration, as they were in chapter 3. Data 
were tested for normal distribution and equal variance using the Kolmogorov-Smirnov test 
and Levene Median test, respectively. If the data showed a normal distribution and equal 
variance, a One Way Repeated Measures Analysis of Variance (One Way ANOVA) was 
carried out to determine whether there were any statistically significant differences 
between the data sets. If a difference was found, this was followed by a post-hoc All 
Pairwise Multiple Comparison Procedures (Holm-Sidak method). 
If the data failed normality and/or equal variance tests, then a Kruskal-Wallis One Way 
ANOVA on ranks was carried out to determine whether there were any statistically 
significant differences between the data sets. If a difference was found this was followed 
by a post hoc All Pairwise Dunn's test. 
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4.3 Results 
After optimisation of the ß1- and ß2-AR RT-PCR assays, tissue samples obtained from the 
propranolol exposure experiments were analysed to determine whether exposure to 
propranolol caused an up or down regulation of ßl- and/or 02-AR mRNA levels in the 
tissues of the brain, heart, liver and gonad of these fathead minnows. 
4.3.1 Amplification of the target sequence 
For each primer pair, an aliquot of amplified product (post RT-PCR) from wells from the 
internal standard at 1e7 molecules/µl, and the liver control, were sent for sequencing 
(Dundee University, Dundee) to determine if the correct sequence was being amplified. 
The sequence of amino acids that the primers should have amplified was 185bp and 226bp 
for the ßl-AR and the ß2-AR, respectively, as set out in Figure 4.19 below. 
, -TTTAGGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGGCGGACCGCAGGTTGCACG 
TGAGCTCGTGCGATCTGTCGCGCTGCACCGG 
J 
A'FGGAGGGAGGGGATAGG'('TGAGCGTGGAGAACACC"I'CCCT 
GCACATGAA"1'GTTTCA"hCT'GGGCTAAACGACTCT"1'C'I'000GI'G'I'CC'GAA 
TATAGCGACC 
Figure 4.19. Sequences of the 01- and ß2-AR amplicons. A. Nucleotides in the 01-AR 
amplicon. Nucleotides highlighted in blue are the primers (131.15F and 01.16R) used fier 
the p1-AR RT-PCR assay. Red amino acids are those in the seventh TMD. B. 
Nucleotides in the ß2-AR amplicon. Nucleotides highlighted in green are the primers 
(ß2.22F and ß2.22R) used for the ß2-AR R1'-PCR assay. Nucleotides highlighted in 
orange show the 5' UTR and those highlighted in red are those in the first TMI). 
The sequencing results were compared to the supposed sequence (see chapter 2) in a 
clustal alignment (wwww\ww. ehi. ac_. uk/'I-ools/clustalw2/index_html). The results are shown in 
Figures 4.20 and 4.21. For each primer pair, Liver F and Liver R are the same sample, and 
Std F and StdR are also the same sample, but each was run with either the forward (111.1 5F 
or ß2.22F)) or reverse (ß1.16R pr 132.238) primer. The first part or last parts of' the 
sequence are missing from each sample because at the start of every run the sequence 
quality is not good enough for the nucleotides to be read. These data show that the DNA 
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obtained from the transcription and amplification of mRNA in the Ri'-PCR assay are 
indeed fragments of either the 0 1-AR or the ß2-AR. 
sequence TGGGGTACGTCAACTCCGCCTTTAACCCCATCATATACTG 60 
StdF TTGATACATCGCGTTACACC-GCATATACTG 30 
LiverF GTAAGACCGCATGGTACGCA-TCATATAATG 30 
StdR CTTCGTATTTTTGAAC 7'GGGGTACGTCAACTCCGCCTTTAACCCCATCATATACTG 60 
LiverR CTTCGTATTTTTGAA TGGGGTACGTCAACTCCGCCTTTAACCCCATCATATACTG 60 
sequence TCGGAGTCCCGACTTTAGGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGGCGGA 120 
StdF TCGGAGT-TCGACTTTACGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGGCGGA 89 
LiverF TCGGAGTCTCGACTTTAGGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGGAGGA 90 
StdR TCGGAGTCCCGACTTTAGGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGGCGGA 120 
LiverR TCGGAGTCCCGACTTTAGGAAAGCCTTTAAGAGGCTGTTGTGTTGTCCGAGGCAGGCGGA 120 
**************************************************k*kk* 
sequence CCGCAGGTTGCACGTGAGCTCGTGCGATCTGTCGCGCTGCACCGc, 
GGGTTATGTGAACTC 180 
StdF CCGTAGGTTGCACGTGAGCTCGTGCGATCTGTCGCGCTGCACCGc; GGGTTATGTGAACTC 149 
LiverF CCGTAGGTTGCACGTGAGCTCGTGCGATCTGTCGCGCTGCACCGGGTTATGTGAACTC 150 
StdR CCGCAGGT-GCACGTGAGCTCGTGCGATCTGCGGGGA 156 
LiverR CCGCAGGT-GCACGTGAGCTC-TGCGAGTCGTTGGTGG 150 
sequence AATGG '-5 
StdF AATGG H4 
LiverF AATGG 55 
StdR 
LiverR 
***** 
Figure 4.20. Comparison of the sequence of the (31-AR amplicon to the results from liver 
and standard samples in both the forward and reverse directions. Nucleotides highlighted 
in blue are the ß1.15F and ß1.16R primers. Alignment was carried out using C'LIJS"TAL 
W (1.83) multiple sequence alignment. 
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StdR TTGTGATCAAAGGTCGAGTG:, AAGAACACTATGTGAGACCAGAACACTT-CCTAAGAGAA 59 
LiverR AGGTGATCAA-GGTCGAGTG:,: 'AAGAACACTATGTGAGACCAGAACACTT-CCTAAGAGAA S8 
sequence AGGTGATCAAGAGTCGAGTG.. AIAGAACACTATGTGAGACCAGAACACTT-CCTAAGAGAA `59 
StdF GCAATTG-TGAGA--CAGACACTT-CCTAAGAGAA 31 
LiverF CGGGAATGGGTGAGA--AGGACACTAACCTAAGAGAG 
******** *********** ** ***** ***** ********* 
3S 
StdR AAGGATTATTTTTGGATAGTGGACTCCTAATTTTAGTCAAAGCTCATGGAGGGAGGGGA'I' II'+ 
LiverR AAGGATTATTTTTGGATAGTGGACTCCTAATTTTAGTCAAAGCTCATGGAGGGAAGGGAT I18 
sequence AAGGATTATTTTTGGATAGTGGACTCCTAATTTTAGTCAAAGCTCATGGAGGGAGGGGAT 1111 
StdF A-AGGTTATTTTTGGATAGTGGACTCCTAATTTTAGTCAAAGCTCATGGAGGGAGGGGAT 90 
LiverF C-GGATTATTTTTGGATAGTGGACTCCTAATTTTAGTCAAAGCTCA'I'GGAGGc; AGr, GGAT ss4 
StdR AGGTTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCA'I'C'I'GC; (; C'I'AAAC'GAC'1'C'I' 1 /'4 
LiverR AGGTTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGC'I'AAACGACTCA I18 
sequence AGGTTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCT 119 
StdF AGGTTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCT 150 
LiverF AGGTTGAGCGTGGAGAACACCTCCCTGCACATGAATGTTTCATCTGGGCTAAACGACTCT 1`4 
StdR -CTCCCGGGCCCGAATATCGG-------------------------- 189 
LiverR -CTCCATTTCCCGAA-ATTGG---- 
sequence TCTCCGGTGTCCGAATATAGCGACý, CAGAGGTGGTCTTAATCAGCAT 
StdF TCTCCGGTGTCCGAATATAGCGACGCAGAGGTGGTTTTAATTAGCAA !1 
LiverF TCTCCGGTGTCCGAATATAGCGACGCAGAGGTGGTTTTAATTAGCAA I1 
Figure 4.21. Comparison of the sequence of the ß2-AR amplicon and the results from 
liver and standard samples in both the forward and reverse directions. Nucleotides 
highlighted in green are the ß2.22F and ß2.23R primers. Alignment was carried out using 
CLUSTAL W (1.83) multiple sequence alignment. 
These sequences were run through a blastx database ) to 
retrieve annotation to the sequences. The results (shown in Figure 4.22) show that the 
fragments from the ßI and the ß2-AR assays are recognised as being fragments of the 131- 
AR or ß2-AR, respectively, and that the correct fragments are being amplified and 
measured in the RT-PCR reaction for both assays 
A. 
PREDICTED: hypothetical protein [Danio rerio] 3-10 
ýG12607.1 unnamed protein product [Tetraodon nigroviridis] iO. 9 2e-14 
_'INP 
001084152.1.1 beta-1 adrenergic receptor [Xenopus laevi... 65.9 8e-10 
770 ?. l' PREDICTED: similar to beta-l-adrenergic r... 5 . 
', le-07 
B. 
,, f : .. 
PREDICTED: similar to betat-adrenergic receptor Soo-07 
rj, . 1, _, - 
"_ hypothetical protein LOC100037315 [Danio ... 5e-06 
Figure 4.22. Results from running each sequence from (A) 01-AR and (B) 02-AR R"1- 
PCR assay in a blastx analysis. These demonstrate that the DNA fragments are from 131 
and 32-ARs, respectively. 
4.3.2 The efficiency of each assay 
As shown in Tables 4.4 and 4.5, the efficiency ranges for all assays were greater than 90 
%, with efficiency values ranging from 93 and ii7% for the (i l -AR assay and between 91 
and 128 % for the ß2-AR assay. 
Plate 
number 
RT-PCR assay: ßl-AR 
Samples R2 Slope Efficiency ('%o) 
1 Liver Exposure 1 0.996 -3.410 96.45 
2 Brain Exposure 1 0.945 -3.202 105.26 
3 Gonad Exposure 1 0.967 -3.175 106.52 
4 Heart Exposures I&2 0.966 -3.493 93.32 
5 Liver Exposure 2 0.972 -3.342 99.17 
6 Brain Exposure 2 0.966 -2.956 117.92 
7 Gonad Exposure 2 0.967 -3.175 106.52 
Table 4.4. Efficiency, slope and 
Efficiency values are all > 90%. 
R2 values for all the (il-AR R1'-11('R assays. 
RT-PCR assay: P2-AR 
Plate 
number 
Samples RZ Slope EfTiciency (`%. ) 
1 Liver Exposure 1 0.995 -3.553 91.18 
2 Brain Exposure 1 0.971 -3.101 1 10,12 
3 Gonad Exposure 1 0.970 -3.113 109.52 
4 Heart Exposures 1&2 0.966 -3.107 109.82 
5 Liver Exposure 2 0.978 -3.269 102.26 
6 Brain Exposure 2 0.939 -2.801 127.52 
7 Gonad Exposure 2 0.9320 -3.157 107.38 
Table 4.5. 
Efficiency 
Efficiency, slope and 
values are all > 90%. 
R2 values for all the j12-AR R1'-PCR assays. 
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4.3.3 Internal standard results 
A liver sample was run in triplicate on each plate at a concentration of 5ng/µl to act as an 
internal control between the different plates. These data were plotted on a graph, as shown 
below in Figures 4.23 and 4.24. These data show that although the same sample was run 
on each plate, some results are statistically significantly different from the other internal 
standard results on different plates. For example, in the ßl-AR assay, the internal standard 
results for plate 5 are 3-fold different to those for plate 6, and in the (32-AR assay, internal 
standard data for plate 7 are statistically different to those of all other plates except plate 3. 
This is not ideal. However, unlike the results of the expression of (3-ARs between tissue 
types, the results for the internal standards for each assay are all within the same order of 
magnitude and overall, although there is a small amount of internal variability between 
plates, the variability in expression levels of the 13-ARs in different tissues is very much 
greater. With regard to comparing data from the same tissue type, each tissue type from 
each exposure was analysed on the same plate in each assay, and because the efficiency of 
each assay was >90 %, the comparability of data within each tissue type is validated. 
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Ü 102 = 
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Figure 4.23. Internal control results for each plate in the (U-AR assay. * shows a 
statistically significant difference between the two data points (p = <0.005). Liver 
samples were run on plates 1&4. Brain on plates 2&5. Gonad on plates 3&6. 
Heart on plate 7.0 Mean and 
X individual results 
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Figure 4.24. Internal control results for the 02-AR assay. * shows result is statistically 
different from all other plates (p = <0.005). Liver samples were run on plates I&4. 
Brain on plates 2&5. Gonad on plates 3&6. f leart on plate 7. 
" Mean and X individual results 
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4.3.4 Expression levels of 11-AR in different tissues 
Expression levels of ßl-AR mRNA in different tissue types was tested under the null 
hypothesis that stated there were no differences in the expression level of (il-AR 
(measured as 01-AR mRNA) between treatment groups within each tissue type. Figure 
4.25 shows the results of ßl-AR expression in Iiver. 
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Figure 4.25. Levels of ß1-AR mRNA in the liver of fathead minnows that were 
exposed to different concentrations of propranolol. * shows a statistically significant 
difference between data groups (p = <0.05). 
" Mean and X individual results. Error bars show standard error. 
The data show that the null hypothesis is rejected for the liver data, as there is a statistically 
significant difference between the 0.1 mg/L treatment group and the DWC, 0.01 and the 
1.0 mg/L groups. However, this apparent response to propranolol is not dose-related. 'l'he 
mean expression level of PI-AR in the 1.0 mg/L treatment group is the lowest of all the 
mean data points. 
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Figure 4.26 shows the expression level of ßl-AR mRNA in the brain at different 
concentrations of propranolol. 
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Figure 4.26. Levels of ß1-AR mRNA in the brain of fathead minnows that were exposed 
to different concentrations of propranolol. " Mean and X individual results. Error bars 
show standard error. 
For brain tissue, the null hypothesis is not rejected, as there are no statistically significant 
differences in the expression levels of ßl-AR between any of the treatment groups. 
However, although not statistically significant, the level of ß1-AR mRNA in the brain at 
1.0 mg/L is again the lowest of all the treatment groups. 
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Figure 4.27 shows the results of the level of ß1-AR expression in the gonad at ditfcrent 
exposure concentrations of propranolol. 
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Figure 4.27. Levels of ßl-AR mRNA in the gonad of fathead minnows that were 
exposed to different concentrations of propranolol. * shows a statistically significant 
difference between data groups (p = <0.05). 
40 Mean and X individual results. Error bars show standard error. 
The null hypothesis is rejected as there is a statistically significant difference between the 
1.0 mg/L treatment group and the DWC and 0.01 mg/l, treatment groups. However, this is 
clearly not dose-related, although there is a statistical difference between the control group 
and the 1.0 mg/L treatment group, as there is an increase in the expression level of (i 1-AR 
in the gonad at 1.0 mg/L compared to the control group. This trend is also apparent from 
the 0.01 and 0.1 mg/L data. In other words, there appears to be some limited evidence of 
an increase in the amount of if 1-AR mRNA with increasing propranolol concentration. 
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Figure 4.28 shows the expression levels of ß1-AR in the heart of fathead minnows exposed 
to different concentrations of propranolol. As stated in the Material and Methods section, 
there were less samples to analyse for the heart (due to pooling of samples) and so there is 
less variability within data points. 
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Figure 4.28. Levels of ßl-AR mRNA in the heart of fathead minnows that were exposed to 
different concentrations of propranolol. * shows a statistically significant difference 
between data groups (p = <0.05). 
0 Mean and X individual results. Error bars show standard error. 
The null hypothesis is rejected as there is a statistically significant difference between the 
0.1 mg/L treatment groups and the 0.001,0.0 1,1.0 mg/I, treatment groups. There is also a 
statistically significant difference between the DWC and 0.001 mg/I, treatment groups. 
However, overall there does not appear to be a dose-related effect. 
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Analysis was also conducted to determine whether there was a difference in ßl-AR 
expression levels between tissue types. The null hypothesis tested was that there was no 
difference in the expression levels of ßl-ARs between different tissues. 
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Figure 4.29. Levels of 131-AR rnRNA in all tested tissue types of fathead minnows that 
were exposed to different concentrations of propranolol. Matching coloured squares and 
ovals at the top of the graph show where statistically significant difference between data 
groups exist (p = <0.05). Mean results shown as coloured circles Error bars show 
standard error. 
"= DWC, 0=0.001 mg/L, 
0=0.01 
mg/L, 
9=0.1 
mg/L, = 1. Omg/1. 
As Figure 4.29 shows, the null hypothesis is rejected. There is a statistically significant 
difference in the expression level of the ßl-AR between the heart and all other tissues. 
There is also a statistically significant difference between the expression level of the P 1- 
AR in the brain compared to liver and gonad tissues. The heart shows the greatest amount 
of ß1-AR expression, followed by brain tissues. There is no statistically significant 
difference in ßl-AR expression level between liver and gonad tissues. 
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4.3.5 Expression level of p2-AR in different tissues 
Analysis of results obtained in the 02-AR RT-PCR was carried out to see whether exposure 
to different concentrations of propranolol caused a change in the level of 132-AR mRNA 
within the same tissue. The null hypothesis was that there are no differences in the 
expression level of 132-AR between treatment groups within the same tissue type. Figure 
4.30 shows the expression level of ß2-AR at different propranolol concentrations in the 
liver. 
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Figure 4.30. Levels of 02-AR mRNA in the liver of fathead minnows that were exposed 
to different concentrations of propranolol. Matching coloured squares and ovals at the 
top of the graph show where statistically significant difference between data groups 
exists (p = <0.05). 0 Mean and X individual results. Error bars show standard error. 
The null hypothesis is rejected. There are statistically significant differences in the 
expression level of ß2-ARs in the DWC treatment group compared to the 0.01,0.1 and 1.0 
mg/L treatment groups. There are also significant differences between the 0.001 mg/L 
treatment group and the 0.1 and 1.0 mg/L treatment groups. Another statistically 
significant difference also exists between 0.01 and 1.0 mg/L treatment groups. This 
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response to propranolol seems to be dose-related, because as the concentration of 
propranolol increases, the expression level of ß2-AR in the liver decreases. 
Figure 4.31 shows the expression level of ß2-AR in the brain of fish exposed to different 
concentrations of propranolol. 
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Figure 4.31. Levels of ß2-AR mRNA in the brain of fathead minnows that were 
exposed to different concentrations of propranolol. * shows a statistically significant 
difference between data groups (p = <0.05). 
0 Mean and X individual results. Error bars show standard error. 
A statistically significant difference exists between the DWC group and the 0.001 mg/L 
treatment group, and so the null hypothesis is rejected. However, this apparent response is 
not dose-related, as none of the other treatment groups show a statistical difference to the 
control group. 
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Figure 4.32 shows the expression level of 02-AR in female gonadal tissue of fish exposed 
to different concentrations of propranolol. 
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Figure 4.32. Levels of ß2-AR mRNA in the gonad in fathead minnows that were 
exposed to different concentrations of propranolol. No statistically significant 
differences are found between treatment groups. 0 Mean and X individual results. 
Error bars show standard error. 
No statistically significant differences are found between treatment groups in the 
expression level of ß2-ARs in brain tissue. The null hypothesis is accepted. 
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Figure 4.33 shows the expression level of 02-AR mRNA in the heart of fish exposed to 
different concentrations of propranolol. 
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Figure 4.33. Levels of ß2-AR mRNA in the heart of fathead minnows that were 
exposed to different concentrations of propranolol. Matching coloured squares and ovals 
at the top of the graph show where statistically significant difference between data 
groups exists (p = <0.05). 
* Mean and X individual results. Error bars show standard 
error. 
The null hypothesis is rejected. There are statistically significant differences between the 
expression levels of ß2-ARs at 1. Omg/L and all other treatment groups, and also 
differences between the 0.001 mg/L treatment group data and the control, 0.01, and 0.1 
mg/L treatment groups. The ß2-AR expression level decreases in a dose-dependent 
manner from the lowest dose. 
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To test whether there were statistical differences in ß2-AR expression levels between tissue 
types, a null hypothesis was set that stated that there were no differences in the expression 
of 02-AR between different tissues. Figure 4.34 shows the expression levels of p2-AR in 
different tissue types. 
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Figure 4.34. Levels of ß2-AR mRNA in all tested tissue types of fathead minnows that 
were exposed to different concentrations of propranolol. * shows a statistically 
significant difference between data groups (p = <0.05). 
Mean results are shown as coloured circles. Error bars show standard error. 
0= DWC, 0=0.001 mg/L, 0=0.01 mg/L, 0=0.1 mg/L, 0= LOmg/l. 
The null hypothesis is rejected. There is a statistically significant difference in the 
expression level of the ß2-AR between the heart and all other tissues. There is also a 
statistically significant difference between the expression level of the ß2-AR in the liver 
and brain and gonad tissues. The heart shows the greatest amount of 02-AR mRNA, 
followed by liver tissue. There is no statistically significant difference in ß2-AR 
expression level between brain and gonad tissues. The dose-related decreases in the 
expression level of (32-AR in both the liver and the heart is again quite apparent in this 
Figure. 
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4.3.5 Comparison of 01- and ß2-AR expression levels 
Figure 4.35 shows the expression levels of 131- and 02-ARs in different tissues. The null 
hypothesis that was tested was that there was no difference in the expression levels of (3 l- 
and ß2-ARs in each tissue. 
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Figure 4.35. Comparison of (31- and ß2-AR expression level s in different tissues that 
were exposed to different concentrations of propranolol. * shows a statistically 
significant difference between data groups (p = <0.05). 
Mean results are shown as coloured circles. Error bars show s tandard error. 
40 = DWC. 0=0.001 mg/L, 40 = 0.01 mg/L, 0=0.1 mg/L, 0 = 1. Omg/l, 
The null hypothesis is rejected, for in every tissue tested there is a statistically significant 
difference between ßl- and ß2-AR expression levels. In fathead minnows, the highest 
levels of ßl-AR expression are found in the brain and heart, whilst the liver and heart show 
high expression levels of ß2-ARs. 
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4.4 Discussion 
Analysis of the heart, liver, brain and gonads of female fathead minnows showed the 
expression levels of (3l- and ß2-ARs to be different in these tissues. Effects of dif Brent 
concentrations of propranolol also showed a dose-related decrease of' p32-AR mRNA level 
in the liver and heart tissues. 
4.4.1 Possible mechanisms for the reduction of ß-AR expression level in response to 
propranolol 
In both the heart and the liver, a down-regulation of ß2-AR expression level was observed 
in a dose-dependent manner. There also seemed to be a small decline in 1i1-AR expression 
in the liver, brain and heart at the 1.0 mg! L exposure to propranolol, but this was not 
statistically significant. 
Down regulation of a receptor is also known as desensitization and whilst stimulation of an 
acute stress response is appropriate as an immediate response to danger, if this process is 
allowed to continue for any length of time, this cellular response can be harmful. I fence 
desensitization is a process that acts as a `safeguard' against over-stimulation of a cellular 
response (Reid & Perry, 1995). There are two types of desensitization, both of which rely 
on phosphorylation of the receptor via G protein-coupled receptor kinasc 2 (GRK2), 
protein kinase A (PKA) and/or (3-arrestins (Hall, 2004). Homologous desensitization is a 
specific down-regulation of a particular agonist-mediated signal, and in this case all other 
systems remain intact. Heterologous desensitization refers to a general decline in 
responsiveness in a multiple of receptor systems (Guimond et al., 2005). Both homologous 
and heterologous desensitization have been found to regulate both 01- and 02-ARs and 
both types have been linked to the development and progression of heart failure (Guimond 
et al., 2005). 
Congestive heart failure is characterized by desensitization of the 0-receptor pathways due 
to sustained increased cardiac adrenergic stimulation i. e. increases in catecholamine 
concentrations (Lower et al., 2000). In the failing heart, concentrations of noradrenaline 
are markedly increased as the sympathetic nervous system is activated to compensate for 
decreased cardiac function (Ellis & Frielle, 1999). However, years of work clearly 
demonstrate that high levels of catecholamines are extremely toxic to myocardium, and to 
overcome this, the heart down-regulates catecholamine responses (i. e. expression of' (1- 
ARs), in an effort to protect myocardial tissue damage (Port & Bristow, 2001). So in 
essence when catecholamine stimulation carries on in the long term, this is a poorly 
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designed homeostatic regulation of the cardiac system, as chronic increases in 
noradrenaline, instead of helping the failing heart, actually compound the situation by 
causing a decrease in receptor availability (Ellis & Frielle, 1999). Since noradrenaline acts 
mainly through ßl-ARs, the desensitization response is seen mainly in (31-ARs (Lemoinc 
et al., 1988). In a healthy adult (less than 50 years old) human heart, the percentage of (31- 
ARs in the ventricular myocardium is between 70 to 80 % of total ARs, however in a 
failing heart this is reduced such that the proportion of 01- and 02-ARs more closely 
approximates 50: 50 ratio (Port & Bristow 2001). ß2-ARs occupy only 20 to 25 % of the 
AR population in a healthy heart and this percentage shows little or no change in a tailing 
heart (Lowes et al., 2000). 
However, 02-ARs are six times more efficient in transducing a given receptor occupancy 
compared to ßl-ARs, and hence (31-ARs have a lower efficacy (intrinsic activity) than f12- 
ARs (Birnbaumer et al., 1994). So, a small change in ß2-AR expression will have a much 
larger effect than a small change in ßl-AR expression. In addition, the heart contains few 
spare (3-ARs, as binding and activation of nearly all the receptors is required for the 
maximal physiology and precise response mechanisms. Hence in order to maintain normal 
cardiac function, it is critical that no small changes in expression of the (3-ARs occurs (Ellis 
& Frielle, 1999). 
The down regulation of the ß2-ARs seen in the fathead minnow at the higher 
concentrations of propranolol could suggest that propranolol was behaving in a similar 
fashion to chronic release of catecholamines in that it was acting as a toxin. If there are 
less receptors available for propranolol to bind to, the effects of the drug are reduced, 
hence the number of ß-ARs became down-regulated as the fish tried to desensitise 
themselves to propranolol. Because both ß2-ARs in the heart and the liver showed a 
down-regulation of ß2-ARs, the mechanism in action could be homologous 
desensitization, as the response is specific (as far as we know) to just one receptor type. 
A study using atenolol also showed ß-AR density to be significantly reduced in the hearts 
of rats exposed to that ß-blocker (Vonhoff et al., 2006). In that study, atenolol was used as 
a reference substance against extracts from the plant Lycopus europmcus, which also 
reduced ß-AR density in the heart. 
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4.4.2 Expression level changes of ß-ARs 
ß-ARs have been found to mediate the adrenergic regulation of trout erythrocyte (red blood 
cell) volume and intracellular pH, which consequently affects the oxygen-carrying 
capabilities of erythrocytes (Reid et al., 1991). During short term catecholarninc release 
and subsequent activation of (3-ARs in erythrocytes, this would help the fish flee from any 
imminent danger by quickly providing a greater uptake of oxygen in the blood, which 
would then be transported to tissues and organs. However, during chronic catecholamine 
exposure, this response could become damaging. Reid and Perry (1995) report the down- 
regulation of ß-ARs on the surface of red blood cells in trout after large chronic increases 
in plasma catecholamine levels. Initially it was supposed that (31- ARs were the dominant 
ß-AR subtype of erythrocytes, however after the advent of more specific quantification 
techniques and the discovery of the 03-AR, it was found that ß3b-ARs are in fact the main 
ß-AR subtype on erythrocytes in trout which controls Na+/H+ exchange (Nickerson et al., 
2003; Perry et al., 1991). Unlike the situation with ßl- and 02-ARs, the desensitization of 
ß3-ARs does not occur via phosphorylation by G protein-coupled receptor kinase 2 
(GRK2), protein kinase A (PKA) and ß-arrestins, and as such does not contain target 
sequences for phosphorylation by these kinases (Strosberg, 1997). Instead, insulin and the 
thyroid hormone T3 have been found to down regulate ß3-AR in some human tissues 
(Strosberg, 1997). 
Unlike catecholamines, cortisol is reported to have an opposing effect on [3-AR expression. 
Cortisol is a corticosteroid hormone produced in the cortex of the adrenal gland and is 
released in humans and fish as a response to stress. It causes an increase in blood pressure, 
blood sugar level and is a known immunosuppressant. Hence, cortisol has been found to 
up-regulate the number of functional surface ß-ARs in the liver, so that accelerated energy 
production can occur as a response to stress (Reid et at., 1992). 
4.4.3 Expression levels of ß-ARs in other animals and fish 
By comparing the expression levels of 01- and ß2-ARs in the same tissue and in diftlerent 
tissues from the fathead minnow (Figure 4.41), it is apparent that there are large 
differences in the expression levels of these two receptors. For example, in the brain, (i 1- 
ARs are predominant over ß2-AR expression by over 1000-fold. In the liver, f12-ARs are 
expressed about 1000-fold times more than ß1 -ARs. In the gonad and heart there is not as 
much differentiation in the expression of these two receptors, however the difference is 
still statistically significant. 02-ARs are expressed at slightly higher concentrations than 
ßl-ARs in the gonad, and in the heart ßl-ARs are expressed more than 132-ARs. Overall, 
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01- and 02-ARs are expressed most highly in the heart, have the lowest levels of 
expression in the gonads, and the expression of 01-ARs in the brain and heart are very 
similar 
In the livers of most species, including humans, the numbers of both ul and f12-ARs are 
high and glycogenolysis occurs primarily via ß2-ARs in normal conditions (lrraji- 
Bencheckroun et al., 2004). Dog livers also have been found to predominantly express the 
p2-AR subtype (Garcia-Sainz et al., 1996). Nickerson et al. (2001) and Moon (2004) both 
found that, by using an RNase protection assay, 02-AR to be highly expressed in the liver 
of rainbow trout. The data from the RT-PCR work carried out in fathead minnow also 
demonstrates high 02-AR expression in the liver and shows that, of the (31 and the [32-AR 
subtypes, it is the principal one, hence the fathead minnow data are comparable to those in 
other species. It is evident from the above data that ß1-ARs are expressed at much lower 
levels than ß2-ARs in the livers of most species. Mersmann (2002) states that (31-ARs 
occupy only 20 % of the ß-AR population in human livers. In the fathead minnow this 
difference is even greater, as the ßl-AR population was found to be less than I% of the 
combined 0 1- and ß2-AR population. 
ß-blockers mainly target the heart, and so it would be expected that the heart has a high 
expression level of ß-ARs. This is true of most animals; 131- and [i2-ARs are found to he 
highly expressed in the hearts of many animals. The predominant ß-AR subtype of hearts 
in mammals is ßl-AR. For example, rat heart is predominantly ßl-AR, pig heart is made 
up of 72 % ßl-ARs, and in humans ßl-ARs are mostly expressed in the heart, with (31-ARs 
making up 70 to 80 % of total ARs in the ventricular myocardium (hall, 2004; Port & 
Bristow 2001; Mersmann 2002; Strosberg, 1997; Machida et al., 1990). The täthead 
minnow RT-PCR assay also showed ßl and 02-ARs to be highly expressed in the heart, 
with ßl-ARs expressed 71% more than 02-ARs, which is very comparable to data from pig 
and human hearts. 
01-ARs are also found in high levels in the brain of animals (]lall, 2004). Frielle et al. 
(1987) state that the pineal gland and cerebral cortex have the highest RNA levels of (il- 
ARs in the brain of rats. Machida et al. (1990) also found, using northern blot analysis, (31- 
AR mRNA levels to be the highest in the pineal gland, thalamus, amygdale, septum, 
hippocampus and anterior basal ganglia, which are all parts of the brain. Again, the results 
from the fathead minnow RT-PCR are comparable to these reports. Fathead minnow P 1- 
AR mRNA was found at high concentrations in the brain, which when calculated showed 
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brain ßl-AR levels to be 21 % of heart ßl-AR expression. This is a comparatively high 
level of expression, as 02-AR representation in the brain was only 0.12 % of (31-AR heart 
expression. 
By using RT-PCR, ßl-ARs have been found to be expressed in mature oocytes of Xenopus 
(Devic et al., 1997). These levels change significantly during early development, and the 
catecholamine concentration in mature oocytes has been found to follow a similar trend to 
PI -AR mRNA expression (Devic et al., 1997). Because ß-ARs have been found in mature 
oocytes provides evidence to support their presence in non-fertilised oocytes, and this may 
explain why ß-ARs were found in the female gonads of fathead minnows, albeit at fairly 
low expression levels. 
f3-ARs have also been found in other fish tissues that were not tested in this study. In trout, 
132-ARs were also found to also be highly expressed in red and white muscle, with lower 
expression levels in the gills, kidney and spleen (Moon, 2004; Nickerson et al., 2001). 
However, in summary, the ßl- and (32-AR expression levels, particularly those in the heart, 
liver and brain tissues of fathead minnows, resemble the pattern of expression bound in 
mammals and other fish. 
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Chapter 5 General discussion 
5.1 Theories to explain the effects of propranolol on fish 
Exposure of propranolol to fathead minnows caused an acute toxicity at 10 mg/L. Before 
the fish at 10 mg/L were euthanized, they were observed to be very disorientated and 
swimming on one side or nosing the bottom of the tank. Propranolol also caused adverse 
effects to the health of fish at 1 mg/L, and a loss of appetite was noted together with slight 
disorientation. Other effects of propranolol included a statistically significant decrease in 
reproduction at 1.0 mg/L, dose-related decreases in male weight, Cl and fatpad weight, and 
a dose-related increase in female GSI. Molecular analysis of 1 1- and ß2-AR expression 
revealed a dose-related decrease in 02-AR expression in the liver and hearts of fathead 
minnows exposed to propranolol. 
The loss of appetite together with the disorientation of the fish and lack of sexual 
behaviour indicates that propranolol was acting as a CNS toxin. It is possible that loss of 
appetite caused the fish to mobilise fat stores, which resulted in reduction of Cl and weight 
of the fish and fatpad. However, the desensitization of ß2-ARs in the heart and liver do not 
support this theory, for if this was the case, a down-regulation of ß-ARs in the brain may 
have been observed. 
Another likely theory is that the effects seen when fish were exposed to propranolol are 
due to energy re-allocation. If propranolol caused the heart rate to be reduced sufficiently, 
there would have been a decrease in oxygen delivery to tissues and hence a reduced energy 
supply to vital tissues and organs. This would account for the observed disorientation of 
the fish and could equate to light-headiness and fainting experienced in humans through 
lack of oxygen. In an effort to survive, the fathead minnows stopped reproducing and 
allocated the remaining energy to survival (Dzialowski et al., 2006). In addition, 
propranolol increased lipolysis, which caused the mobilisation of fat stores, a primary store 
of energy in fish, which resulted in decreased weight, Cl and fatpad weight (Vianen et al., 
2002). This theory is supported by the desensitisation of (32-ARs in the heart and liver. if 
both of these organs were targeted by propranolol, which caused a decreasing heart rate 
and increasing lipolysis, the fish, in an effort to survive, down regulated (3-ARs in these 
organs to try to minimise the toxic effects of propranolol. 
Of the two theories, the later is more probable as the molecular data indicate that the heart 
and liver were affected by propranolol. Without much more research, the mechanisms of 
action of propranolol underpinning the effects observed will remain theories only. As most 
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organs have ARs, often more than one type, propranolol (a non-selective (i-blocker) could 
cause direct effects on almost any organ and hence any physiological process. The indirect 
effects (due, for example, to changes in energy metabolism) are almost infinite. However, 
the aim of the project was to conduct an environmental risk assessment of propranolol on 
fish, not to tease out the exact mechanisms of action behind any effects. 
5.2 Aquatic risk assessment of propranolol 
The detection of pharmaceuticals in a variety of water bodies at a range of concentrations 
has raised concern worldwide. The testing that these bioactive ingredients undergo before 
they are released into the environment has, up until recently, not sufficiently attempted to 
address the chronic effects of these drugs. By carrying out the pair-breeding assays in this 
study, a lot of data were collected that assessed the chronic effects of propranolol on 
fathead minnows. These included data not only on the reproductive capabilities of the fish, 
but also provided information on general health parameters and also appropriate molecular 
information (on quantification of ß-AR expression) that helped in understanding the 
mechanisms underlying changes in the holistic parameters. Molecular work can also help 
explain data collected from physical parameters. Propranolol targets (3 1- and (32-ARs in 
humans, and since the homology between human and fathead (3-ARs is very high, it can he 
assumed that propranolol will also target ß-ARs in fathead minnows. Using RT-PCR, the 
tissues that express these receptors can be identified and hence enable us to predict which 
organs might be affected by the drug. This intelligent-based testing strategy uses the 
mode of action of the drug to aid in hypothesis testing and in predicting where effects may 
be occurring. This approach should help identify chronic effects which may have been 
overlooked if standard Organization for Economic Cooperation and Development (OFtl'1)) 
ecotoxicology tests had been used alone. 
Propranolol has been detected in surface waters at concentrations ranging from 0.00001 to 
0.00056 mg/L and in wastewater effluent at concentrations ranging from 0.0022 to 
0.000002 mg/L (Gros et al., 2007; Ashton et al., 2004; Huggett et al. 2003; Ternes 1998). 
In this study, dose-related effects of propranolol on fathead minnows were observed at 
concentrations as low as 0.1 mg/L, with severe disruption to health occurring at 1.0 mg/L. 
In determining the level of risk of propranolol to fathead minnows, this study has shown 
that at environmental concentrations, propranolol poses no risk to fathead minnows. When 
using these data obtained in the pair-breeding assays to calculate a PEC: PNEC ratio, the 
risk characterisation ratio equals 0.056, as shown 
in Figure 5.1. The ratio is less than 1, 
which means propranolol is classified in this assessment as not being of potential concern. 
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PEC 0.00056 
Risk characterisation ratio = PNEC = 0.01 = 0.056 
Figure 5.1. Calculation of the PEC/PNEC ratio for propranolol using data obtained 
from the pair-breeding assays with fathead minnows. 
With respect to assessing the risk of propranolol to all aquatic life, published literature so 
far shows no effects in plants, bacteria, invertebrates or fish at concentrations that are low 
enough to be found in the environment. The only data to suggest anything to the contrary 
are data published by Huggett et al. (2002), where it was reported that Japanese medaka 
showed reduced hatchability and egg production at 0.0005mg/L. If data from Iluggett et 
al. (2002) are included in the ratio calculation, the risk characterisation ratio is calculated 
as being 1.12, showing that propranolol is a chemical that is of potential concern. 
However, as discussed in chapter 3, there are queries over the reproducibility of these data. 
This example highlights how the ratio is only as accurate as the data used in the calculation 
and if, as proposed by loannidis (2005), that `most published research findings are false', 
then this ratio can often be incorrect. 
PEC 0.00056 
Risk characterisation ratio = PNEC = 0.009 = 0.062 
Figure 5.2. Calculation of the PEC/PNEC ratio for propranolol using data from the 
literature 
The PEC/PNEC ratio calculated from published data listed in this thesis, without including 
the Huggett et al. (2002) data, is 0.062, as shown in Figure 5.2. This ratio is less than 1, 
and comparable to the risk characterisation ratio obtained 
from the fathead minnow pair- 
breeding assays. Hence, based on what is known currently, it can he concluded that 
propranolol is not a pharmaceutical of potential concern to the aquatic environment. 
5.3 Propranolol and other ß-blockers 
ß-blockers are often grouped together in one class of pharmaceuticals, and although they 
all act on ß-ARs, they can differ greatly in their specificity and 
lipophilic properties. The 
differences in physical parameters between n-blockers means that the toxicity to aquatic 
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organisms also differs between each individual n-blocker. For example, propranolol, due 
to its relatively high log Kow of 3.48, can easily cross the blood: brain barrier and act as a 
serotonin receptor antagonist, whereas atenolol, which has a log Kow of 0.23, cannot cross 
the blood: brain barrier. This means that atenolol is less toxic to the brain and 
consequently has fewer CNS side effects in humans compared to propranolol. 
The high log Kow of propranolol means that it has the potential to bioaccumulate in tissues 
and organs, at greater concentrations than other less lipophilic ß-blockers, and hence the 
internal concentrations of propranolol can often exceed those in the water surrounding the 
organism. This study provides an example, as propranolol plasma concentrations of 
fathead minnows placed in 0.1 and 1.0 mg/L of propranolol far exceeded the water 
concentrations of the drug. In the 1.0 mg/L tanks, the concentration in the plasma of male 
fish was as much as 1546 % greater than the actual mean water concentration. A parallel 
pair-breeding assay has been conducted with atenolol and the plasma concentrations of 
atenolol ranged from 1.8 to 12.2 % of the water concentrations (Winter et al., 2008). This 
is a huge difference between the two ß-blockers and another reason why they should not be 
classed as the same kind of pharmaceutical when considering the risks they may pose to 
the environment. The metabolism of ß-blockers in humans is also very different, in that 90 
% of propranolol is metabolised, which differs greatly to atenolol, of which only 10 % is 
metabolised (Maurer et al., 2007). Currently nothing is known about the metabolism of 11- 
blockers in fish. 
Further examples of the differences between ß-blockers are seen in ecotoxicological data. 
Propranolol, when tested on plants, bacteria, algae, invertebrates and fish, has lower FC's 
values compared to other ß-blockers, and this difference can be as much as a 1000401d. 
The general toxicity trend of some ß-blockers is propranolol > nietoprolol > atenolol > 
sotalol. This trend is also reflected in the PEC/PNEC values of atenolol and mctoprolol, 
which have PEC/PNEC ratios much less than 1 (0.00077 and 0.28, respectively, ('louvers, 
2005). 
Hence, one very compelling, and important message, is that one (3-blocken is not the sane 
as another (3-blocker when considering their ecotoxicities. However, it would be a huge 
task to treat every pharmaceutical separately from all others and in addition, with regard to 
ecotoxicology, it would be ethically unsound to do so. It may be that physical properties of 
drugs within each type of pharmaceutical should have some bearing as to how they are 
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classified. For example, drugs with similar log Kow values, within the same class of drug. 
could be combined. 
5.4 Reproduction as an ecotoxicological endpoint 
The propranolol pair-breeding tests conducted in this study used reproduction as the main 
endpoint. Reproduction is a vital process and when an animal has a reduced energy supply 
or is under stress, then that animal may forgo reproduction in order to survive (Dzialowski 
et al., 2006). Hence, reproduction is a good indicator that may highlight when something 
is not right. However, had reproduction been the only endpoint in the pair-breeding 
assays, it may have been concluded that propranolol was having a reproductive toxic effect 
(i. e. a specific and direct effect on the reproductive system). Instead, by having additional 
endpoints, such as fatpad weight, weight of fish, weight of gonads and molecular 
endpoints, a better understanding of the internal mechanisms at work can be gained. Other 
studies also show that reproduction is not always the most sensitive biomarker, for 
example, in a pair-breeding assay with atenolol, fathead minnow reproduction showed a 
LOEC of>10mg/L, yet the most sensitive fathead minnow chronic test endpoint was male 
condition index, which had a LOEC of 3.2 mg/L (Winter et al., 2008). 
Many pharmaceuticals are designed with a specific mode of action and by transferring 
existing knowledge about drugs and mechanisms of action across taxonomic classes, a 
wealth of information can be gained. As this study demonstrates, it is only by taking these 
mechanisms into account when carrying out ecotoxicology testing that it is observed that 
these drugs are capable of having an effect at much lower concentrations than would he 
observed if reproduction was the only endpoint. It could be argued that if the fish is in 
relatively good health, it still has the energy reserves available to reproduce. I lowever, as 
the hatchability data from this study shows, the number of days for eggs to hatch was 
significantly increased in the 0.1 mg/I, treatment tanks (fish exposed to 1.0 mg/1, did not 
spawn enough to analyse their eggs), so although the fish were still reproducing. the 
progeny may not have survived, as they took longer to hatch and hence many have been 
under increased predation threat. Hence, intelligent testing could be a basis for 
environmental risk assessment. 
5.5 The `fish plasma model' approach 
The results from this study provide support for the `fish plasma model' proposed by 
Huggett et al, (2003). In this study, the effect ratios for the 0.1 mg/1, and 1.0 mg/1, 
treatment tanks are less than 1, indicating that drug plasma concentrations in these fish are 
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greater than the drug concentration in human plasma which is needed to elicit a therapeutic 
effect. This corresponds well with the statistically significant effects that were observed in 
the fish exposed to these concentrations of propranolol. The model also predicts that at 
0.01 mg/L of propranolol, no effects should be observed in fathead minnows, because the 
propranolol plasma levels are not greater than the drug concentration in human plasma 
which would be needed to obtain a response. The results are consistent with the model 
predictions, as no effects of propranolol were observed below 0.1 mg/L. 
This model has proved more sensitive compared to a traditional reproductive endpoint, as 
it predicts a response at the 0.1 mg/L concentration, which the pair-breeding assay alone 
would have failed to detect. Hence, the transfer of knowledge from humans to fish is very 
effective in this case, and very accurately supports the fish plasma model hypothesis of 
Huggett et al. (2003). 
5.6 Further work 
With respect to areas of work to concentrate on if the research was continued. there are 
several points for consideration. 
Having characterised the molecular sequence for the ß1- and (32-ARs, the characterisation 
of the 03-AR should be carried out. Nickelson et al. (2003) isolated 2 subtypes of the f13- 
AR, of which the ß3a-AR was highly expressed in the heart and gill, whilst 133b-AR was 
found to be highly expressed in red blood cells in rainbow trout (Oncorhvnchus nrt'kis. c). 
In humans, 03-AR has a markedly different expression pattern to (31- and (32-ARs in that it 
is highly expressed in brown and white adipose tissue, and research now provides a 
consistent picture of the role of ß3-ARs in humans with respect to lipid metabolism 
(Strosberg, 1997). P3-AR has also been detected in the left atrium of the human heart, and 
if 03a-AR is also found in the heart of trout, it raises questions as to the purpose it has 
there. Is it involved in heart function and if it is, does it interact in any way with 131- and 
(32-ARs (Strosberg, 1997). 
A very interesting study would be to determine whether propranolol actually binds to the 
fathead minnow ßl- and ß2-ARs, and to what degree i. e. to find the binding affinity of 
propranolol to fathead minnow ß-ARs. Similar work has been carried out by Ruuskanen et 
al. (2005), whereby a2-ARs were expressed in Chinese 
hamster ovary (C'110) cells and 
competitive ligand binding assays were carried out using adrenaline and phentolamine. 
This approach would be most interesting, as it would add weight to the evidence already 
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collected in this study that propranolol was binding to ß-ARs in the fathead minnow, and 
causing its effects through this binding. 
Besides binding to ß-ARs, propranolol is also known to act as a serotonin receptor 
antagonist, by interacting with the 5-hydroxytryptophan receptor in the brain (Dzialowski 
et al., 2005; Westerlund, 1985). Since one hypothesis to explain many of the c1iects 
observed in this study was that propranolol was causing CNS side-effects, it would be 
interesting to investigate whether propranolol was acting as a serotonin antagonist. This 
could be done by first determining whether or not propranolol hinds to the fish 5-I1]' 
receptor. If binding is possible, serotonin concentrations in the plasma and brain could he 
measured and it could be determined whether propranolol was causing an up or down 
regulation of 5-hydroxytryptophan receptors in the brain. The higher the affinity 
propranolol has for the 5-HT receptor in fish compared to the (3-ARs, the more likely 
proranolol's effects are mediated not through the 13-AR, but instead the 5-IIT receptor. 
Another interesting endpoint would be to follow up the second hypothesis and determine 
whether propranolol did actually physically decrease heart rate in the fathead minnow at 
high concentrations of propranolol. 
The issue of mixtures of pharmaceuticals in ecotoxicology is a very relevant one, for it is 
not the case that a fish or any aquatic organism is exposed to only one pharmaceutical at a 
time. The more realistic scenario is that aquatic organisms are exposed to a variety of 
different chemicals at the same time, of which some combinations of chemicals can 
exponentially increase the biological activity of some drugs. A mixture can include a 
range of pharmaceuticals and their metabolites that could target a multitude of different 
receptors, enzymes and proteins. As this study shows, a range of different [3-Blockers have 
been detected in the environment and hence a number of them would be present in the 
aquatic environment at the same time. Further work could be to combine concentrations of 
all ß-blockers, or at least a mixture of those that are found at the highest concentrations in 
the environment, to determine the effects of this mixture on fish. 
Pharmaceuticals in the environment is an emerging topic that has highlighted that many of 
the pharmaceuticals and personal care products that are used end up in aquatic and 
terrestrial environments. The design of these drugs means that they are often persistent in 
the environment in biologically active forms. However, as this study demonstrates, many 
of the effects of these drugs on aquatic organisms occur at concentrations that are above 
those found in the environment. Despite this, there is a wealth of evidence that illustrates 
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how some drugs. such as ethinylestradiol and diclofenac, can sometimes cause catastrophic 
effects on wildlife at concentrations present in the environment. So the issue is, ii'we are 
to unintentionally add these chemicals to the environment, we must first be certain and 
responsible enough to ensure that repeats of these tragic incidences (many millions of 
vultures have been killed by diclofenac in the last few years) do not occur. In particular, 
thought must be given to ensure that new drugs are tested thoroughly with intelligent 
testing in mind that includes the mode of action of the drug, hopefully to ensure that 
pharmaceuticals do not enter our environment at concentrations able to cause harm to the 
organisms living there. 
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Appendix A. 
Chemical structures of commonly used p3-blockers. 
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The pDrive cloning vector referred to in 2.2.9. 
13 
pDrive Cloning Vector 
3.85kb 
i 
E\ °ý 
13 
1-i 
u 
U: 
17 promoter 
Acc651 
Kpnl 
Sphl 
Pstl 
Mful 
SnaBi 
BarHI 
EcoR I 
EcoRl 
Sall 
Accl 
Hincll 
Hindill 
Xhol 
Avr Il /Sty l 
Nhe l 
Xbal 
Eco721 
BstXl 
EcoO 1091 
Apal 
SacI 
Noll 
SP6 prornoter 
Element Position (bp) 
Multiple cloning site 266-393 
LacZ cc-peptide 216-593 
T7 RNA polymerase promoter 239-258 
T7 transcription start 256 
SP6 RNA polymerase promoter 398-417 
SP6 transcription start 400 
Ampicillin resistance gene 1175-2032 
Kanamycin resistance gene 2181-2993 
pUC origin 3668 
Phage fl origin 588-1043 
Primer binding sites: * 
M 13 forward (-20) 431-447 
M 13 forward (-40) 451-467 
M13 reverse 209-224 
T7 promoter primer 239-258 
SP6 promoter primer 400-418 
10 x TBE buffer: 
The following components were added to a1L flask and made up to 1L with distilled 
water. 
109 g Tris Base 
7.3 g EDTA 
55 g Boric acid 
1x TBE buffer: 
100ml of 10 x TBE buffer was made up to 1L with distilled water. 
L. B. Agar: 
The following components were made up to 500 ml with Millipore water and autoclaved at 
15 pounds per square inch for 15 minutes. 
2.5 g Yeast Extract 
5g Triptone 
2.5 g Sodium chloride 
7.5 g Agar 
L. B. Broth: 
The following components were made up to 500 ml with Millipore water and autoclaved at 
15 pounds per square inch for 15 minutes. 
2.5 g Yeast Extract 
5g Triptone 
2.5 g Sodium chloride 
Loading buffer: 
The following components were made up to volume with purite water, shaken and 
aliquoted into 5 ml tubes for storage at -20 °C until needed. 
Component For 100 ml For 50 ml 
20 % Ficoll 400 20g log 
0.1 M sodium EDTA pH 8.0 20 ml 10 ml 
I%S. D. S Ig 0.5 g 
0.25 % Bromophenol Blue 0.25 g 0.125 g 
0.25 % Xylene cyanol 0.25 g 0.125 g 
Coding translation for degenerative primers: 
R=A+G Y=C=T M=A+C 
K=G+T S=G+C W=A+T 
